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CHAPTER 1
GENERAL INTRODUCTION
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INTRODUCTION
Polycystic liver disease (PLD) is a genetic disorder characterized by progressive growth 
of multiple liver cysts.1 It is part of the phenotype of two inherited disorders: autosomal 
dominant polycystic liver disease (ADPLD) and as an extrarenal manifestation of 
autosomal dominant polycystic kidney disease (ADPKD). ADPLD is a rare disease with an 
estimated incidence of 1:158000,2 while ADPKD is far more common (1:1000-1:2000).3,4 
Although both diseases have different genetic backgrounds, the clinical manifestation 
and therapeutic approach of PLD is similar.1 
Pathophysiology
Liver cysts consist of cholangiocyte-derived epithelial cells and are the consequence of 
ductal plate malformation during the embryonic liver development.5 In contrast to normal 
bile duct formation, disconnected complexes of intralobular bile ductules do not go into 
regression.6,7 Progressive dilatation of these abnormal ductules lead to formation of cysts.7 
Clinical presentation
The diagnose PLD is arbitrarily defined as more than twenty liver cysts on imaging.2 
The natural growth rate of liver cysts is estimated at 0.9-1.6% in 6-12 months,1 although 
there is large heterogeneity. Clinical presentation varies from a few liver cysts up to 
liver volumes of more than ten liter (Figure 1).8 Liver cysts usually start to appear in 
puberty and increase with age.4,9 ADPLD and ADPKD mutations prevail equally in males 
and females due to their autosomal dominant heritance. However, the fact that women 
present with significant higher liver volumes than men suggests a hormonal component 
in cyst growth.2,4,7,10,11 In contrast to many other liver diseases, abnormalities in liver 
enzymes or synthesis capacity are rare. Cyst-related complications such as hemorrhage 
rupture or infection can occur, but the incidence is low.2 Although PLD is asymptomatic in 
the majority of patients,12 continuous growth of liver cysts results in severe hepatomegaly 
in a subset of patients. This can result in abdominal distension, pain in abdomen, flank or 
costal margin, dyspnea and mobility problems.1,13
Therapy 
For symptomatic patients, a number of liver volume reducing therapies is available 
including aspiration sclerotherapy, fenestration, partial liver resection, liver transplantation 
and somatostatin analogues. The choice of therapy depends on size and location of 
the liver cysts. Figure 2 shows a proposed treatment algorithm. Aspiration sclerotherapy 
is the first-choice option for patients with a large (> 5 centimeter), dominant cyst that 
is likely to be responsible for symptoms.13 This technique involves aspiration of the cyst 
fluid under imaging guidance, followed by injection of a sclerosing agent. Fenestration 
is a combination of surgical deroofing and aspiration and is indicated when the liver 
phenotype consists of multiple large cysts.13 Partial liver resection is reserved for patients 
with massive diffuse cystic disease and resection size varies from a single segment up to an 
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extended lobectomy.13 Liver transplantation is the only curative option in the therapeutic 
spectrum of PLD. Due to its invasive character and the scarcity of organs, it is indicated 
in patients with severely impaired quality of life (QoL) or untreatable complications.13 
Finally, increased knowledge of the pathophysiology of PLD has led to the introduction 
of somatostatin analogues, a 3’-5’-cyclic adenosine monophosphate (cAMP) inhibitor.14 
Somatostatin analogues reduced liver cyst volume with an average of five percent after 
6 – 12 months in various clinical trials.15-20
Figure 1. Coronal (upper panels) and axial (lower panels) MRI images (T2) of different liver volumes. Liver 
cysts present as heavily T2 weighted sequences (white) on MRI. Liver volumes are approximately (A) 2000 
mL, (B) 3500 mL, (C) 5500 mL and, (D) 7500 mL.
Figure 2. Treatment algorithm for polycystic liver disease
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Outcome measures in polycystic liver disease
Studies assessing the efficacy of therapies in PLD have in common that they use cyst or 
liver volume as primary outcome.11,21,22 Liver volume can be measured by manual tracing 
of the liver on imaging slides.23 A software program interpolates between the slices and 
calculates the areas within the indicated circumference. Several studies showed that 
liver volumes can be measured reliably with this method and small differences can be 
detected.16,19,24,25 
Alternative endpoints are patient-reported outcomes such as symptoms and QoL. 
These outcomes are no biological markers that can be measured directly. To quantify 
patients’ health status, subjective patient-reported outcomes are necessary. Patient-
reported outcomes are defined as any endpoint derived from patient reports and are 
usually measured with questionnaires.26,27 They can be divided in generic and disease-
specific patient-reported outcomes. Generic questionnaires such as the Short-Form 36 
(SF-36) measure concepts that are applicable to multiple diseases and health states and are 
used to compare the impact of different diseases on QoL. Disease specific questionnaires 
are tailored towards problems that occur specifically in the disease of interest and have 
usually better ability to detect change in health status than generic measures. 
GAPS IN KNOWLEDGE
It is unclear to which extent PLD leads to diminished QoL and whether liver volume 
and mass-related symptoms are associated with QoL in these patients. Understanding 
factors that drive QoL in PLD can identify therapeutic targets. Although liver volume is 
an objective measure that can reflect disease severity, this does not necessarily reflect 
patient well-being. From patient perspective, liver volume is only a surrogate outcome 
that mediates treatment success. As the natural course of PLD is usually benign, therapies 
for PLD should focus on improving patient-reported health instead of mere liver volume. 
However, the effect of existing therapies on patient-reported health is not thoroughly 
investigated yet. To investigate this, reliable and valid patient-reported outcomes are 
required. Existing generic patient-reported outcomes lack sensitivity to capture specific 
PLD-related problems.28-31 Several disease-specific patient-reported outcomes are available 
to assess gastrointestinal symptoms, but none of them captures the whole spectrum 
of symptoms as seen in PLD.32-38 A new disease-specific patient-reported outcome that 
captures PLD-related symptoms should be developed to evaluate the effectiveness of 
current and new therapies on patient-reported health. 
The aim of this thesis is to define patient-reported health in patients with polycystic liver 
disease. To answer this aim, three objectives were generated:
I. To assess the impact of polycystic liver disease on quality of life
II. To develop and validate a patient-reported polycystic liver disease questionnaire
III. To investigate which therapies improve patient-reported health in polycystic 
liver disease
12
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I.  To assess the impact of polycystic liver disease on quality of life
We have investigated whether quality of life is reduced in ADPLD and ADPKD patients 
compared to the general population. We focused specifically on ADPKD patients with 
coexisting PLD. 
Chapter 2 describes the results of a cross-sectional independent patient data analysis 
of two randomized controlled trials that investigated QoL measured with the SF-36 
in patients with severe PLD. We hypothesized that QoL in patients with severe PLD is 
significantly diminished compared to the general population and that lower QoL is 
associated with more abdominal symptoms and larger liver volumes. 
In Chapter 3, we performed a systematic review of the impact of disease-severity on 
QoL in the total spectrum of ADPKD patients. Our hypothesis was that QoL in ADPKD 
is lower compared to the reference population and that PLD is an important factor that 
drives QoL impairment in ADPKD. To investigate this, we performed a meta-analysis on 
pooled data of studies that investigated QoL with a patient-reported outcome in ADPKD. 
As a secondary objective, we investigated the effect of the disease severity markers renal 
function, kidney volume and liver volume on QoL with a meta-regression analysis. 
II. To develop and validate a patient-reported polycystic liver disease  
    questionnaire
Chapter 4 reports the development and validation of a disease-specific questionnaire 
to assess patient-reported symptoms in polycystic liver disease. Our hypothesis was 
that a disease-specific questionnaire has discriminative ability to distinguish between 
patients and controls and is likely to be responsive to changes in patients’ health. First, 
we identified PLD-specific symptoms by literature review and interviewing patients 
and clinicians. Secondly, we investigated several forms of validity including reliability, 
convergent validity, reproducibility and discriminative validity of the developed polycystic 
liver disease questionnaire (PLD-Q) in a Dutch PLD cohort. To further improve the PLD-Q, 
this process was repeated in an American population of PLD patients. 
In Chapter 5, the developed PLD-Q was used to describe the impact of liver volume 
on symptom burden. As a secondary objective, we assessed the impact of different PLD 
stages on QoL. This was a cross-sectional analysis of data from two prospective studies 
that together reflected the total spectrum of liver volumes. 
In Chapter 6, we assessed whether the PLD-Q is a better outcome than cyst volume 
reduction from patients’ perspective in a randomized controlled trial including patients 
treated with aspiration sclerotherapy. 
To assess if we could extent the use of the PLD-Q to other diseases with similar 
symptomatology, we adjusted and validated this questionnaire to measure symptoms in 
patients with cirrhotic ascites (Ascites-Q). Results of this study are described in Chapter 
7. The Ascites-Q was tested in a prospective cohort of patients with refractory ascites that 
underwent paracentesis to diminish fluid-related symptoms. 
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III. To investigate which therapies improve patient-reported health in  
     polycystic liver disease
Somatostatin analogues effectively reduce liver volume in PLD patients. Chapter 8 
describes their effect on QoL in a longitudinal independent patient data analysis of two 
randomized clinical trials. Our secondary objective was to identify factors associated with 
change in QoL in PLD patients during follow up. Studied factors included demographics, 
height-adjusted liver volume, change in liver volume and somatostatin analogue-
associated side effects. We hypothesized that the physical domain of QoL improves after 
treatment with somatostatin analogues. 
Finally, Chapter 9 provides a general discussion and future perspectives of this thesis. This 
chapter summarizes our results and discusses future steps to continue improvement of 
patient-reported health in patients with polycystic liver disease.
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CHAPTER 2
EVALUATING QUALITY OF LIFE IN PATIENTS WITH 
POLYCYSTIC LIVER DISEASE AND DETERMINING  
THE IMPACT OF SYMPTOMS AND LIVER VOLUME
Titus F.M. Wijnands1; Myrte K. Neijenhuis1; Wietske Kievit2; Frederik Nevens3; 
Marie C. Hogan4; Vicente E. Torres4; Tom J.G. Gevers1; Joost P.H. Drenth1
1 Department of Gastroenterology and Hepatology, Radboud University Nijmegen  
  Medical Center, Nijmegen, the Netherlands
2 Department of Health Evidence, Radboud University Nijmegen Medical Center,  
  Nijmegen, the Netherlands
3 Department of Hepatology, University Hospital Leuven, Leuven, Belgium 
4 Division of Nephrology and Hypertension, Mayo Clinic College of Medicine,  
  Rochester, Minnesota, US
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ABSTRACT
Background
Polycystic liver disease (PLD) follows a progressive course ultimately leading to severe 
hepatomegaly and mechanical symptoms in a subset of patients. It is still unknown 
to what extent this compromises quality of life (QoL). We aimed to determine QoL in 
PLD patients and investigate its association with concurrent abdominal symptoms and 
liver volume.
Methods
Pooled data of 92 severe PLD patients from two randomized clinical trials were used 
for our cross-sectional analysis. QoL was assessed using the generic Short-Form 36 
(SF-36) resulting in eight scale scores and the summarizing physical (PCS) and mental 
component score (MCS). Subsequently, these were compared to the general population. 
Abdominal symptoms were measured with a standardized, 7-point scale questionnaire 
in 54 patients. We dichotomized symptoms for absence or presence and compared 
them with the component scores. Finally, the correlation between liver volume and QoL 
was explored.
Results
Demographics showed severe polycystic livers (mean volume 4906 ± 2315 mL). PCS was 
significantly lower compared to the general population (P<0.001), in contrast to a similar 
MCS (P=0.82). PLD patients had statistically significant (P<0.05) diminished physical 
functioning, role physical, general health, vitality and social functioning scores. Upper- 
and lower abdominal pain and dyspnea were significantly associated with a reduced PCS 
(P<0.01). No correlation was found between liver volume and QoL.
Conclusion
PLD patients had significantly lower QoL in the physical dimension compared to 
the general population. Abdominal pain and dyspnea had a significant impact on this 
physical dimension of QoL.
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INTRODUCTION
The presence of multiple fluid filled hepatic cysts constitutes polycystic liver disease (PLD). 
PLD occurs in the setting of two hereditary disorders: autosomal dominant polycystic 
kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD). ADPKD 
is marked by multiple renal cysts eventually leading to progressive renal disease with 
increasing age.1,2 In ADPKD, liver cysts are the most frequent extra-renal manifestation, 
with an overall prevalence of 83%.3 In ADPLD there are multiple liver cysts without apparent 
extrahepatic manifestations. Typically, PLD is an asymptomatic disease. In a subset of 
patients, however, PLD follows a progressive course of continuous growth in number and 
size of liver cysts eventually leading to massive hepatomegaly.4 This results in symptoms 
of abdominal distension and pain, dyspnea, early satiety, nausea, and regurgitation.4-6 It 
is dissimilar from other liver diseases because fibrosis, cirrhosis and end-stage liver disease 
rarely, if ever, occurs in PLD. The primary aim of available treatment options is to reduce 
liver volume with the hope to alleviate (mechanical) symptoms.7-9 Surgical procedures, 
such as cyst fenestration, aim to reduce cyst burden but bear the risk of complications. 
This is the reason why non-surgical options such as treatment with somatostatin analogs 
have been developed with an aim to reduce liver volume. Indeed, the primary outcome of 
several pivotal trials with somatostatin analogues was reduction of total liver volume.10-14
However, liver volume is a surrogate endpoint, and while it may improve the symptoms 
of patients with PLD, it is relevant to develop more accurate parameters of patient reported 
outcome measures. As such, assessment of patients’ quality of life (QoL) could be an 
alternative key endpoint of treatment success. Indeed, QoL is frequently investigated in 
chronic diseases to achieve a more complete understanding of the impact of a disease on 
the patients’ life.15-17 In this study we evaluated QoL in a pooled sample of symptomatic 
PLD patients in comparison with the general population. Furthermore, we evaluated 
whether abdominal symptoms and liver volume are associated with the outcome of 
QoL. Our ultimate goal was to obtain a clear understanding of QoL in symptomatic PLD 
patients in order to identify new treatment targets.
METHODS
Study design and patient sample
This cross-sectional study pooled and explored the data from two previously published 
randomized clinical trials (NCT00565097 and NCT00426153) that investigated 
the efficacy of somatostatin analogues in PLD patients.10,11 Both trials assessed QoL as 
secondary endpoint. We used the baseline data (assessment before therapy) for the cross-
sectional analysis. Extensive details of the study population and procedures have been 
described elsewhere.10,11 Briefly, the inclusion criteria were: patients aged 18 years or 
older diagnosed with PLD. One trial included PLD patients with a liver volume > 4000 mL 
or symptomatic disease, while the second trial included PLD patients with more than 20 
hepatic cysts.10,11 Criteria for exclusion in both trials were estrogen therapy, pregnancy 
or breast-feeding, symptomatic gallstones, dialysis dependency and (a history of) severe 
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illnesses that would interfere with the study. For our analysis, patients with a history of 
kidney transplantation were additionally excluded to rule out bias of post-transplantation 
medication on QoL.
Quality of life
QoL was measured using the Short-Form 36 (SF-36 version 1). This generic questionnaire 
consists of eight scales representing functional health and well-being.18 These scales can 
roughly be divided in either physical scales (physical functioning, role-physical and bodily 
pain), mental scales (mental health, role-emotional, social functioning) or a combination 
of both (vitality and general health).19 Scale scores range from 0 to 100, with lower 
scores suggesting lower QoL. The scales can subsequently be summarized into two norm-
based values: the physical component score (PCS) and mental component score (MCS). 
These component scores can be compared to a reference norm (50 ± 10) calculated from 
a sample reflecting the general population.20 Component scores provide an overall view 
of QoL and reduce the amount of testing in statistical analyses.21
In this study, the summarizing PCS and MCS were compared with the universal 
reference norm.20 Subsequently, as to evaluate QoL in more detail, mean scale scores were 
compared with normative data derived from a US sample.18 To assure suitability for Dutch 
PLD patients, we performed a sensitivity analysis comparing the scores of Dutch PLD 
patients with a nation-specific reference group.22 Moreover, women were predominant 
in both trials whereas the reference sample has an equal gender distribution. Normative 
general population data show that females generally have lower QoL scores than 
males.18,20 In order to correct for a possible bias with respect to this gender difference, 
component scores of PLD patients were additionally compared with the generally lower 
female reference (PCS 49.07 ± 10.42; MCS 49.33 ± 10.32).20 Finally, possible differences 
in QoL between ADPKD and ADPLD were examined by comparing component scores 
between both groups.
PLD-related symptoms
The Dutch trial included a standardized gastro-intestinal symptoms questionnaire assessing 
the presence of 11 symptoms over the past 4 weeks, using a 7-point Likert scale, ranging 
from 0 (‘none’) to 6 (‘severe’).23 Included symptoms are: lower and upper abdominal 
pain, heartburn, regurgitation, nausea, vomiting, loss of appetite and, early satiety. 
Three PLD-specific questions were added: dyspnea, increasing abdominal volume and 
involuntary weight loss. The questionnaire ends with a visual analog scale (VAS) specific 
for abdominal pain. To evaluate the association between the presence of symptoms and 
QoL, patients were dichotomized for absence (scores of 0 - 1) or presence (2 – 6) of 
each symptom. Subsequently, component scores were compared between these groups. 
Finally, we performed a correlation analysis between component scores and the VAS for 
abdominal pain.
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Liver volume
Both trials conducted CT or MRI-imaging to measure total liver volumes. Detailed 
information about liver- and kidney volume measurement has been provided earlier.10,14 
To investigate a possible correlation between liver volume and QoL, correlation analyses 
were performed between liver volume and component scores. Subsequently, subgroup 
analysis with stratification for underlying diagnosis was performed between liver volume 
and QoL in either ADPKD or ADPLD.
Statistics
Continuous variables were expressed as mean ± SD. The independent t-test was used 
to compare QoL scale and component scores with the general population. In case 
a statistically significant lower PCS or MCS was found in the PLD group compared to 
the general population (i.e. under the reference norm of 50 ± 10), further evaluation of 
possible associations with abdominal symptoms and liver volume was performed. We used 
the Mann-Whitney U test for categorical data (abdominal symptoms) and the Spearman’s 
correlation test for continuous data (VAS and liver volume). As liver volumes are skewed, 
these were converted to logarithmic values. Statistical analysis was performed using IBM 
SPSS statistics 20 (SPSS Inc, Chicago, IL, US). All reported P-values were two tailed, values 
<0.05 were considered statistically significant. The significance level for the evaluation of 
abdominal symptoms was calculated to a P-value lower than 0.0045 using the Bonferroni 
correction in order to correct for multiple testing.
RESULTS 
Demographics
Combining the data of the two trials led to a total of 96 patients. Four patients were 
excluded due to a history of kidney transplantation resulting in 92 PLD patients suitable 
for our analyses. Demographics of included patients are presented for both trials 
separately in Table 1. The mean liver volume of this cohort was 4906 ± 2315 mL. As 
expected in PLD, both studies contained a large majority of female patients (89.1%). 
The distribution of ADPKD or ADPLD was significantly different between the trials 
(P<0.05), however comparing renal function and volume between the groups showed no 
statistical significant differences.
Quality of life
PLD patients scored significantly lower on physical items compared to the reference norm 
(PCS 43.85 ± 10.82; P<0.001), whereas the scores on mental items were comparable 
(MCS 50.24 ± 9.99; P=0.82). Specifically, PLD patients scored lower on items for physical 
functioning, role physical, general health, vitality and social functioning (see Figure 1). 
These results maintained when the Dutch PLD data were compared to national rather 
than US based references. 
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To ensure that the differences in PCS were not a result of the predominance of females 
in our sample, we compared PCS and MCS to the lower reference norm separated for 
female gender.20 This resulted in a sustained significant difference for PCS (P<0.001). 
Furthermore, comparing QoL summary scores between ADPKD and ADPLD showed no 
significant differences.
Table 1. Demographics 
Dutch trial (v. Keimpema) US trial (Hogan) P -value
Number of patients 54 38
Age in years 50.0 ± 8.3 (32.6 – 68.0) 48.8 ± 8.5 (34.0 – 69.0) 0.50
Sex: male/female (%) 7/47 (13.0% / 87.0%) 3/35 (7.9% / 92.1%) 0.44
Diagnosis: ADPKD/ADPLD (%) 32/22 (59.3% / 40.7%) 30/8 (78.9% / 21.1%) 0.047
Liver volume, mL 4702.8 ± 2034.4  
(1728.2 – 10252.2)
5190.5 ± 2661.3  
(2234.1 – 12711.0)
0.33
Right and left kidney volume, mL 1078.7 ± 730.0  
(342.8 – 3064.6)
1049.2 ± 728.3  
(320.3 – 3351.5)
0.63
MDRD-GFR, mL/min/1.73m2 73.2 ± 23.4  
(21.0 – 110.1)
66.4 ± 23.2  
(19.3 – 112.5)
0.18
Unless indicated otherwise, data are mean ± SD (range). Kidney volume was exclusively measured in ADPKD patients. 
MDRD-GFR: Modification of Diet in Renal Disease-Glomerular Filtration Rate.
Figure 1. Baseline SF-36 scale scores of 92 polycystic liver disease patients compared with the American 
general population. * P<0.05; ** P<0.001
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Symptoms and quality of life
The most frequent reported symptoms in PLD patients were postprandial fullness, 
increasing abdominal volume, dyspnea and upper abdominal pain (Table 2). 
Table 2. Frequency of reported abdominal symptoms in PLD sample
Abdominal symptoms n/N (%)
Postprandial fullness 36/54 (66.7)
Increasing abdominal volume 34/54 (63.0)
Dyspnea 27/54 (50.0)
Upper abdominal pain 26/54 (48.1)
Regurgitation 24/54 (44.4)
Lower abdominal pain 18/54 (34.0)
Loss of appetite 18/54 (33.3)
Heartburn 17/54 (31.5)
Nausea 14/54 (25.5)
Involuntary weight loss 8/54 (14.8)
Vomiting 7/54 (13.0)
Frequency (n/N) of symptoms reported ≥ 2 on a 7-point adjectival scale (ranging from 0 – 6)
To further evaluate the impact of abdominal symptoms on the lower physical 
dimension of QoL we compared the mean PCS for each symptom separately between 
patients with (score 2 – 6) or without (0 – 1) symptoms. We found that presence of 
upper abdominal pain, lower abdominal pain and dyspnea was significantly associated 
(P<0.0045) with a lower mean PCS, these are presented in Figure 2. Moreover, we 
found that higher abdominal pain VAS scores were significantly correlated with poorer 
PCS (R=-0.58; P<0.001), see Figure 3. Nausea, loss of appetite, postprandial fullness, 
increasing abdominal volume and unintentional weight loss were associated with a lower 
PCS but the association disappeared after Bonferroni correction.
Liver volume and quality of life 
We found no correlation between liver volumes and PCS in the total PLD sample 
(R=-0.158; P=0.21). Subgroup analysis with stratification for underlying diagnosis (ADPLD 
or ADPKD) to investigate a possible association between liver volume and PCS did not 
identify any significant correlation.
DISCUSSION
In this cross-sectional study, we found that PLD patients have significantly reduced 
physical dimensions of QoL, whereas the mental dimension was unaffected.
Lower PCS reflects limitations or disabilities in the physical spectrum.20 In the setting 
of PLD we may infer that this is caused by the heavy burden and consequences of 
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Figure 2. Boxplots presenting symptoms associated with a significantly lower PCS. The mean PCS is noted 
next to each boxplot; P<0.0045.
a severely increased abdominal volume. Normal MCS values reflect healthy psychological 
and mental status, suggesting that PLD patients cope efficiently with their disease.
Several studies investigated QoL in PLD in relation to surgical therapies such as liver 
transplantation and cyst fenestration.24-26 These studies generally showed similar or 
improved QoL after surgical procedures. However, none of these retrospective studies 
compared their pre-operative data to a healthy reference norm. Therefore, it was 
unknown if and in which way QoL is restricted in PLD. 
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A previous study investigating QoL in patients with chronic liver disease found 
substantially reduced QoL compared to the general population for both physical and 
mental dimensions.15 PLD was not included in this analysis. A comparison with our study 
shows that PLD patients generally have a better physical QoL (PCS 43.9) compared to 
patients with other chronic liver diseases: chronic hepatitis (PCS 41), cholestatic liver 
disease (PCS 39), and hepatocellular disease (PCS 31). Studies investigating QoL in other 
chronic gastrointestinal diseases showed comparable reduced QoL outcome to our PLD 
sample. A prospective study of 471 gastroesophageal reflux disease patients found an 
impaired PCS of 45.9, while another study investigating QoL in irritable bowel syndrome 
showed a significantly reduced PCS of 42.7.16,17
Studies investigating the impact of abdominal symptoms on QoL in gastrointestinal 
disorders showed that increased severity of symptoms are associated with lower QoL 
scores.16,27,28 In this study, the presence of upper and lower abdominal pain and dyspnea 
was associated to a lower QoL. These findings were in agreement with the positive 
correlation between abdominal pain and a lower PCS. Translating the reduced physical 
QoL coinciding with these symptoms is important for clinical reasons. Health professionals 
could focus their attention to treating these symptoms or provide PLD patients with 
coping strategies in order to improve QoL.
In contrast to what we expected, we failed to detect a correlation between liver 
volumes and QoL. 
A possible explanation could be that this pooled PLD sample predominantly consisted 
of PLD patients with severe polycystic livers (mean liver volume = 4906 mL ± 2315). 
As a consequence, the impact of liver volume on QoL in our analysis might have been 
smaller because all included patients already had large liver volumes. We speculate 
that asymptomatic patients have smaller polycystic livers and consequently a normal 
QoL. Indeed, a previous study showed significantly higher polycystic liver volumes in 
symptomatic patients compared to asymptomatic patients.6
Figure 3. Correlation between PCS and the VAS for abdominal pain. Higher abdominal pain VAS scores 
correlated with poorer PCS.
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The strengths of this study include the use of a pooled cross-sectional analysis of two 
PLD trials leading to a relatively large sample size for PLD (n=92) and the use of a widely 
accepted and validated generic QoL-questionnaire. 
There are some limitations that come with this study. First, this study investigated 
QoL in two different nations. Cultural differences between nations result in different 
mean reference scores. In the absence of a global reference SF-36 norm it is 
accepted to compare the outcome with the general US population as provided by 
the SF-36 manual.18,21 To assure that the detected differences were not a result of 
the comparison with the US norm, we performed a sensitivity analysis. Comparison 
of results obtained in Dutch PLD patients with the national SF-36 reference yielded 
similar results. Moreover, investigating QoL in two different nations also provides 
a strength of this study, allowing extrapolation of our findings to a broader population. 
Secondly, the utilization of generic questionnaires has its disadvantages being less 
responsive to the specific nature of a disease.29 Both applied questionnaires have 
a timeframe of four weeks suitable for assessment of chronic symptoms. The majority 
of PLD-related symptoms have a chronic course. However, some PLD-related symptoms 
are caused by acute cystic complications. A previous retrospective cohort in isolated 
PLD patients showed a prevalence of 14.6% cyst hemorrhages, 4.4% cyst ruptures, 
and 5.8% cyst infections with a median follow-up of 8.2 years.4 Symptoms associated 
to cystic complications occur in short and intermittent periods and are possibly missed 
within the timeframe of these instruments. It is unclear to which extent these cystic 
complications affect QoL in PLD patients. Therefore, we recommend the construction 
of a PLD-specific questionnaire, which captures the frequency and impact of acute and 
chronic symptoms over a longer timeframe. Ideally, this instrument should also be able to 
assess the ‘minimal clinically important change’ to evaluate the clinical relevance of QoL 
improvement or deterioration over time.
Thirdly, our sample consisted partly of ADPKD patients. The reduced PCS could therefore 
also be the consequence of concomitant polycystic kidneys. However, mean combined 
kidney volumes of both trials were relatively moderate (1064 ± 723 mL) compared 
with the severe polycystic liver volumes (4906 ± 2315 mL). Indeed, sensitivity analysis 
showed that QoL results were similar between ADPKD and ADPLD patients. Furthermore, 
both trials in our study contained a large majority of female patients, corresponding to 
the predominance of female PLD patients with symptomatic disease.4,5,30 Females generally 
report lower QoL compared to males.20 To correct for this, we compared female summary 
scores directly to our PLD group. The reduced PCS remained significantly different, 
indicating that these differences were not merely a result of the female predominance in 
this study but reflect an actual decrease of QoL. 
Finally, our results are liable to selection-bias of symptomatic patients as a result 
of the design of both trials. However, since symptomatic disease is the most frequent 
indication for treatment in PLD, this subset of symptomatic patients was of primary 
interest for our study.8
In conclusion, this cross-sectional study of symptomatic PLD patients showed 
a clear negative impact of PLD on the physical dimension of quality of life compared 
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to the general population. Symptoms of upper and lower abdominal pain and dyspnea 
compromised this physical dimension. These findings implicate that addressing attention 
to these associated symptoms and trying to relieve them might improve quality of life 
in PLD
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ABSTRACT
Background and aim
Little is known about determinants of quality of life (QoL) in autosomal dominant polycystic 
kidney disease (ADPKD). Recent studies suggest that QoL in ADPKD is determined by 
more factors than mere renal function. We investigated the effect of ADPKD on QoL and 
evaluated how Qol is affected by disease severity markers renal function, kidney volume 
and liver volume. 
Methods
We performed a systematic review, meta-analysis and meta-regression analyses of cohort 
studies and randomized controlled trials investigating patient-reported QoL in adult 
patients with ADPKD not yet on dialysis. EMBASE, MEDLINE, and Web of Science were 
searched to August 2015 without language restrictions. Two investigators independently 
reviewed title, abstracts and full text of potentially relevant citations to determine 
eligibility. We compared pooled QoL summary scores of ADPKD patients using a random-
effects meta-analytic model. These scores were compared with mean and age-corrected 
reference scores of the general population. In a meta-regression analysis, we investigated 
the univariate effect of renal function, kidney volume and liver volume on QoL. 
Results
We included nine studies in meta-analysis including 1623 patients who completed 
the SF-36 questionnaire. Pooled physical (PCS) and mental component scores (MCS) of 
the SF-36 of individuals with ADPKD were lower than those of the reference population 
(45.7 vs. 50.0 and 47.8 vs. 50.0 points, both P<0.001). QoL of ADPKD patients remained 
lower after comparison with age-corrected reference values (age 35-44 year; PCS 52.2, 
MCS 49.9 points, both P<0.05). Larger liver volume negatively impacted PCS (P<0.001) 
and MCS (P=0.001), whereas there was no association with renal function (PCS P=0.1, 
MCS P=0.9) and kidney volume (PCS P=0.5, MCS P=0.5). Total liver and kidney volume 
had no impact on PCS (P=0.1), but did have impact on MCS (P=0.02).
Conclusion 
QoL reported by non-dialysis patients with ADPKD is impaired compared to the general 
population. Large liver volume was the most important factor that diminishes QoL.
PROSPERO International Registry number CRD42015026428
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BACKGROUND
A growing body of evidence on QoL in chronic kidney disease (CKD) suggests that quality 
of life (QoL) is not determined merely by renal function.1-3 The presence of anemia and 
cardiovascular disease can also have substantial negative impact on QoL.1-3 In autosomal 
dominant polycystic kidney disease (ADPKD), anemia,4,5 and cardiovascular diseases6 are 
less frequent compared to other kidney diseases. This suggests that other disease-specific 
factors may contribute to QoL impairment in ADPKD.7  
ADPKD is defined by progressive renal cyst development, leading to enlarged kidneys, 
kidney failure and eventually end stage kidney disease.8 Kidney manifestations of ADPKD 
include acute and chronic pain, hematuria, nephrolithiasis, and cyst infection.9 This 
disease is associated with a range of extrarenal manifestations, including liver cysts which 
occur in the majority of patients, mitral valve abnormalities and intracranial aneurysms.10 
Clinical symptoms in ADPKD seems to be a function of kidney and liver size, and are not 
primarily related to kidney function decline.11
Large kidneys and liver volumes compress adjacent organs and structures leading to 
symptoms that may impair QoL such as fullness, early satiety and pain.12,13  Further, it has 
been demonstrated that kidney enlargement occurs well before renal function decline 
and severe polycystic liver disease may also occur in early stage ADPKD.8,12,14 This indicates 
that physical manifestations of ADPKD which may adversely affect QoL are present before 
renal function deficits are detected.8,13
How disease severity markers, such as renal function, kidney volume and liver volume, 
affect QoL in ADPKD is uncertain. Several studies showed at best very weak correlations 
among these variables.12-16 Most studies included a selected population of patients with 
ADPKD based on either chronic kidney disease (CKD) stage or organ volumes which 
limits drawing robust conclusions on the relation between disease severity markers and 
QoL across the clinical spectrum of ADPKD. Understanding factors that impact QoL of 
individuals with ADPKD can guide treatment decisions and improve holistic patient-
centered care beyond simply monitoring renal function.7
This systematic review and meta-analysis investigates the effect of ADPKD on QoL. As 
secondary outcome, we assessed the effect of the disease severity markers renal function, 
kidney volume and liver volume on QoL in ADPKD.  
METHODS
This systematic review was conducted according to a research protocol registered in 
the PROSPERO international prospective register of systematic reviews (registration 
number CRD42015026428). We reported this systematic review in accordance with 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines (Supplementary Table 1).17 
Eligibility criteria
We included studies that met the following inclusion criteria: (1) cohort studies and 
randomized controlled trials (RCTs); (2) adult patients >18 years, with a diagnosis 
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of ADPKD18 and; (3) use of a patient-reported outcome to reflect QoL. We excluded 
studies that (1) used a patient-reported outcome without summary score of individual 
questions, (2) studies that investigated QoL with a one-item visual analogue scale (VAS) 
only as it often provides insufficient QoL information,19 (3) longitudinal intervention 
studies that provided no baseline QoL scores and, (4) studies that did not report 
original data. 
Search strategy
A medical librarian (P.E.) developed and executed a systematic search combining 
the search terms and Medical Subject Headings (MeSH) for ‘ADPKD’ and ‘renal function’ 
or ‘kidney volume’ or ‘liver volume’ and ‘quality of life’ in the electronic databases 
of EMBASE, MEDLINE, and Web of Science. Letters to the editor, editorials and case 
reports were excluded. Supplementary Table 2 provides an example of one full electronic 
search. We searched for conference abstracts in abstract books of the American Society 
of Nephrology (ASN), World Congress of Nephrology (WCN) and the European Renal 
Association – European Transplant and Dialysis Association (ERA-EDTA) published 
between August 2012 and August 2015 and unpublished studies in the database of 
clinicaltrials.gov. Reference lists of included articles and relevant reviews were screened 
for additional leads. Two investigators (M.N. and M.H.) independently reviewed title and 
abstracts to determine eligibility. Disagreements between M.N and M.H. were included 
for full text review. Subsequently, both investigators screened full text of eligible studies 
and disagreement between M.N and M.H. was resolved by discussion with a third 
author (T.G.). Corresponding authors of original articles were contacted for additional 
information if needed. Cohen’s kappa was calculated as measure of agreement on study 
selection. A value between 0.40-0.59 was considered as fair agreement, 0.60-0.74 as 
good agreement and 0.75 or higher as excellent agreement.20 
Quality assessment    
Since there is no standard tool available to assess the risk of bias for uncontrolled studies, 
we used items derived from the Newcastle-Ottawa Scale to assess risk of bias on study and 
outcome level.21 We scored the categories (1) study population selection; (2) completeness 
of reported results; (3) used patient-reported outcome instrument; (4) recall period and; 
(5) response rate as low or high risk of bias followed by an overall conclusion of the risk 
of bias (low, moderate or high risk of bias) as judged by two independent reviewers. 
Outcome
Primary outcome was summary QoL score measured with a patient-reported outcome 
instrument at baseline. We included studies in meta-analysis and meta regression that 
used a patient-reported outcome measure that was used in 3 or more studies.22 Scores of 
individuals with ADPKD were compared with reference values if available.
We expected that the SF-36 was used in most studies, as it is the most frequently 
used PRO worldwide and is often used in kidney studies.23,24 The SF-36 is a generic QoL 
35
3
SY
STEM
A
TIC
 REV
IEW
 - Q
U
A
LITY
 O
F LIFE IN
 PO
LY
C
Y
STIC
 K
ID
N
EY
 D
ISEA
SE
measure that composes of eight domains (physical functioning, role-physical, bodily 
pain, general health, social functioning, vitality, role-emotional, and mental health) that 
can be summarized in two composite scales; the physical component scale (PCS) and 
mental component scale (MCS).25 These summary scores can reduce type I errors by 
avoiding multiple testing and can distinguish better between different health state levels 
than the eight separate domains.26 A higher PCS or MCS score indicate a better QoL. 
Population-based reference values for both component scales are set to 50 points with 
a standard deviation of 10 points.27 We calculated component scores of the SF-36 using 
US norm values, as previous studies showed a similar impact of chronic diseases on QoL 
across different countries.28 
Data extraction 
M.N. extracted data of the included articles using a standardized data collection form 
to record (1) study characteristics: first author, year of publication, country of origin, 
study design and number of participants; (2) patient characteristics: age, gender, 
chronic kidney disease (CKD) stage as defined by KDIGO,29 mean renal function defined 
as (estimated) GFR in ml/min/1.73m2, median kidney and liver volume measured with 
volumetric software or ellipsoid formula (kidney volume only); (3) QoL data: baseline 
summary scores of patient-reported outcome instruments. For studies that presented only 
serum creatinine as measure of renal function, we calculated the eGFR with the chronic 
kidney disease epidemiology collaboration (CKD-EPI) formula and modification of diet in 
renal disease (MDRD) formula.30 Total liver and kidney volume was calculated by summing 
liver and kidney volumes. In RCTs, baseline QoL scores of both placebo and intervention 
groups of RCTs were pooled. QoL data of subgroups stratified by renal function was 
handled separately. Summary scores were recalculated when the original authors used 
a scoring algorithm which was different from the official published scoring manual. W.K. 
reviewed the complete dataset for completeness and accuracy.
Data analysis
To calculate the effect of ADPKD on QoL, we performed a pre-specified analysis using 
a random-effects meta-analytic model of DerSimonian and Laird.31 The random effect 
model is used if large heterogeneity is expected and adjusts for differences in study 
size. Heterogeneity was assessed using I2 statistics and a cut-off value of I2>50% was 
considered as substantial heterogeneity.32 When population-based reference values of 
included patient-reported outcomes were available, we compared whether the pooled 
mean scores of ADPKD patients were significantly different compared to the general 
population with an independent t-test. When the pooled mean of ADPKD patients was 
significantly lower than the general population, we compared these with age-corrected 
values to assess whether this difference remained significant. Additional sensitivity 
analyses including high quality studies only were performed to assess the influence of 
study quality.    
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To explore the effect of disease severity markers on QoL, we performed a pre-specified 
univariate meta-regression analysis in which the dependent variable was QoL score (PCS 
or MCS) and the independent variables were renal function, kidney volume, liver volume 
and total liver and kidney volume. As additional exploratory analysis, we performed 
the primary meta-regression excluding studies with severe liver involvement (defined as 
median liver volume >3000 mL, based on a previous published classification14). Kidney 
and liver volumes have a skewed distribution and were logarithmically transformed. If 
a study provided no standard deviation (SD), standard error (SE) or interquartile range 
[IQR] of the summary QoL score, we imputed SD from the mean SD of other included 
studies. As a sensitivity analysis, we compared the results of the meta-regression of eGFR 
calculated with the CKD-EPI with eGFR calculated with the MDRD formula. Analyses were 
performed using the statistical program OpenMetaAnalyst.33 For all analyses, P< 0.05 was 
considered statistically significant.
RESULTS
From a total of 373 unique articles identified by our systematic search, 11 studies matched 
our inclusion criteria.13,15,16,34-41 Figure 1 shows the PRISMA flow diagram with specified 
reasons for exclusion. There was excellent agreement between the two reviewers on 
study selection (Cohen’s Kappa 0.89). We found only two studies that investigated 
QoL in patients with ADPKD on dialysis (n=108 and n=5 respectively), which prevented 
a reliable meta-analysis in this subgroup.15,34 We contacted eight authors for additional 
information that was not published in the original articles and received relevant data from 
six of them.15,34-36,38,39 Four studies included a mixed population of patients with isolated 
polycystic liver disease (ADPLD) and polycystic liver disease as extrarenal manifestation 
of ADPKD.35,36,39,40 For all these studies, we obtained separate ADPKD group data by 
contacting the authors.
Eight studies used the SF-36 as patient-reported outcome and one study used the KDQOL-
SF1.3, a combined questionnaire of the SF-36 and 43 kidney disease-specific questions. 
The gastrointestinal symptom scale was administrated together with the SF-36 or EQ-5D 
in three studies.36,40,41 As there is no validated total score of the gastrointestinal symptoms 
scale and the EQ-5D was used in only two studies, this resulted in exclusion of two studies 
for meta-analysis.40,41 Other patient-reported outcomes administrated together with 
the SF-36 were used in less than three studies and were also excluded from further analyses 
(see Table 1). After applying these eligibility criteria, only studies that used SF-36 data 
were eligible for inclusion.
Characteristics and quality of included studies
Table 1 describes the characteristics of the nine studies included in meta-analysis.13,15,16,34-39 
The majority were longitudinal interventional studies (n=7), including three randomized 
controlled trials. The nine studies included 1623 non-dialysis patients. At least 753 
patients had CKD stage 1-2 and 478 CKD 3-4. There was insufficient individual patient 
data on the renal function of 250 patients to distinguish between CKD stage 1-4. One 
study (n=29) did not provide renal function of the included patients,37 resulting in 1594 
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available patients to assess the impact of renal function on QoL. Seven studies reported 
kidney volumes (n=1238) of the included patients.13,15,16,35-37,39 Five studies reported liver 
volume (n=1057),13,15,35,36,39 including four studies with severe polycystic liver disease 
patients (median liver volume >3000 mL).15,35,36,39 The SD of the PCS and MCS was 
imputed in four studies. Patients were on average 44 years and 45% was male. Pooled 
mean (e)GFR was 58 mL/min/1.73m2 (95% CI 47 to 69), kidney and liver volumes were 
respectively 1465 mL (95% CI 1146 to 1784) and 3599 mL (95% CI 3010 to 4187). This 
indicates enlargements of approximately 4 and 2.5 times compared to normal kidneys 
(300 mL for females and 400 mL for males) and livers (1400 mL for females, 1700 mL for 
males), respectively.
A detailed quality assessment of the studies is presented in Supplementary Table 3. 
There was a low risk of bias in the majority of the studies (n=8), only one study was rated 
as having a high risk of bias (insufficient information on study population selection and 
very low response rate). 
QoL in ADPKD
Figure 2 shows the results of the pooled SF-36 scores of the PCS (A) and MCS (B). 
The mean PCS of individuals with ADPKD was 45.7 points (95% CI 42.7 to 48.7), 
although there was significant heterogeneity (I2 95.4%, P<0.001). This was significantly 
different from the mean score of the general population (PCS 50 points, 95% CI 49.6 
to 50.4, P<0.001). On the MCS, patients scored 47.8 points (95% CI 45.7 to 49.8), with 
again large heterogeneity (I2 90.7%, P<0.001). Also this score was lower compared to 
Figure 1. PRISMA Flow-diagram of study inclusion
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the general population (PCS 50 points, 95% CI 49.6 to 50.4, P<0.05). Compared with 
age-corrected reference values (age 35-44 year; PCS 52.2, 95% CI 51.5 to 52.8 and 
MCS 49.9 points, 95% CI 49.1 to 50.7, both P<0.001), QoL of ADPKD patients remained 
significantly lower. Sensitivity analysis including high quality studies only showed no 
differences in pooled scores compared to the analyses including all studies. 
The relationship between markers of disease severity and QoL in 
APDKD patients
The relationship of the disease severity markers renal function, kidney volume, liver 
volume and total liver and kidney volume on PCS is shown in Figure 3. Larger liver volume 
negatively impacted PCS (ß= -10.7, 95% CI -16.4 to -5.0, P<0.001). We observed no 
significant effect of renal function (ß= 0.1, 95% CI -0.03 to 0.2, P=0.1), kidney volume 
(ß= 2.5, 95% CI -5.2 to 10.3, P=0.5) and total liver and kidney volume (ß= -10.2, 95% 
CI -22.3 to 1.8, P=0.10). On MCS, larger liver volume (ß= -4.7, 95% CI -7.5 to -1.8, 
P=0.001) and total liver and kidney volume (ß= -5.6, 95% CI -10.0 to -1.1, P=0.02) had 
significant impact, while renal function (ß= -0.005, 95% CI -0.08 to 0.07, P=0.9) and 
kidney volume (ß= -1.5, 95% CI -5.6 to 2.5, P=0. 5) did not (Supplementary Figure 1).
Figure 2. Pooled physical (A) and mental (B) component score of the SF-36 of individuals with ADPKD. 
ADPKD patients (black line) scored lower than the general population (grey line). 
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Figure 3. Meta-regression analysis of the physical component score of the SF-36 with the factors (A) 
(e)GFR (ml/min/1.73m2), (B) Kidney volume, (C) Liver volume and (D) Total liver and kidney volume. 
Volumes are presented on a logarithmic scale. 34Barros et al, 2011; 35Hogan et al, 2012; 36Keimpema et al, 
2009; 37Lee et al, 2003; 13aMiskulin et al, 2014 subgroup eGFR 20-44*; 13bMiskulin et al, 2014 subgroup 
eGFR 45-60; 13cMiskulin et al, 2014 subgroup eGFR ≥60; 16Rizk et al, 2009; 38aSimms et al, 2015 subgroup 
eGFR <30; 38bSimms et al, 2015 subgroup eGFR 30-60; 38cSimms et al, 2015 subgroup eGFR >60; 15Suwabe 
et al, 2013; 39Temmerman et al, 2014. *No kidney and liver imaging in this subgroup, not included in 
figures B-D. 
Figure 4. Meta-regression analysis of the physical component score of the SF-36 with the factors (A) 
eGFR (ml/min/1.73m2) and (B) Kidney volume after exclusion of studies with severe liver involvement. 
Volumes are presented on a logarithmic scale. 34Barros et al, 2011; 37Lee et al, 2003; 13aMiskulin et al, 2014 
subgroup eGFR 20-44*; 13bMiskulin et al, 2014 subgroup eGFR 45-60; 13cMiskulin et al, 2014 subgroup 
eGFR ≥60; 16Rizk et al, 2009; 38aSimms et al, 2015 subgroup eGFR <30; 38bSimms et al, 2015 subgroup 
eGFR 30-60; 38cSimms et al, 2015 subgroup eGFR >60. *No kidney and liver imaging in this subgroup, not 
included in figure B.
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Sensitivity analyses showed similar results using the MDRD formula to calculate renal 
function or when low quality studies were excluded. In studies with mild to moderate 
liver involvement (median liver volume ≤3000 mL), renal function did have a negative 
impact on PCS (ß= 0.1, 95% CI 0.05 to 0.2, P=0.02), but there was no effect of kidney 
volume (ß= -7.8, 95% CI 23.2 to 7.7, P=0.3; Figure 4). On the MCS, neither renal function 
(ß= -0.02, 95% CI -0.11 to 0.08, P=0.8) nor kidney volume (ß= -2.9, 95% CI -10.2 to 4.3, 
P=0.4) had impact (Supplementary Figure 2). 
DISCUSSION
We show that ADPKD negatively impacts QoL, particularly through the effect of the disease 
on parameters of the physical domain. Individuals with ADPKD had lower PCS and MCS 
compared to population-based reference values. We found large heterogeneity across 
QoL of individuals with ADPKD. In the primary meta-regression performed to explain this 
heterogeneity, larger liver volume, but not renal function and kidney volume, correlated 
with lower physical and mental components of health status in ADPKD. However, after 
exclusion of studies of patients with large liver volumes, lower renal function was also 
correlated with lower PCS. 
Large liver volume had a negative effect on QoL in ADPKD, indicating that liver volume 
is an important parameter that should be accounted for when investigating QoL in this 
population. However, the strong female predominance in severe polycystic liver disease 
studies (74 vs. 53%, P<0.001) and inclusion of slightly older patients (mean age 51 ± 10 
vs. 43 ± 12 year, P=0.24) in studies with mild to moderate liver involvement can also 
contribute to QoL impairment in these patients.27 Comparing general reference values 
of younger males (35 – 44 years) with older females (45 – 54 years), resulted in a mean 
difference of 4.5 and 0.2 points for PCS and MCS, respectively. The loss of QoL in the liver 
volume meta-regression analysis was larger than these differences (ß= -10.7 points per 
logarithm for PCS and ß= -4.7 for MCS), suggesting an independent additional effect of 
liver volume on QoL. 
Our exploratory analysis suggests that QoL declines during progression towards 
CKD stage 5 in patients without severe polycystic liver disease. This indicates that renal 
function is also an important factor of QoL in ADPKD, but this effect was negated by 
the strong impact of liver volume in the total group. An independent patient data analysis 
with correction for liver volume is necessary to draw definitive conclusions about the role 
of renal function and kidney volume on QoL. 
A previous study showed that patients with larger kidney volume reported more pain 
that impacted their daily life compared to patients with smaller kidneys.13 We did not find 
a significant impact of kidney volume on QoL, possibly because only a limited number 
of studies in our meta-analysis included patients with large kidney volumes. A large 
observational study including 450 ADPKD patients of CKD stages 1-4 (DIPAK) is currently 
being conducted in the Netherlands. This study may reveal whether large kidney volume 
contributes to a decrease in QoL.       
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A strength of this study is that we conducted this systematic review by rigorously 
following a published protocol with pre-specified analyses. Meta-regression including 
disease severity markers provides insight into the heterogeneous results of QoL found in 
earlier studies. 
Our study comes with a number of limitations. First, not all studies reported values of 
all disease severity markers, which limited the number of studies included in our meta-
regression analysis. Furthermore, not all potential modifiers of QoL in ADPKD could 
be included in this study. Earlier studies have shown that comorbidity, the use of pain 
medication, presence of a cerebral aneurysm, and lower education levels are associated 
with lower QoL in this population.16,38 Two qualitative studies showed that genetic guilt 
also might be an important factor that influences QoL.42,43 The lack of detail in the articles 
under study precluded systematic analysis of these factors. 
Secondly, part of heterogeneity in QoL might also be explained by study design. 
Most included studies were intervention studies. Patients involved in these studies do 
not resemble the general ADPKD patient population. QoL of patients participating in 
intervention studies was generally lower compared to patients from observational studies, 
likely due to the reality that most interventional studies have included patients with larger 
livers. However, the large variability in disease severity markers enabled us to thoroughly 
investigate the impact of these factors on QoL in individuals with ADPKD.
Third, we could include only QoL data collected with a generic PRO, which is likely less 
sensitive to detect disease burden than disease-specific measures.44 On the other hand, 
an unpublished global observational study of 3409 individuals with ADPKD showed that 
the PCS of the SF-12, a short version of the SF-36, could differentiate QoL between CKD 
1 and CKD 3a, while the disease-specific ADPKD Impact Scale could differentiate CKD 1 
from CKD stage 3b.45 This suggests that the PCS distinguishes between individuals with 
ADPKD in a slightly earlier phase than the disease-specific ADPKD Impact Scale. The MCS 
of the SF-12 was unable to differentiate between CKD 1 and other disease stages, 
indicating that this component score is insensitive to change in this disease population.    
This systematic review on QoL in ADPKD clearly identified knowledge gaps. Data on 
QoL in patients with ADPKD and more advanced stages of CKD were insufficient to be 
assessed. As liver volume appears to impact QoL, clinicians should check liver disease 
severity periodically and consider liver volume reducing therapies in severe hepatomegaly 
as a strategy to improve patients’ wellbeing. Indeed, research shows that reduction of 
liver volume with somatostatin analogues improves QoL in severe polycystic liver disease.46 
However, currently data is lacking on the effect of other therapies on QoL. In patients 
without severe polycystic liver disease, QoL was negatively impacted by renal function. 
Vasopressin V2 receptor antagonists slow renal function decline, but additional studies 
should investigate whether the possible positive effect on QoL is counteracted by side 
effects such as aquaresis.  
In conclusion, there is limited representative data available on the impact of disease 
severity markers on QoL in ADPKD. Existing data showed that QoL of non-dialysis ADPKD 
patients is impaired compared to the general population. Large liver volume was the most 
important factor that diminishes QoL.
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SUPPLEMENTARY MATERIALS
Supplementary Figure 1. Meta-regression analysis of the mental component score of the SF-36 with 
the factors (A) (e)GFR (ml/min/1.73m2) (B) Kidney volume in mL, (C) Liver volume in mL and (D) Total liver 
and kidney volume in mL. Volumes are presented on a logarithmic scale. 34Barros et al, 2011; 35Hogan 
et al, 2012; 36Keimpema et al, 2009; 37Lee et al, 2003; 13aMiskulin et al, 2014 subgroup eGFR 20-44*; 
13bMiskulin et al, 2014 subgroup eGFR 45-60; 13cMiskulin et al, 2014 subgroup eGFR ≥60; 16Rizk et al, 
2009; 38aSimms et al, 2015 subgroup eGFR <30; 38bSimms et al, 2015 subgroup eGFR 30-60; 38cSimms et al, 
2015 subgroup eGFR >60; 15Suwabe et al, 2013; 39Temmerman et al, 2014. *No kidney and liver imaging 
in this subgroup, not included in figures B-D.
Supplementary Figure 2. Meta-regression analysis of the mental component score of the SF-36 with 
the factors (A) (e)GFR (ml/min/1.73m2) and (B) Kidney volume in studies with mild to moderate liver 
involvement. Volumes are presented on a logarithmic scale. 34Barros et al, 2011; 37Lee et al, 2003; 
13aMiskulin et al, 2014 subgroup eGFR 20-44*; 13bMiskulin et al, 2014 subgroup eGFR 45-60; 13cMiskulin 
et al, 2014 subgroup eGFR ≥60; 16Rizk et al, 2009; 38aSimms et al, 2015 subgroup eGFR <30; 38bSimms et 
al, 2015 subgroup eGFR 30-60; 38cSimms et al, 2015 subgroup eGFR >60. *No kidney and liver imaging 
in this subgroup, not included in figure B.
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Supplementary Table 1. Prisma Checklist
Section/topic # Checklist item Reported on 
page #
Title
Title 1 Identify the report as a systematic review, meta-analysis, or both. #1
Abstract
Structured 
summary
2 Provide a structured summary including, as applicable:  
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.
#2
Introduction 3 Describe the rationale for the review in the context of what is 
already known. 
#4
Rationale 4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS). 
#4
Objectives 4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS). 
#5
Methods
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide registration 
information including registration number. 
#5
Eligibility 
criteria 
6 Specify study characteristics (e.g., PICOS, length of follow-up) and 
report characteristics (e.g., years considered, language, publication 
status) used as criteria for eligibility, giving rationale. 
#5
Information 
sources 
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional studies) 
in the search and date last searched. 
#6
Search 8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated. 
Supplementary 
Table 2
Study 
selection 
9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in 
the meta-analysis). 
#6
Data collection 
process 
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for  
obtaining and confirming data from investigators. 
#7
Data items 11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and simplifications 
made. 
#7
Risk of bias 
in individual 
studies 
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at 
the study or outcome level), and how this information is to be  
used in any data synthesis. 
#6
Summary 
measures 
13 State the principal summary measures (e.g., risk ratio, difference  
in means). 
#8
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Supplementary Table 1. (continued)
Section/topic # Checklist item
Reported on 
page #
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect 
the cumulative evidence (e.g., publication bias, selective reporting 
within studies). 
Not reported 
Additional 
analyses 
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
were pre-specified. 
#8
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram. 
#9 + Figure 1
Study 
characteristics 
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations. 
#9 + Table 1
Risk of bias 
within studies 
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12). 
#10 + 
Supplementary 
Table 3
Results of 
individual 
studies 
20 For all outcomes considered (benefits or harms), present, for each 
study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot. 
#10-11 + 
Figure 2
Synthesis of 
results 
21 Present results of each meta-analysis done, including confidence 
intervals and measures of consistency. 
#10-11+ 
Figure 2
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see 
Item 15). 
Not reported
Additional 
analysis 
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]). 
#11 + figure 
3-4 and 
Supplementary 
Figure 1 + 2
Discussion
Summary of 
evidence 
24 Summarize the main findings including the strength of evidence 
for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers). 
#12
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), 
and at review-level (e.g., incomplete retrieval of identified  
research, reporting bias). 
#13-14
Conclusions 26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research. 
#14
Funding
Funding 27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for  
the systematic review. 
#15
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Supplementary Table 2. Example of the search strategy (MEDLINE) 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946  
to Present
# Searches Results Search Type
1 exp kidney diseases, cystic/ 13464 Advanced
2 (((cystic or polycystic) adj3 (renal or kidney)) or pkd or pckd or adpkd).
mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier]
16952 Advanced
3 1 or 2 17577 Advanced
4 exp kidney diseases, cystic/ph, pp, ah or (2 and (pathophysiol* or 
physiopathol* or function* or volume* or dysfunction*).mp.) [mp=title, 
abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]
4516 Advanced
5 3 and (exp kidney function tests/ or exp kidney/ah, pp, ph) 1131 Advanced
6 4 or 5 4830 Advanced
7 (sf36 or “sf 36” or “short form 36”).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier]
18256 Advanced
8 quality of life/ or hrqol.mp. or “functional capacity”.mp. or adl.mp. 
or activities of daily living/ [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier]
184841 Advanced
9 (anxiety or depression or life expectancy or life style or social support or 
lifestyle).mp. or stress, psychological/ or distress*.mp. or fear*.mp. or 
family*.mp. or pain*.mp. or psychosocial*.mp. or discomfort*.mp. or 
symptom*.mp. or satiety.mp. or disability.mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier]
2730834 Advanced
10 (guilt or fatigue or sleep* or social life* or productiv* or intimacy or 
intimate).mp. or exp sexual dysfunctions, psychological/ or exp sexual 
dysfunction, physiological/ [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier]
339034 Advanced
11 6 and 7 7 Advanced
12 or/8-10 3047299 Advanced
13 6 and (12 or px.fs.) 924 Advanced
14 limit 11 to (clinical trial, all or clinical trial, phase i or clinical trial, phase 
ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or 
comparative study or controlled clinical trial or evaluation studies or meta 
analysis or multicenter study or observational study or pragmatic clinical 
trial or randomized controlled trial)
5 Advanced
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Supplementary Table 2. (continued)
# Searches Results Search Type
15 13 and (“cross section*”.mp. or follow-up studies/ or “health status”.
mp. or longitudinal*.mp.) [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier]
78 Advanced
16 13 and questionnaire*.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier]
23 Advanced
17 13 and (cohort* or prospective* or retrospective*).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]
132 Advanced
18 or/14-17 187 Advanced
19 remove duplicates from 18 177 Advanced
20 limit 19 to “all adult (19 plus years)” 119 Advanced
21 19 and (adult* or “middle age*” or “young adult*” or elder* or older).
mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier]
129 Advanced
22 20 or 21 129
Supplementary Table 3. Risk of bias assessment cross-sectional QoL studies 
Study level Outcome level Conclusion
Study 
population 
selection
Completeness 
of reported 
results
Used PRO 
instrument
Recall 
perioda  
Response 
rateb 
Barros  
et al, 2011
- - - - - Low
Hogan  
et al, 2010
- - - - - Low
Keimpema  
et al, 2009
- - - - - Low
Lee et al, 2003 + - - - + High
Miskulin  
et al, 2014
- - - - - Low
Rizk et al, 2009 - - - - - Low
Simms  
et at, 2015
- - - - - Low
Suwabe  
et al, 2013
- - - - - Low
Temmerman  
et al, 2014
- - - - - Low
Risk of bias summary of the included studies as judged by the authors. Definition of symbols: − low risk of bias; ? unclear 
risk of bias; + high risk of bias. aRecall period longer than 1 month was defined as high risk of bias.1 bResponse rate < 
80% or 60-80% and no non responders analysis was defined as high risk of bias.2
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CHAPTER 4
DEVELOPMENT AND VALIDATION OF  
A DISEASE-SPECIFIC QUESTIONNAIRE TO  
ASSESS PATIENT-REPORTED SYMPTOMS  
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ABSTRACT
Background and aim
Treatment of polycystic liver disease (PLD) focuses on symptom improvement. Generic 
questionnaires lack sensitivity to capture PLD-related symptoms, a prerequisite to 
determine effectiveness of therapy. 
Methods
We developed and validated a disease-specific questionnaire that assesses symptoms 
in PLD (PLD-Q). We identified 16 PLD-related symptoms (total score 0-100 points) by 
literature review and interviews with patients and clinicians. The developed PLD-Q was 
validated in Dutch (n=200) and US (n=203) PLD patients. We assessed the correlation of 
PLD-Q total score with EORTC symptom scale, global health visual analogue scale (VAS) 
of EQ-5D and liver volume. To test discriminative validity, we compared PLD-Q total scores 
of patients with different PLD-severity stages (Gigot classification), and PLD-Q total scores 
of PLD patients with general controls and polycystic kidney disease patients without PLD. 
Reproducibility was tested by comparing original test scores with two week retest scores. 
Results
In total, 167 Dutch and 124 US patients returned the questionnaire. Correlation between 
PLD-Q total score and EORTC symptom scale (NL r=0.788; US r=0.811) and global health 
VAS (NL r=-0.517; US r=-0.593) was good. There was no correlation of PLD-Q total score 
with liver volume (NL r=0.138, P=0.236; US r=0.254, P=0.052). Gigot type III individuals 
scored numerically higher than type II patients (NL 46 vs. 40, P=0.089; US 48 vs. 36, 
P=0.055). PLD patients scored higher on the PLD-Q total score than general controls 
(NL 42 vs. 17; US 40 vs. 13 points) and polycystic kidney disease patients without PLD 
(22 points). Reproducibility of PLD-Q was excellent (NL r=0.94 and US 0.96).
Conclusion
PLD-Q is a valid, reproducible and sensitive disease-specific questionnaire which can be 
used to assess PLD-related symptoms in clinical care and future research.
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INTRODUCTION
Polycystic liver disease (PLD) is a condition characterized by multiple liver cysts. PLD is 
associated with two inherited conditions: isolated in autosomal dominant polycystic liver 
disease (ADPLD) and as an extra renal manifestation in autosomal dominant polycystic 
kidney disease (ADPKD).1,2 In a proportion of patients, progressive disease leads to mass-
related symptoms such as early satiety and abdominal fullness, resulting in reduced quality 
of life.3,4 Treatment is indicated in symptomatic patients only.5 
Progress in development of new treatments for PLD is hampered by the perceived 
lack of a widely accepted outcome measure for effectiveness. Past studies investigating 
the effectiveness of current or new treatments have used liver volume as primary 
outcome.3,6-10 Liver volume is thought to be an objective surrogate marker that could 
reflect disease severity. However, the relationship between liver volume and disease 
burden is not straightforward, as it does not always empirically correlate with patient 
well-being.4,11 The ultimate goal of PLD treatment is symptom relief and improvement of 
quality of life.5
Several generic patient-reported outcomes are available to assess either quality of 
life or gastrointestinal symptoms, but they are not validated in PLD.12-18 These generic 
patient-reported outcomes do not capture the specific domains related to PLD such as 
increased abdominal girth or dyspnea.4,11,19,20 As a result, there is a substantial gap in 
the ability to detect clinically significant changes in PLD-related patient reported well-
being as a measure of treatment outcome. A questionnaire that assesses the wide range 
of problems experienced by PLD patients is more likely to be responsive to changes in 
patients’ wellbeing. 
The aim of this study was to develop and validate a PLD-specific questionnaire (PLD-Q) 
that captures patient-reported frequency and discomfort of PLD associated symptoms in 
a Dutch and US cohort of PLD patients in order to evaluate effectiveness of therapies. 
METHODS
We conducted a prospective study from May 2013 - April 2015 at the Department 
of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, 
the Netherlands (NL) and at the Department of Internal Medicine, Mayo Clinic, 
Rochester, Minnesota, United States (US) following the Food and Drug Administration 
(FDA) guidelines on patient-reported outcome measure development.21 This study was 
conducted in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. 
The protocol was approved by the Institutional Review Board of both centers and patients 
gave informed consent. We developed and validated the PLD-Q in three cycles, and 
each step led to further improvement of the questionnaire. Figure 1 shows a schematic 
overview of the development and validation process. 
Selection of PLD patients
We selected patients of 18 years and older with PLD defined as >20 liver cysts on 
ultrasound, magnetic resonance imaging or computed tomography that were evaluated 
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at the medical centers <10 years prior to inclusion.5 Exclusion criteria included a history 
of liver or kidney transplantation, dialysis dependency, and liver surgery within six months 
prior to inclusion. For our validation studies, we additionally excluded patients enrolled 
in investigational drug studies for PLD or ADPKD (somatostatin analogues or vasopressin 
V2 receptor antagonists).
22,23 We identified eligible Dutch patients from the PLD registry 
of Radboud University Medical Center. The Mayo Clinic Data Discovery and Query 
Builder was used to identify US PLD-patients with the search terms ‘polycystic liver’ or 
‘cystic liver’. 
Development of the PLD-Q
We started with building in appropriate questionnaire items relating to key issues for 
PLD patients (content validity).24 These PLD-specific symptoms were identified in three 
resources; extensive literature search and in depth interviews with Dutch PLD patients and 
Figure 1. Schematic overview of the development and validation process of the polycystic liver disease 
questionnaire (PLD-Q). The PLD-Q was developed and validated in the Netherlands. Subsequently, 
the PLD-Q was translated, culturally adapted, improved and validated in a US cohort of PLD patients. 
We assessed numerous characteristics of the PLD-Q including reliability, score distributions, convergent 
validity, reproducibility, and discriminative validity of the PLD-Q.
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clinicians. Interviews were continued until we reached saturation, which was defined as 
the point where no new items emerged. An established qualitative approach was used to 
create consensus on the most relevant items for the PLD-Q through survey series (the Delphi 
method,25 Supplementary File 1 and Supplementary Figure 1). The questionnaire was 
pretested in patients to test comprehensibility and changes were made based on their 
comments. The original Dutch version of the PLD-Q was translated into English using 
forward and backward translation including three individual translators for each step.26 
We adapted the translated PLD-Q cross-culturally and tested this version in a cohort 
of US PLD patients for inconsistencies after translation. Finally, we conducted cognitive 
debriefings, a patient focus group, and two clinician focus groups in the US for further 
improvement of the PLD-Q. The improved version of the PLD-Q was tested in a large 
cohort of US patients. 
The score of each patient-reported symptom included in the PLD-Q can be calculated 
by adding a frequency (Likert scale; 1=never, 6=always) and discomfort (Likert scale; 
1=not at all, 5= a lot) score of each symptom. Total scores were transformed into a score 
ranging from 0-100 points, where a higher score represents a higher symptom burden. 
The total PLD-Q score was calculated if ≤1 question score was missing. We chose a recall 
period of one month due to the chronic nature of PLD.27
Validation of the PLD-Q
Data collection 
A study package was mailed to eligible patients containing the developed PLD-Q, 
the symptom scale of the European Organization for Research and Treatment of Cancer 
(EORTC) and the global health visual analogue scale (VAS) of the EQ5D.20,28 The EORTC 
symptom scale is designed to assess general symptoms in cancer patients participating 
in clinical trials, while the global health VAS is a general measure for quality of life. 
A reminder was sent to non-responders four weeks after the initial questionnaire and 
patients were contacted by phone if they had not returned their questionnaire. 
Reliability
The PLD-Q was designed to measure a single domain which can be summed in a total 
score. We explored unidimensionality of the PLD-Q with exploratory factor analysis 
(varimax rotation). Unidimensionality was considered suitable when the first factor 
accounts for more than 20% of the total variability and the variance of the first factor 
was >4 times the variance of the other factors.29 Internal consistency of the questionnaire 
was calculated using Cronbach’s alpha and a value of 0.7 was set as the threshold for 
good internal consistency.30
Score distributions and missing results
To test if the PLD-Q discriminates between patients on the extreme ends of the scale 
we investigated score distributions and the proportion of patients who got the lowest 
and highest total score (floor and ceiling effects, respectively). We used a cutoff value of 
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≥15% to indicate low discrimination.30 We investigated missing values to assess whether 
patients understood and accepted the PLD-Q questions. Less than 10% missing values 
was considered acceptable for the total PLD-Q score and all individual questions.
Correlation PLD-Q scores with quality of life measures
We hypothesized that the PLD-Q total score is positively correlated with the EORTC 
symptom scale score and negatively correlated with the global health VAS (convergent 
validity). We calculated Spearman’s correlation coefficients (r) and a correlation coefficient 
of >0.4, P<0.05 was considered as evidence for convergent validity. 
Correlation PLD-Q scores with organ volumes
We also calculated Spearman’s correlation coefficients (r) between questionnaire scores 
and height-adjusted liver volumes in a subgroup of patients that underwent a CT or 
MRI within two years prior to study inclusion. Measurements of liver volumes were 
performed using stereology followed by semi-automated segmentation in the US 
and manual segmentation in the Netherlands, as published previously.31,32 As clinical 
presentation of symptoms is highly variable across patients with similar liver volumes, we 
expected a low correlation between the PLD-Q score and height-adjusted liver volume 
(r=0.2–0.4, P<0.05). 
Correlation PLD-Q scores with Gigot classification
Polycystic liver disease can be classified according to the Gigot classification.33 Patients 
with Gigot type I (<10 large cysts) were excluded in this study since the number of cysts of 
these patients does not meet the PLD definition (>20 cysts). Gigot type II classifies cases 
with diffuse involvement of liver parenchyma by multiple medium-sized cysts with large 
areas of noncystic liver parenchyma remaining. Gigot type III is defined by large numbers 
of small and medium-sized liver cysts spread diffusely through the liver parenchyma; 
only a few areas of normal parenchyma are present. Patients with recent imaging were 
classified according to the Gigot classification by two independent researchers that were 
blinded for the PLD-Q scores (NL: T.W. and M.N; US: M.E and T.K.) We expected that 
patients classified as Gigot type III score higher on the PLD-Q total score than patients 
with Gigot type II livers. This was tested using the independent t-test.
Reproducibility
To assess the similarity of answers after repeated measurements under consistent conditions 
(reproducibility), we performed a retest after two weeks in a random subgroup of patients 
(n=45 in NL and n=100 in the US). We calculated the intraclass correlation coefficient 
between scores obtained at the different time points. An intraclass correlation coefficient 
of >0.7 indicates good reproducibility.30 To detect systematic error in reproducibility, we 
plotted the differences between test and retest scores with the Bland-Altman method.34
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PLD-specificity of PLD-Q items
Finally, we assessed whether the included symptoms of the PLD-Q are liver specific by 
comparing PLD-Q total scores of patients with two different control groups; a generic 
control group and an ADPKD control group without PLD (discriminative validity). 
The ADPKD control group with large polycystic kidneys but without PLD was selected 
to discriminate between symptoms arising from large kidneys versus symptoms from 
hepatomegaly, since the majority of patients with PLD have also cystic kidneys. Controls 
from the generic population were matched on age and gender and were recruited at 
random public gatherings in the Netherlands. In the US, we mailed a study package to 
a cohort of generic controls (1:2) that visited the Mayo Clinic within the last year prior to 
inclusion. US controls were matched on age, gender, race and state using SAS© version 
9.3 (SAS Institute Inc., North Carolina, US). We selected the ADPKD control group from 
the ADPKD database at the Mayo Clinic. Inclusion criteria were height-adjusted kidney 
volume of >750 mL and height-adjusted liver volume of <1000 mL or < 20 liver cysts.11 
Exclusion criteria for controls were the similar to the exclusion criteria for patients. 
Patient and control characteristics were compared using the independent t-test. Scores 
of patients and both control groups were compared using the Mann-Whitney U test. 
Significance was defined as P<0.05 in all analyses.
RESULTS 
Development of the PLD-Q
Saturation of key issues for PLD patients was reached after interviewing 19 Dutch PLD 
patients and 6 clinicians (hepatologists n=4, nephrologists n=2). Supplementary Table 
1 shows characteristics of patients included in the interviews. In total, 36 PLD-related 
items were generated. After the Delphi survey, the 14 items ‘feeling full’, ‘bloating’, 
‘stomach tension’, ‘lack of appetite’, ‘early satiety’, ‘pressure or pain rib cage’, ‘pain in 
side’, ‘stomach pain’, ‘shortness of breath’, ‘limited mobility’, ‘tiredness’, ‘anxiety about 
the future’, ‘dissatisfaction size abdomen’, and ‘discomfort during intercourse’ were 
considered relevant to include in the PLD-Q (Supplementary Table 2). During the pretest of 
the developed PLD-Q, patients considered the item ‘nausea’ important and this item was 
therefore retained in the questionnaire. ‘Bloating’ and ‘stomach tension’ were considered 
redundant to ‘feeling full’ leading to rejection of these items.
After translation, the US PLD-Q pilot study (n=54) showed no large differences compared 
to the Dutch PLD-Q (Supplementary File 2 and Supplementary Figure 2). We conducted 
nine cognitive debriefings, and included six PLD patients in the patient focus group 
(Supplementary Table 1). In total, two clinician focus groups were conducted including 
hepatologists (n=2), nephrologists (n=4), a liver surgeon (n=1), and a transplant surgeon 
(n=1). Patients reported that the questionnaire was easy to understand and preferred 
the PLD-Q above general quality of life questionnaires to address their symptoms. Five 
questions were rephrased for easier understanding. US patients and clinicians felt that 
three questions were missing; acid reflux, back pain and, concern of liver growth. These 
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three questions were added to the 13 items of the Dutch PLD-Q. Supplementary Table 4 
shows changes between the translated PLD-Q used in the pilot study and the improved 
version of the PLD-Q after cognitive interviews and focus groups in the US. The final 
version of the PLD-Q is shown in Supplementary File 3. 
VALIDATION OF THE PLD-Q 
Characteristics of included patients and controls 
The Dutch PLD registry included 211 eligible patients for the validation study. Eleven 
patients were excluded after sending the questionnaire (death (n=1), renal replacement 
therapy or liver transplantation (n=7) and use of investigational drugs for PLD (n=3)). Of 
200 remaining patients, 167 patients returned the questionnaire (response rate 84%). 
In the US cohort, 216 eligible patients were identified. In this cohort, 13 patients were 
excluded after sending the questionnaires (death (n=2), renal replacement therapy or liver 
transplantation (n=5), use of investigational drugs for PLD (n=5) and recent liver surgery 
(n=1)). Of 203 remaining patients, 124 patients returned the questionnaire (response rate 
61%). Characteristics of the included patients are shown in Table 1. Age, gender and 
disease of responders and non-responders were comparable in both groups. 
For the general control group, we included 183 Dutch and 170 US controls with similar 
characteristics as the included PLD cohort. In the ADPKD control group, we identified 69 
ADPKD controls of whom nine patients were excluded after sending the questionnaire 
(renal replacement therapy (n=2), recent nephrectomy (n=1), investigational drugs (n=5) 
and no correct postal address (n=1)). Of the remaining 60 patients, 32 patients returned 
their questionnaire (response rate 53%). Table 1 shows the characteristics of the included 
control groups. ADPKD controls were younger than PLD patients (P=0.009) and more 
ADPKD controls were male (P<0.001). However, combined total liver kidney volume was 
not significantly different (P=0.215). 
Table 1. Characteristics of included patients and controls 
Dutch PLD 
patients
(n=167/200)
Dutch general 
controls 
(n=183/183)
US PLD  
patients
(n=124/203)
US general 
controls
(n=170/406)
US ADPKD 
controls 
(n=32/60)
Female (%) 84 79 86 88 47
Age (years) ± SD 56 ± 11 57 (20-90) 56 ± 15 59 ± 10 50 ± 13
ADPLD/ADPKD (%) 54/46 N/A 18/82 N/A 0/100 
Liver volume, mL [IQR] 2720  
[1625 - 3947]a
N/A 1649  
[1273 - 2629]a 
N/A 829  
[750 – 984]
Kidney volume, mL [IQR] 536  
[374 -1045]b
N/A 672  
[486 – 1395]b
N/A 1447  
[1093 – 1830]
Total liver kidney 
volume, mL [IQR]
3307  
[2408 - 4818]
N/A 2623  
[1924 - 3718]b
N/A 2337  
[1936 - 2666]
Data is presented as mean ± standard deviation for normally distributed variables and median [interquartile range] for 
non-normally distributed variables. Organ volumes are height corrected. aLiver volumes are measured in a subgroup of 
76 Dutch and 60 US PLD patients. bKidney and total liver kidney volumes are measured in ADPKD patients only (Dutch 
n=49, US n=52). N/A, not applicable.
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Reliability
Factor analysis showed that the variability of the PLD-Q was largely explained by the first 
factor (NL 47% and US 54% of the total variability), while the other factors contributed 
little to the variance (NL 11 and 8% and US 7%)(Supplementary Table 4), supporting 
a unidimensional structure of the PLD-Q. Internal consistency of the PLD-Q was excellent 
(Cronbachs alpha 0.796 and 0.840 respectively). 
Score distributions
Median total PLD-Q score was 42 [IQR 26 – 52] points in the Netherlands and 40 
[IQR 25 – 57] points in the US. Scores were normally distributed (mean 39 ± 18 and 
42 ± 21 respectively) and ranged from 0-88 points and 3-93 respectively. A score of 0 
points (floor effect) was found in two Dutch patients (1%) and in none of the US patients. 
No patients scored the maximum of 100 points (ceiling effect). Missing results of the total 
scores (NL 1% and US 4% respectively) and individual items (0-4%) were low, except 
for sexual intercourse in US patients (7%). However, none of the questions exceeded 
the predefined cut-off value of 10% missing results.
Correlation PLD-Q scores with quality of life measures
The PLD-Q total score showed a positive correlation with the symptom scale of 
the EORTC in both cohorts (NL 0.788 and US 0.811, P<0.001), indicating that patients 
with more PLD-associated symptoms on the PLD-Q had also a higher symptom burden 
on the EORTC symptom scale. The global health VAS showed a negative correlation 
with the PLD-Q total score (NL 0.517 and US 0.599, P<0.001). This shows that patients 
with a high symptom burden on the PLD-Q score have a low global health status. Both 
directions and magnitudes of the correlation coefficients were consistent with our 
predefined hypotheses. 
Correlation PLD-Q scores with organ volumes
We identified 76 Dutch patients and 60 US patients with recent imaging. PLD-Q total 
scores ranged from 3-74 points, (mean 43 ± 16) and 3 -93 points (mean 41 ± 23) 
respectively, comparable to the total validation group scores. There was no significant 
correlation between the PLD-Q total score and height-corrected liver volume (NL r=0.138, 
P=0.236 and US r=0.254, P=0.052). 
Correlation PLD-Q scores with Gigot classification
From the identified PLD patients with recent imaging, 78 patients (42 Dutch; 36 US) were 
classified as Gigot type II (median height-corrected liver volumes 1871 mL [IQR 1250 - 
2586] and 1387 mL [IQR 1211 - 1791] respectively), and 58 patients (34 Dutch; 24 US) 
as Gigot type III (median height-corrected liver volume 4073 [IQR 3009 - 5307] and 2657 
ml [IQR 1679 - 3473] respectively). Gigot type III individuals scored numerically higher on 
the PLD-Q total score compared to Gigot type II patients in both countries (respectively 
46 ± 16 vs. 40 ± 17 and 48 ± 25 vs. 36 ± 22), although these differences were not 
significantly different (P=0.089 and P=0.055).
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Reproducibility
Test-retest was performed in 40 patients that returned the retest in the Netherlands. 
Mean total score of the test in the Dutch cohort was 45 ± 16 and 44 ± 16 of the retest, 
showing excellent reproducibility (intraclass correlation coefficient 0.94 (95% CI 0.88 – 
0.97)). In the US, 94 patients returned the retest of which 6 could not be used as a result 
of missing values in test or retest. The mean difference between test and retest in this 
group was 2 points (95% CI 0 – 3), again resulting in excellent reproducibility (intraclass 
correlation coefficient 0.96 (95% CI 0.94 – 0.97)). Bland-Altman plots of the difference 
between test and retest showed equal spread above and beneath the mean difference 
indicating the lack of a systematic bias (see Figure 2). 
Figure 2. Bland-Altman plots show no systematic error between test and retest in the Dutch (left panel) 
and US (right panel) cohorts. The actual differences between test and retest are equally spread above and 
beneath the average difference of test-retest. The dotted lines reflect the 95% limits of agreement.
PLD-specificity of PLD-Q items
PLD patients scored significantly higher compared to the general controls on the PLD-Q 
total score (NL 42 points [IQR 26 – 52] vs. 17 points [IQR 12 – 26], P<0.001 and US 
40 points [IQR 26 – 57] vs. 13 points [IQR 7 – 22], P<0.001 (see Figure 3)) and all 
individual items in both cohorts. Compared to the ADPKD controls (without PLD), US 
PLD patients scored higher on the total score (40 points [IQR 26 – 57] vs. 22 points 
[IQR 12 – 33], P<0.001) and all individual questions except for back pain (P=0.173). ADPKD 
controls scored higher than US general controls (22 points, [IQR 12 – 33] vs. 13 points 
[IQR 7 – 22]; P=0.006).
DISCUSSION
The PLD-Q is the first prospectively designed disease-specific questionnaire for patients with 
PLD developed with input from patients, clinicians and experts in quality of life research. 
This study provides evidence of content validity, reliability, good score distributions, 
convergent validity, reproducibility and discriminative validity of the PLD-Q in a Dutch and 
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US cohort. We show that the PLD-Q is able to identify PLD-specific symptoms and that 
these symptoms correlate with quality of life. The PLD-Q was easy to understand which 
undoubtedly contributed to high completion rates and a small proportion of missing data. 
Parallel with development and validation of the PLD-Q, a Belgian group developed 
a ‘polycystic liver disease complaint-specific assessment’ (POLCA) tool, emphasizing 
the need of a better patient-reported outcome in PLD.35 Six highly educated panel members 
designed the POLCA in Dutch by analyzing literature and medical records. POLCA was 
validated in 61 PLD patients included in a clinical trial. Compared with PLD-Q, POLCA 
does not include the items dyspnea, pain or pressure in the ribcage, limited mobility, fear 
or anxiety for the future, and discomfort with intercourse, while our data suggest that 
these symptoms impact PLD burden. These differences might be explained by the lack of 
patient involvement in the development of POLCA, which limits content validity.24,36 It is 
unclear whether absence of pretesting in patients has led to reduced comprehensibility 
of the POLCA, as the proportion of missing data is not provided. Finally, reproducibility of 
the POLCA was not tested. Therefore clinically important change in POLCA scores cannot 
be distinguished from measurement error.30
The PLD-Q showed no significant correlation with liver volume in the subgroup of 
patients that had recent imaging. Although we expected that patients with larger liver 
volumes had more symptoms measured with a disease-specific measure, this finding is 
consistent with earlier studies. A recent study that used the SF-36, a generic quality of life 
measure, showed no correlation with liver volume in severe PLD patients.4 The same applies 
for the disease-specific POLCA, as no correlation between POLCA scores and liver volume 
was detected. Only one large study of ADPKD patients with early chronic kidney disease 
Figure 3. Total PLD-Q scores of PLD patients, ADPKD controls and general controls in the Dutch and 
US cohorts. PLD patients scored significantly higher than ADPKD controls and general controls. ADPKD 
controls scored higher than US general controls. 
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not selected for PLD severity (n=558) demonstrated a weak correlation between physical 
component scores of the SF-36 and liver volume.11 Symptom presentation depends on 
different personal factors including body habitus, culture and coping strategies,37,38 and it 
might be possible that PLD-Q scores do not correlate with liver volume in the total group, 
but correlate with individual changes in liver volume over time. Symptoms may also 
correlate with cyst growth rate rather than total volume. Further validation of the PLD-Q 
in longitudinal studies will be needed to test these hypotheses.
PLD patients scored higher on all items included in the PLD-Q compared to controls, 
with the exception of the item back pain. ADPKD controls reported back pain scores 
similar to our PLD cohort. Indeed, back pain is a frequent symptom reported in a previous 
study that included ADPKD patients with smaller liver volumes, suggesting that the item 
is not liver specific.39 However, we show here that PLD does contribute to back pain, 
a reason to retain back pain as an item in the PLD-Q. 
A strength of this study is the rigorous development and validation of the PLD-Q 
conform proposed quality criteria.30 We included patients in all aspects of the development 
process, as patient-derived measurements are shown to be more valuable than tools 
derived from non-patient populations such as experts only.40 We included patients 
with mild to severe disease and their scores ranged to almost all possible scores of 
the scale, indicating that this scale provides relevant information for patients in different 
severity stages. We also confirmed the results from the Dutch cohort in a native English 
speaking cohort after thorough translation and cultural adaptation. Testing the PLD-Q in 
a geographically and demographically diverse population improves the generalizability of 
the results. In a rare disease such as PLD, international collaborations will help accelerate 
progress towards treatment. Finally, inclusion of two different control groups has led 
to a better interpretation of PLD-Q scores since patient scores can be compared with 
reference values.
A limitation of this study is that we have not shown responsiveness, the degree to 
which a measure can detect clinically important change over time, of the PLD-Q.30 Obvious 
changes in PLD symptoms are expected after liver resection or liver transplantation, as 
the effect of somatostatin analogues on liver volume is relatively small.41 We are currently 
testing the responsiveness of the PLD-Q in a prospective study of patients subjected to liver 
resection. The first four patients that have completed the PLD-Q prior to and six month 
after the procedure showed large improvements in scores, suggesting responsiveness of 
the PLD-Q, but additional data are needed to bolster these results. The fact that the PLD-Q 
can differentiate between patients with different Gigot stages of PLD and control groups 
provides additional preliminary evidence for responsiveness of the PLD-Q, as virtually all 
patient-reported outcomes that can differentiate among clinically distinct groups are 
found to be responsive to change.42 
The one month recall time frame of the PLD-Q may be less sensitive to symptoms of 
cystic complications such as cyst hemorrhages, ruptures and infections that may influence 
quality of life. However, interviews and cognitive debriefings confirmed a 4-week recall 
period as suitable period in our patient population. In addition, a large case series of 137 
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PLD cases showed an incidence of 20 cyst hemorrhages, 12 cyst infections and 6 cyst 
ruptures during a mean follow up period of more than 8 years, indicating that episodes 
of acute pain are rare.43 
In the vast majority of PLD patients, the indication of treatment is based on symptoms.44 
The PLD-Q provides a new tool that is likely to be more sensitive to small but important 
differences in the health status of patients after treatment interventions. The PLD-Q can 
be considered as patient-reported outcome in clinical trials to support future claims to 
approve medical treatment.19 Apart from research purposes, the PLD-Q might be useful 
in clinical evaluation of PLD. Periodic monitoring of symptoms in PLD patients can guide, 
start or stop decisions in medical treatment or may determine timing of surgery or liver 
transplantation. It would be interesting to evaluate the ability of the PLD-Q to distinguish 
between fast and slow progressors in a population with progressive disease. This requires 
a rigorous prospective design with long-term follow up and this type of data is not 
available yet.
We advise to administer the PLD-Q in combination with a generic quality of life 
questionnaire to provide a complete health status assessment in PLD patients. When 
adding a generic questionnaire, it is preferably to choose a tool that has been validated 
previously in the target population. Furthermore, short questionnaires are better to curtail 
patient burden.
To conclude, we have developed and validated a robust disease-specific questionnaire 
for polycystic liver disease (PLD-Q) that reflects symptom burden and its impact on patient 
well-being in a Dutch and US patient cohort. We recommend the PLD-Q as a patient-
reported outcome to assess PLD-related symptoms in clinical care and future research.    
POTENTIAL USERS OF THE PLD-Q 
The authors reserve copyright for the PLD-Q questionnaire and encourage potential users 
to contact the authors. No charges or restrictions are placed on using the PLD-Q for 
non-commercial purposes. 
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SUPPLEMENTARY MATERIALS
Supplementary Table 1. Characteristics of included patients and clinicians in the development phases of 
the PLD-Q
Dutch patients 
(n=19)
US patients cognitive 
interviews (n=9)
US patients focus group 
(n=6)
Female, n (%) 18 (94) 9 (100) 6 (100)
Age (years) ± SD 53 ± 7 56 ± 6 47 ± 6
ADPLD/ADPKD, n (%) 11/8 (58/42) 3/9 (33/67) 0/6
Liver volume, mL (IQR) 3884 (2713-5967) 2055 (1478 - 3441) 2432 (1671 - 3659)
Kidney volume, mL (IQR) a 318 (274 - 393) 535 (374 - 820) 358 (242 - 805)
Data is presented as mean ± standard deviation for normally distributed variables and median (interquartile range) 
for non-normally distributed variables. Organ volumes are height corrected. aKidney volumes are measured in ADPKD 
patients only.
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Supplementary Table 3. Changes PLD-Q pilot version after cognitive debriefings and patient and clinicians 
focus groups 
Item Pilot version PLD-Q Improved PLD-Q Comment
Fullness How often did you feel 
full?
How often did you 
experience fullness in 
your abdomen related to 
your polycystic liver?
Added ‘related to your 
polycystic liver’ to 
distinguish between 
fullness after a meal 
and fullness because of 
a polycystic liver 
Early satiety How often were you 
quickly satiated, or did you 
eat a smaller portion as 
a result of being quickly 
satiated?
How often have you felt 
full up too quickly after 
beginning to eat? 
Not all patients understood 
the word satiated. 
Acid reflux - How often did you have 
acid reflux?
Patients and clinicians 
agreed item was missing
Abdominal pain How often did you have 
stomach pain?
How often did you have 
abdominal pain?
Stomach pain was 
considered as only 
the region of the stomach 
by patients and clinicians, 
not the whole abdomen. 
Back pain - How often did you have 
back pain? 
Patients and clinicians 
agreed item was missing 
Shortness of breath How often were you short 
of breath after physical 
exertion?
How often were you 
short of breath after 
physical exertion (for 
example climbing 
the stairs)?
Added example to improve 
understanding
Concern of liver 
growth
- How often were you 
concerned that your 
abdomen is getting 
larger?
Patients and clinicians 
agreed item was missing
Discomfort 
intercourse
‘No sexual intercourse’ 
option
- Removed ‘no sexual 
intercourse’ option as it 
leads to confusion and 
problems with data analysis
Discomfort 
intercourse
How often did you 
have a problem with 
intercourse?
How often did 
your polycystic liver 
disease cause you to 
have a problem with 
intercourse?
In old question patients 
were unable to address 
their problem. Some 
patients did not have 
intercourse because of their 
polycystic liver. 
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Supplementary Table 4. Result factor analysis 
Item
Dutch cohort US cohort
Factor 1 Factor 2 Factor 3 Factor 1 Factor 2
Q1. Feeling full 0.793 0.331 0.140 0.803 0.172
Q2. Lack of appetite 0.755 0.425 -0.034 0.775 -0.264
Q3. Early satiety 0.763 0.330 0.049 0.796 0.065
Q4. Acid Reflux N/A N/A N/A 0.530 -0.054
Q5. Nausea 0.432 0.581 -0.026 0.762 -0.269
Q6. Pressure or pain rib cage 0.755 0.030 -0.099 0.763 -0.249
Q7. Pain in side 0.665 -0.028 -0.456 0.741 -0.373
Q8. Abdominal pain 0.651 0.298 0.274 0.771 -0.373
Q9. Back pain N/A N/A N/A 0.618 -0.024
Q10. Shortness of breath 0.675 -0.305 -0.319 0.725 0.040
Q11. Limited mobility 0.820 -0.350 -0.151 0.771 0.016
Q12. Tiredness 0.665 -0.226 -0.369 0.782 0.011
Q13. Anxiety about the future 0.532 -0.371 0.438 0.651 0.316
Q14. Concern abdomen getting larger N/A N/A N/A 0.769 0.433
Q15. Dissatisfaction size abdomen 0.702 -0.230 0.429 0.759 0.479
Q16. Intercourse discomfort 0.636 -0.443 0.217 0.635 0.104
Eigenvalues 6.154 1.480 1.000 8.572 1.048
% of variance 47 11 8 54 7
To determine a factor, the eigenvalue has to exceed 1. The factor analysis shows that the variability is largely explained 
by the first factor, suggesting unidimensionality of the questionnaire. N/A; not applicable.
SUPPLEMENTARY FILE 1. METHODS AND RESULTS DELPHI 
SURVEY FOR ITEM SELECTION OF THE PLD-Q
Conducting the Delphi survey for item selection
The Delphi survey consisted of a two-round survey in a panel of 15 clinicians using 
a web-based questionnaire. The questionnaire was designed to assess which of 
the generated items were considered as relevant for a PLD-specific questionnaire sensitive 
to detect changes in the occurrence of PLD associated symptoms. Each item was scored 
on an end-anchored rating scale of 1-9, were 1=not relevant and 9=highly relevant. 
Experts completed the questionnaires anonymously to prevent them from influencing 
each other’s answers. The facilitator provides summarized answers after each round 
and the experts are asked to reconsider their answer in view of the general opinion. 
The second round contained only items were no consensus was reached in the first round. 
See Supplementary Figure 1 for a systematic overview of the Delphi Survey. 
Item selection
After the first round we calculated the median ratings of each item and we considered 
ratings of 1-3 as no or very low relevance, 4-6 as medium relevance, and 7-9 as high 
relevance for the questionnaire. Five levels of consensus were established: unanimous 
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SUPPLEMENTARY FILE 2. RESULTS OF THE PILOT VERSION OF  
THE ENGLISH PLD-Q IN A US COHORT
We identified 216 US patients that fitted our inclusion criteria. Of them, 54 patients were 
selected based on matching age and gender of the Dutch cohort. In total, 34 patients 
(91% female, 35% ADPLD) with a mean age of 57 years returned their questionnaire 
(response rate 63%). Mean score in the US cohort was 45 ± 20 points (range 9-91). No 
total score could be calculated in 2 patients due to missing results. Missing results of 
the individual questionnaires ranged between 0 and 2.9%. There were no floor (0%) or 
ceiling effects (0%). The PLD-Q total score showed a positive correlation to the symptom 
scale of the EORTC QLQ-C30 of r=0.835, P=0.002 and a negative correlation to the global 
health status of the EQ-5D of 0.544, P=0.002. Score distributions were similar across 
the Dutch and US population, see Supplementary Figure 2. 
Supplementary Figure 1. Flowchart Delphi survey for item selection. Consensus rated as percentage of 
experts which rated in one of the three ranges (1-3, 4-6 or 7-9*) of the questionnaire; Unanimous: 100%, 
Strong consensus: <100% and ≥80%, Moderate = <80 and ≥70, Weak consensus =< 70 and ≥60, No 
consensus <60%. Range 1-3 is considered as not relevant, 4-6 as neutral and 7-9 as relevant. Moderate1; 
after first Delphi round, moderate2; after second Delphi round
(100% of the clinicians have ratings in one of the three ranges 1-3, 4-6 or 7-9), strong 
(80- 99%); moderate (70-79%); weak consensus (60 – 69%) and no consensus (<60%). 
After the second round, we considered 80-100 % agreement as consensus. We selected 
items for the questionnaire if they were rated as relevant (mean score 7-9) and consensus 
was reached. Supplementary Figure 1 shows an overview of the item selection process. 
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Supplementary Figure 2. Score distributions of the Dutch PLD-Q and the pilot version of 
the English PLD-Q. 
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SUPPLEMENTARY FILE 3. FINAL VERSION OF THE POLYCYSTIC 
LIVER DISEASE QUESTIONNAIRE (PLD-Q)
Instructions: this questionnaire consists of 16 questions. The questions relate to the past 
month. Please try to answer all the questions. For each question mark one box, see 
the example below:
Never Seldom Sometimes Regularly Often Always
     
1a. How often did you experience fullness in your abdomen related to your 
polycystic liver? 
Never Seldom Sometimes Regularly Often Always
     
1b. How much did this bother you? 
Not at all A little Somewhat Quite a bit A lot
    
2a. How often did you experience lack of appetite? 
2b. How much did this bother you? 
3a. How often have you felt full quickly after beginning to eat? 
3b. How much did this bother you? 
4a. How often did you have acid reflux?
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
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4b. How much did this bother you? 
5a. How often did you experience nausea? 
5b. How much did this bother you? 
6a. How often did you feel pain or pressure in your rib cage? 
6b. How much did this bother you? 
7a. How often did you have pain in your side?
7b. How much did this bother you? 
8a. How often did you have abdominal pain?
8b. How much did this bother you? 
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
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9a. How often did you have back pain? 
9b. How much did this bother you? 
10a. How often were you short of breath after physical exertion (for example climbing 
the stairs)? 
10b. How much did this bother you? 
11a. How often were you limited in your mobility? 
11b. How much did this bother you? 
12a. How often were you tired? 
12b. How much did this bother you?
13a. How often were you fearful or anxious when you thought about the future?
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
13b. How much did this bother you?
14a. How often were you concerned that the size of your abdomen is 
getting larger? 
14b. How much did this bother you?
15a. How often were you dissatisfied by the size of your abdomen?
15b. How much did this bother you?
16a. How often did your polycystic liver disease cause you to have a problem 
with intercourse?
16b. How much did this bother you?
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    

UEG journal [Epub ahead of print]
CHAPTER 5
IMPACT OF LIVER VOLUME ON POLYCYSTIC 
LIVER DISEASE-RELATED SYMPTOMS AND 
QUALITY OF LIFE
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ABSTRACT
Background and aim
Symptoms in polycystic liver disease (PLD) are thought to be caused by compression of 
organs and structures by the enlarged liver. We aimed to assess the impact of liver volume 
on symptoms and quality of life (QoL) in PLD.
Methods
We included PLD patients from two prospective studies that used the PLD-questionnaire 
(PLD-Q) for symptom assessment. QoL was assessed through SF-36, summarized in 
a physical (PCS) and mental (MCS) component score. Liver volume was correlated with 
PLD-Q total scores. Patients were classified based on height-corrected liver volume in mild 
(<1600 mL), moderate (1600-3200 mL), and severe (>3200 mL) disease. PLD-Q and QoL 
(PCS and MCS) scores were compared across disease stages. 
Results
We included 82 of 131 patients from the original studies (disease stages; mild n=26, 
moderate n=33, and severe n=23). Patients with larger liver volume reported higher 
symptom burden (r=0.516, P<0.001). Symptom scores increased with disease progression, 
except for abdominal pain (P=0.088). PCS decreased with advancing disease (P<0.001), 
in contrast to MCS (P=0.055). Moderate (P=0.007) and severe (P<0.001) PLD patients had 
lower PCS scores than the general population.  
Conclusion
PLD with larger liver volume is more likely to be symptomatic and is associated with 
lower QoL. 
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INTRODUCTION
Polycystic liver disease (PLD) is characterized by formation of multiple cysts that causes 
progressive liver enlargement.1 It occurs isolated in autosomal dominant polycystic liver 
disease (ADPLD) and in coexistence of kidney cysts in autosomal dominant polycystic 
kidney disease (ADPKD).1,2 As liver function impairment is absent in PLD, the contention is 
that PLD-related symptoms are caused by compression of adjacent organs and structures 
by the enlarged cystic liver.
Improving insight in mechanisms underlying the development of PLD-related 
symptoms is paramount to optimize treatment strategies, as indications for therapy in 
PLD are almost completely driven by symptoms. Knowledge on symptom patterns and 
quality of life (QoL) in different disease stages informs patients about the natural course 
of the disease.
A recent Korean study reported more abdominal symptoms in PLD patients with larger 
liver volumes. However, it is unknown whether these results can be translated to a Western 
population as anthropometric properties of Asians are different and culture can influence 
symptom presentation.3,4 Furthermore, this study used a general gastrointestinal symptom 
rating scale instead of a validated PLD questionnaire,5 which lacks PLD-related problems 
such as fear and anxiety about the future, limited mobility, tiredness and problems with 
intercourse.6 A complete assessment of PLD-related symptoms is important to fully 
comprehend the impact of liver volume on PLD. Finally, the impact of liver volume on QoL 
in different disease stages remains to be elucidated.  
In this analysis we investigated the impact of liver volume on PLD-related symptoms 
and QoL in a Western PLD population using data from two prospective studies that 
reflects different PLD disease stages. 
METHODS
Study design
We pooled baseline data from two prospective studies that used the polycystic liver disease 
questionnaire (PLD-Q) to assess symptoms in PLD; (1) DIPAK Observational Study and (2) 
the CURSOR study. The DIPAK Observational study is a multi center, longitudinal study 
to investigate disease progression in ADPKD. We included patients that were enrolled 
in Radboud University Medical Center, Nijmegen, the Netherlands before March 2016. 
CURSOR is an international, multicenter, randomized controlled clinical trial that assesses 
the efficacy of ursodeoxycholic acid as volume reducing treatment in symptomatic PLD.7 
Patients were enrolled from May 2014 through February 2015 in Radboud University 
Medical Center, Nijmegen, the Netherlands, Academic Medical Center, Amsterdam, 
the Netherlands, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain. 
Original studies were approved by local institutional review boards and were conducted 
according to the ethical guidelines of the 1975 declaration of Helsinki. In case a patient 
participated in both studies, we used the most recent data. 
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Patients
Adult PLD patients who completed the PLD-Q and imaging (CT in CURSOR and MRI in 
DIPAK patients) at baseline were eligible for this analysis. PLD was defined as ≥20 hepatic 
cysts on MRI or CT, which was judged independently by two investigators (M.N. and 
S.V.). Patients were categorized by a previously published disease classification for PLD.5 
Mild disease was defined as <1600 mL height-corrected liver volume (htLV), moderate as 
1600-3200 mL and >3200 mL as severe disease. We excluded patients with abdominal 
surgery six months prior to baseline and patients with more than one month between 
scan and PLD-Q to limit bias in the relation between symptoms and liver volume. 
Polycystic liver disease questionnaire 
Patients completed the PLD-Q (version 1) to assess frequency and discomfort of PLD-
associated symptoms.6 The PLD-Q is an extensively validated patient-reported outcome 
measure including thirteen disease-specific symptoms. Each individual symptom is 
assessed with a frequency (six-point Likert scale ‘never’ to ‘always’) and discomfort 
(5-point Likert scale ‘not at all’ to ‘a lot’) question. Severity scores of individual symptoms 
are the sum of the frequency and discomfort score (range 2-11). A severity score of 2-3 
can be considered as no symptoms, 4-5 as mild, 6-7 as moderate, 8-9 as moderately-
severe and 10-11 as severe symptoms. The PLD-Q total score is the sum of all severity 
scores and was transformed to a score of 0-100, where a higher score represents a higher 
symptom burden. Total scores were missing when ≥2 severity scores were missing.  
Quality of life 
Quality of Life (QoL) was assessed with the Short-Form 36 (SF-36), a generic questionnaire 
that contains 36 questions which can be summarized in a physical (PCS) and mental 
(MCS) component scale.8 The scores of the PCS and MCS range from 8-73 and 10-74 
respectively, whereas lower scores represent a lower QoL. Scores and missing data of 
the SF-36 were handled according to the user’s manual.8 
Liver volumes
Liver and kidney volumes were measured with a segmentation technique, which involves 
manual tracing of the liver boundaries. A software program interpolates between CT or MRI 
slices and calculates the areas within the indicated circumference. For liver segmentation 
we included liver parenchyma and cysts, the gallbladder, vessels surrounded by liver 
parenchyma and vessels that are part of the liver hilum. Kidney segmentation included 
kidney tissue, kidney cysts, pyelum and main kidney vessels when fully surrounded 
by kidney tissue. Excluded were pyelum and kidney vessels when not surrounded by 
kidney tissue. 
For CT scans we used Pinnacle3® volumetric software version 9.10 (Philips Radiation 
Oncology Systems; Fitchburg, WI, US), which is validated previously for PLD.9-11 MRI 
scans were measured with ITK-SNAP version 3.4.0 (Penn Image Computing and Science 
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Laboratory, Philadelphia, PA, US and Scientific Computing and Imaging Institute, Salt 
Lake City, UT, US). We validated ITK-SNAP to measure liver volumes in PLD for this study 
(Supplementary File) and found a mean difference in liver volume of 1.8% ± 1.1 between 
ITK-SNAP measurements and Pinnacle3®. Variability between ITK-SNAP measurements 
of two independent investigators was -0.4% ± 1.4. These differences were considered 
acceptable for the purpose of our study. 
Statistical analysis
Patient characteristics are presented across disease stages as median with interquartile 
range [IQR] or as proportion of total and compared with Kruskall-Wallis test or chi-squared 
test. Liver (htLV) and kidney (htKV) volumes were height-corrected and log transformed 
to get normally distributed variables for further analysis. Correlation between htLV and 
PLD-Q total score was calculated with Spearman’s correlation coefficient. As the CURSOR 
study included symptomatic patients with larger liver volumes, we performed a sensitivity 
analysis in DIPAK patients to assess whether selection bias has confounded this correlation. 
Subsequently, we assessed whether the relation between htLV and symptoms remained 
significantly after adjustment for possible confounders with a multivariate analysis. We 
entered the PLD-Q total score as independent variable and htLV, age, gender, diagnosis 
and original study (CURSOR or DIPAK) as dependent variables. In the subgroup of ADPKD 
patients, we also entered htKV and renal function (estimated glomerular filtration rate 
using the Modification of Diet in Renal Disease) in the multivariate model. 
To assess whether individual symptoms and QoL (PCS and MCS) were distributed 
differently across disease stages, scores were compared with Kruskall-Wallis test. A one-
sample Wilcoxon rank test was performed to determine whether QoL scores (PCS and 
MCS) were different from general population norm scores. As PLD occurs predominantly 
in females, we used female reference norm scores (51.03 [41.10 – 55.86] and MCS: 
52.80 [43.40 – 57.19]).8 Significant differences were compared with age matched female 
reference values to assess whether the difference holds true.8 Statistical analyses were 
performed in SPSS version 22.0 (IBM Corp., Armonk, NY, US). The significance level was 
set to a P-value<0.05.
RESULTS
Patient characteristics 
From the 131 patients included in the original studies, 82 patients were eligible for 
this study. Figure 1 depicts reasons for exclusion. Table 1 shows patient characteristics 
categorized by disease stage. We included 26 mild PLD patients, 33 patients with 
moderate disease, and 23 patients had severe PLD. Median age, gender, and underlying 
diagnosis (ADPKD or ADPLD) were not significantly different across the disease stages. 
In the ADPKD subgroup, also no differences between renal function and kidney volume 
were found. 
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Figure 1. Flowchart shows reasons for exclusion from original studies. Of the 131 patients assessed for 
eligibility, 82 were included in the study. 
Table 1. Characteristics of included patients categorized by disease stage
Mild 
<1600 mL 
(n=26)
Moderate 
1600-3200 mL 
(n=33)
Severe >3200 mL
(n=23)
P-value
Age, median [IQR], years 48 [33 – 57] 49 [46 – 57] 43 [40 – 56] 0.232b
Female, n (%) 18 (69) 28 (85) 21 (91) 0.14c 
Diagnosis ADPKD, n (%) 24 (92) 24 (73) 17 (52) 0.139c
HtLV (mL/m), median [IQR] 1087 [924 – 1306] 2375 [1941 –2754] 4571 [3868 – 5411] 0.002b
HtKV (mL/m), median [IQR]a 801 [374 – 1191] 836 [361 – 1275] 614 [380 – 1480] 0.258b
Renal function (eGFR), 
median [IQR]a
73 [44 – 86] 64 [46 – 77] 71 [54 – 84] 0.177b
aKidney volumes and renal function of ADPKD patients only. P-values tested with bKruskal-Wallis test or cChi-Square test. 
Abbreviations: eGFR, estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula, htKV, 
height corrected kidney volume, htLV, height corrected liver volume. 
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Symptom distribution
PLD-Q total score could be calculated in all patients. Figure 2 shows the distribution of 
symptoms in the total study population. The majority had at least mild symptoms of 
tiredness (81.7%), fullness (78.0%), dissatisfaction abdomen size (72.8%) and limited 
mobility (72%). Only 36.6% experienced lack of appetite (mild or higher severity). 
The most burdensome symptom, scored as moderately-severe or severe was dissatisfaction 
abdomen size (40.8%), followed by pain and pressure in the rib cage (32.1%), tiredness 
(29.2%), fullness (28.0%) and limited mobility (26.8%). None of the patients experienced 
severe nausea or abdominal pain. 
Figure 2. Severity of individual symptoms (%) as scored on the polycystic liver disease questionnaire 
(PLD-Q) in the total study population. Scores are ranging from 2 to 11, whereas higher scores correspond 
with more severe symptoms (darker bars). 
Correlation symptoms and height corrected liver volume
Patients with larger htLV reported higher symptom burden measured with the PLD-Q 
(r=0.532, P<0.001). Sensitivity analysis in DIPAK patients showed also a significant 
correlation (r=0.621, P<0.001). In the multivariate model, the association between 
symptoms measured with the PLD-Q and htLV remained significant (P<0.001) after 
adjustment of age (P=0.50), gender (P=0.02), diagnosis (P=0.05) and original study 
(P=0.19) (Table 2). In the ADPKD subgroup, symptom burden was still associated with htLV 
(P<0.001) after adjustment for age (P=0.69), gender (P=0.02), original study (P=0.24), 
htKV (P=0.27) and renal function (P=0.46). 
Severity of individual symptoms across disease stages
Figure 3 shows the median individual symptom scores per disease stage. All individual 
symptom scores were higher at more advanced disease stages, except for abdominal 
pain (P=0.088). In mild PLD, only one symptom of mild nature was present (tiredness). 
In moderate PLD, patients had five symptoms of at least moderate severity and this 
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Figure 3. Median individual symptom scores per disease stage. A severity score of 2-3 can be considered 
as no symptoms (center), 4-5 as mild, 6-7 as moderate, 8-9, as moderately-severe, and  10-11 as severe 
symptoms (most outer lines).
Figure 4. Left panel: physical component scores (PCS) decreased significantly with advancing disease 
stages (P=0.021). Right panel: no significant effect of disease stage on the mental component scale 
(MCS) (P=0.055). The dotted line reflects the reference value of the general population. Disease stages are 
defined as: mild <1600 mL, moderate 1600-3200 mL; and severe >3200 mL height corrected liver volume. 
increased to seven symptoms of this nature in severe PLD. The most burdensome symptom 
with a moderately-severe nature was dissatisfaction abdomen size in moderate and 
severe stages. 
Quality of life across disease stages
SF-36 data was available in 79 patients (mild n=24; moderate n=32; and severe disease 
n=23). The PCS decreased significantly with advancing disease stage (P=0.021), while 
there was no significant effect of disease stage on the MCS (P=0.055) (Figure 4). PCS of 
mild PLD patients was similar to the female reference population (53.30 [42.47 – 55.86] 
vs. 51.03, P=0.93). The PCS of moderate (46.15 [32.16 – 53.81] vs. 51.03, P=0.007) and 
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severe (44.09 [38.93 – 46.94] vs. 51.03, P<0.001) PLD patients was significantly lower 
compared to the female reference population. This difference remained after comparing 
with an age matched reference population (PCS 51.61, P=0.004 and P<0.001). 
DISCUSSION
We show that PLD patients with more severe hepatomegaly have a higher symptom 
burden, with increasing symptom severity across all components of the PLD-Q, 
except for abdominal pain. QoL, particularly the physical component, decreases with 
advancing disease and drops below levels seen in the general population in patients 
with htLV ≥1600 mL. 
Liver volume impacted symptom burden and QoL in those with moderate disease 
stage and beyond, suggesting that liver volume reducing therapies are beneficial in 
these patients. As patients with htLV ≥1600 also have a higher risk of pressure-related 
complications compared to patients with smaller livers,5 this liver volume can be used as 
evidence-based inclusion criteria for symptomatic disease in future studies. 
There were no large differences in symptom patterns per disease stage between 
the Western and Asian population,5 indicating that possible differences in culture and 
anthropometric properties has no large effect on symptom development in PLD. 
Surprisingly, abdominal pain was not associated with disease stage. Although 
frequency of abdominal pain seems to be increased in PLD compared to the general 
population,6,12 we found no correlation with liver volume. This accords with another large 
study in 1043 ADPKD patients that also did not establish a relation between abdominal 
pain and liver or kidney volume.13 It is possible that cyst growth rather than mere static 
liver volume is responsible for symptoms of abdominal pain. 
The main strength of this study is that we were able to include the whole spectrum of 
liver volumes from rather normal volumes (htLV 834 mL) to very severe hepatomegaly with 
htLVs up to ten times as large (htLV 8382 mL). Our cohort was highly enriched with severe 
PLD because inclusion mainly took place at a national referral center. In comparison, 
the prevalence of this stage in the general ADPKD population is approximately 5%, leading 
to similar numbers of patients with severe PLD in our study compared to large studies that 
include over 450 patients.5,14 This enrichment enabled us to compare symptoms and QoL 
across different disease stages. 
We used a reliable and extensively validated disease-specific questionnaire to assess 
symptom burden in PLD.6 This instrument allows us to investigate the broad spectrum 
of symptoms in PLD, while generic gastrointestinal questionnaires underrepresent some 
problems related to PLD. 
Limitation of the cross-sectional design is that we could not assess the effect of liver 
volume growth on symptoms. Although the CURSOR trial has a longitudinal design, mean 
increase in liver volumes was only four percent, which is too small to conclude whether 
change in liver volume lead to aggravation of symptoms.7 This longitudinal relationship 
should be a topic for future studies, for instance when follow up data of the DIPAK study 
becomes available. 
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Second, the CURSOR included symptomatic patients with (uncorrected) liver volumes 
>2500 mL, while the DIPAK inclusion criteria are independent of symptoms and liver 
volume. The enrichment of symptomatic patients with larger livers may result in a spurious 
correlation between symptoms and liver volume. However, the fact that correlation 
between symptoms and liver volume was even stronger in the sensitivity analysis restricted 
to DIPAK enrolled patients fuels the contention that this correlation is independent of 
inclusion criteria. 
Finally, we pooled two studies with different imaging modalities. To validate pooling 
of MRI and CT images in our study, we compared the two different volumetric software 
packages and differences were small (1.8%). In addition, a randomized controlled 
trial that assesses changes in liver volume after somatostatin analogue treatment also 
found excellent correlation between liver volumes measured from CT and MRI images.15 
Therefore, we think that this has not influenced our results. 
This study suggests that alternative diagnosis than merely PLD should be considered 
in patients with mild PLD presenting with moderate to severe symptoms. In case of 
ADPKD, symptoms might be related to large polycystic kidneys rather than liver when 
PLD stage does not correlate with the experienced symptoms. Given that tiredness and 
dissatisfaction abdomen size were respectively the most frequent and burdensome 
symptoms, clinicians should support adequate coping strategies to reduce this burden. 
We suggest that abdominal pain should not be the primary indication to start therapy, 
since no study so far has detected a relation with static liver volume or cyst growth. 
In conclusion, larger liver volume has a negative impact on symptoms and QoL 
in PLD. Particularly, polycystic livers above twice the normal size (≥1600 mL htLV) are 
associated with symptomatic disease and QoL impairment. We suggest this volume 
as evidence-based inclusion criteria for future studies investigating new therapies for 
symptomatic PLD. 
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Supplemental Figure 1. Left panel: Bland-Altman plot shows a 1.8% ± 1.1 difference between liver 
volumes of five scans measured with ITK-SNAP compared to Pinnacle3® software. Right panel: Bland-
Altman plot shows a 0.4% difference between ten MRI liver volume measurements of two investigators 
(MN and SV) using ITK-SNAP software. The dotted lines reflect the 95% limits of agreement.    
SUPPLEMENTARY MATERIAL
Supplementary File 1. Validation ITK-SNAP for liver and kidney volume 
measurement
To validate MRI measurements with ITK-SNAP, we investigated measurement bias with 
Bland-Altman plots. The first step was to compare measurements of five randomly 
selected CTs with the validated software Pinnacle3® to the new software ITK-SNAP. We 
found a mean difference of 1.8% ± 1.1 between ITK-SNAP measurements compared to 
Pinnacle3® calculated with the Bland-Altman method (Supplementary Figure 1, left panel). 
This was considered acceptable for our study purpose, as we expected that the relation 
with symptoms and liver volume is not dependent on a few milliliters difference. 
The second step was to compare CT and MRI measurements of two patients that had 
both imaging modalities performed within 0 and 69 days from each other with ITK-SNAP. 
Differences were -0.4% and +1.3% between CT and MRI measurements. Interobserver 
variability of ITK-SNAP was tested by comparing ten MRI scans measurements of two 
authors (M.N. and S.V.). The Bland-Altman plot showed a mean difference of -0.4% ± 1.4 
(Supplementary Figure 1, right panel).
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ABSTRACT 
Background and aim
Traditionally, cyst volume reduction is used as outcome in aspiration sclerotherapy of 
hepatic cysts. From patient-centered view, clinical response is more important. We 
assessed whether symptom reduction is a better outcome than cyst volume reduction in 
aspiration sclerotherapy. Secondary, we identified the minimally important change (MIC) 
that resulted in a clinically relevant improvement for both outcomes. 
Methods
We included patients with symptomatic, large (>5cm), hepatic cysts that participated 
in a randomized controlled trial (NCT02048319). At baseline and six months after 
treatment, symptoms were assessed with the polycystic liver disease questionnaire 
(PLD-Q) and ultrasound-guided cyst volume measurement was performed. As golden 
standard, patient-reported treatment success was assessed on a five-point anchor 
question. We tested whether PLD-Q scores and cyst volumes changed after aspiration 
sclerotherapy (responsiveness). Changes in PLD-Q scores and cyst volume were compared 
across treatment success ratings (discriminative ability). ROC-analysis was used to identify 
the MIC that distinguished between patients with treatment success and patients that 
did not improve. 
Results
We included 32 of 34 patients from the original trial. Aspiration sclerotherapy changed 
PLD-Q score (38 points to 18 points, P<0.001) and cyst volume (479 mL to 68 mL, 
P<0.001) significantly. PLD-Q change showed orderly improvement classified by change 
in health status (P=0.001). The MIC of the PLD-Q score was -16 points (AUC 0.807, 
P=0.008). Cyst volume reduction was not different across health status change groups 
(P=0.136). Therefore no MIC could be calculated. 
Conclusion 
Symptom relief measured with the PLD-Q is a better outcome measure for treatment 
success of aspiration sclerotherapy than technical outcomes in hepatic cysts. 
99
6
M
EA
SU
RIN
G
 TREA
TM
EN
T EFFIC
A
C
Y
 IN
 A
SPIRA
TIO
N
 SC
LERO
TH
ERA
PY
 
INTRODUCTION
Hepatic cysts are fluid-filled cavities in the liver varying in volume from a few milliliters 
to liters.1 Most are found incidentally as isolated cysts but some patients present with 
inherited polycystic liver disease (PLD).2 Large cysts that occupy a major part of the liver 
can lead to symptoms such as pain or discomfort.3 A minimally-invasive treatment 
option for large cysts is aspiration sclerotherapy, which involves complete drainage of 
cyst fluid followed by injection of a sclerosing agent which destructs the fluid-producing 
cyst epithelium.4 
Traditionally, technical measures such as cyst volume reduction are used as outcome 
of efficacy in aspiration sclerotherapy.5-7 Only a limited number of studies investigated 
clinical outcomes such as symptomatic relief and none of these studies used this as 
primary endpoint. From a patient-centered view, clinical response is the most important 
outcome when treating a benign condition such as hepatic cysts. 
Recently, we developed and validated a polycystic liver disease questionnaire (PLD-Q) 
that assesses frequency and discomfort of thirteen disease-specific symptoms in PLD.8 
However, it is unclear whether this is a valuable instrument to evaluate clinical response 
in patients treated with aspiration sclerotherapy. 
The primary aim of this analysis was to assess whether symptom reduction is 
a better outcome measure than cyst volume reduction for treatment success from 
patients’ perspective in patients treated by aspiration sclerotherapy. As a secondary 
objective, we identified the minimally important change (MIC) in PLD-Q score or cyst 
volume reduction that resulted in a clinically relevant improvement in health status after 
aspiration-sclerotherapy. 
METHODS
Study population and design
We included patients from a previously conducted randomized, double-blind, placebo-
controlled clinical trial that assessed the additional effect of the somatostatin analogue 
pasireotide on aspiration sclerotherapy (NCT02048319).9 This study was conducted at 
Radboud University Medical Center, Nijmegen, the Netherlands from April 2014 to April 
2016 and approved by the Institutional Review Board. Informed consent was obtained 
from all patients. An extensive description of design and methods was published 
previously.9 In short, all patients received aspiration sclerotherapy for symptomatic, large 
(>5cm), non-neoplastic, non-hydatid hepatic cysts. Only solitary and dominant cysts 
(largest cyst in PLD) that seemed causative for the perceived symptoms were included. 
An ultrasound-guided cyst puncture was performed for cyst fluid drainage. Subsequently, 
ethanol was injected and re-aspirated after 10 minutes of sclerotherapy. Patients were 
randomized (1:1) to two additional injections of pasireotide or placebo. Endpoints were 
proportional change (%) in cyst volume and change in symptoms after six months follow 
up. This study showed a strong reduction of the cyst volume without added beneficial 
effect of pasireotide (-23.6% in pasireotide-arm vs. -21.8% in placebo group, P=0.96).9
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Clinical outcome 
To track changes in symptoms, patients completed the PLD-Q (version 1) two weeks 
prior to and six months after treatment.8 The questionnaire included thirteen symptoms 
that can be summed into a total PLD-Q score, ranging from 0 (asymptomatic) to 100 
(severely symptomatic). Scoring and missing values were handled following the user 
manual.8 Clinical response was defined as median change in PLD-Q total score six months 
after treatment.
Technical outcome
Cyst volumes were measured in triplicate by two blinded investigators with ultrasonography 
using a 3.5 MHz convex transducer (Acuson X150TM, Siemens) at baseline and six months 
after treatment. Cyst volume was calculated by multiplying the mean orthogonal 
diameters using the ellipsoid formula (D1*D2*D3*0.523).10 Technical response was 
defined as median proportional change (%) in cyst volume of the treated cyst six months 
after aspiration sclerotherapy.
Treatment success
To assess whether the PLD-Q is a more appropriate outcome than cyst volume reduction 
for treatment success in patients with solitary cysts or PLD treated with aspiration 
sclerotherapy, we measured responsiveness and discriminative ability of these outcomes. 
Responsiveness is defined as the ability of an outcome measure to detect change over 
time, while discriminative ability is the degree to which a test can distinguish between 
groups of patients.11 Clinical and technical outcomes were compared with patient-
reported treatment success after therapy. Patients were asked to rate their change in 
health on a five-point anchor question (‘much worse’ to ‘much better’) six months after 
treatment. In the era of patient-centered care, patients’ judgment is often used as golden 
standard for treatment success.12 
Statistics
We pooled intervention and placebo arms for all analyses as there was no additional 
effect of pasireotide. Baseline characteristics were presented as absolute numbers and 
percentage or median and interquartile range. To assess whether we could combine 
patients with solitary cysts and PLD patients, we compared patient characteristics and 
baseline scores with Mann-Whitney U test or chi-square when appropriate. 
We tested responsiveness of the PLD-Q and cyst volume by comparing pre- and post-
treatment values with Wilcoxon signed-rank test. To assess discriminative ability, we 
tested whether median changes in PLD-Q scores and proportional cyst volume reduction 
were significantly different across patient-reported treatment success ratings using 
Kruskal Wallis test. The categories ‘somewhat worse’ and ‘much worse’ were combined 
for analyses as the number of patients in these categories were very low. 
As statistical significant change after therapy does not necessarily indicate clinical 
relevant change, the MIC in technical or clinical outcome which patients perceive as 
101
6
M
EA
SU
RIN
G
 TREA
TM
EN
T EFFIC
A
C
Y
 IN
 A
SPIRA
TIO
N
 SC
LERO
TH
ERA
PY
 
beneficial was defined.13 The MIC was calculated if there was a correlation of ≥0.30 
(Spearman) of patient-reported treatment success with change in PLD-Q score or 
proportional cyst volume reduction.12 In outcomes that fulfilled this criterion, the MIC was 
defined as change that distinguished best between patients that classified themselves 
as ‘improved‘ (‘somewhat better’ or ‘much better’) and ‘not improved‘ (‘much worse‘, 
‘somewhat worse’ and ‘about the same’). This cut-off point was the value closest 
(Euclidean distance) to the left upper corner of a receiver operating characteristic (ROC) 
curve.14 Patients that reached the MIC were defined as good responders to aspiration 
sclerotherapy. The proportion of good responders indicates the likelihood of a patient 
to clinically benefit from treatment.15 Applying this definition for good responders, we 
assessed baseline factors associated with treatment success by comparing characteristics 
of good responders and patients that did not reach the MIC with Mann-Whitney U test 
or chi-square when appropriate. Significant continuous factors were further explored 
with ROC analysis to assess which cut-off point differentiated best between good 
responders and patients that did not reach the MIC. P-values of <0.05 were considered 
as statistical significant. Analyses were performed with IBM SPSS Statistics version 22 
(SPSS Inc., Chicago, IL).
RESULTS
From the 34 patients included in the original trial, two patients were excluded because 
of failed aspiration sclerotherapy (n=1) and missing baseline PLD-Q (n=1). Baseline 
characteristics are described in Table 1. There were no significant differences between 
patients with solitary cysts and PLD, enabling us to pool them.  
Table 1. Baseline characteristics
Total group
n=32
Solitary cysts
n=11
PLD
n=21
P-value 
Age, years 54 [48 to 61] 52 [49 to 61] 55 [47 to 61] 0.67
Female sex, n (%) 30 (94) 11 (100) 19 (90) 0.29
PLD-Q total score 39 [26 to 52] 44 [28 to 64] 37 [25 to 51] 0.53
Cyst volume, mL 479 [260 to 847] 378 [211 to 1253] 491 [298 to 728] 0.94
Hemorrhagic cyst fluid 14 (44) 5 (45) 9 (43) 0.71
Variables are shown as median [IQR] unless noted otherwise. Differences between patients with solitary cysts and 
polycystic liver disease (PLD) were analyzed by Mann-Whitney U test or chi-square when appropriate.
Responsiveness
There was a significant change in total PLD-Q score (median 38 points [26 to 52] to 18 
points [11 to 33], P<0.001) and cyst volume (median 479 mL [260 to 847] to 68 mL 
[11 to 156], P<0.001) after aspiration sclerotherapy. All individual symptoms of the PLD-Q 
showed a decline after treatment (P<0.05), except for fear or anxiety for the future 
(P=0.83) (Figure 1). 
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Discriminative ability 
As defined by patient-reported treatment success, most patients improved after therapy 
(‘somewhat better’ n=10, ‘much better’ n=13), six patients remained ‘the same’ and 
three patients rated their health status as ‘worse’ (‘somewhat worse’ n=1, ‘much worse’ 
n=2). Table 2 shows an orderly improvement in median changes in PLD-Q total score 
classified by change in health status (‘much better’ median -28 points [-37 to -23], 
‘somewhat better’ median -12 points [-17 to -5], ‘about the same’ median -9 points 
[-20 to 2], ‘worse’ median 1 point [-14 to 3], P=0.001). Median proportional reduction in 
cyst volume was not significantly different across the health status groups (‘much better’ 
median 72% [52 to 89], ‘somewhat better’ median 90% [91 to 99], ‘about the same’ 
median 79% [60 to 97], ‘worse’ 87% [66 to 97], P=0.136, Table 2). 
Figure 1. Symptoms prior (blue line) to aspiration sclerotherapy (AS) compared with six months after 
therapy (red line). *P<0.05, **P<0.001. 
Table 2. Change in scores categorized by five health status change groups.
Self reported rating of change Change in PLD-Q score Cyst volume reduction (%)
Much better n=13 -28 [-37 to -23] 72 [52 to 89]
Somewhat better n=10 -12 [-17 to -5] 90 [91 to 99]
About the same n=6 -9 [-20 to 2] 79 [60 to 97] 
Worse n=3 1 [-14 to 3]a 87 [66 to 97]a
Data presented as estimated median changes [IQR]. aWorse is a combination of the self–reported categories somewhat 
worse (n=1) and much worse (n=2).
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Minimal important change 
Correlation between change in PLD-Q score and patient-reported treatment success was 
high (r=0.699, P<0.001) indicating that the PLD-Q can be used to calculate the MIC. 
Based on ROC curve analysis, the MIC of the PLD-Q total score that distinguished 
best between improvement and no improvement was a median decrease of 16 points 
(sensitivity 65%, specificity 78%, AUC 0.807, P=0.008) (Figure 2). There was no 
significant correlation between proportional cyst volume reduction and patient-reported 
treatment success (r=0.209, P=0.250) and therefore we could not calculate the MIC of this 
outcome measure. 
In total, 17 out of 32 patients (53%) passed the threshold of MIC of the PLD-Q and 
could be defined as good responder to aspiration sclerotherapy. Gender (P=0.120), age 
(P=0.142), cyst volume (P=0.433) and hemorrhagic cyst fluid (P=0.200) at baseline were 
not significantly different between responders and patients that did not reach the MIC. 
Among responders, more patients had solitary cysts (9 out of 11, 82%) compared to PLD 
(13 out of 21, 38%), P=0.021. Median baseline PLD-Q score of responders was higher 
compared to scores of patients with non-clinically relevant changes in health status after 
therapy (median 46 [35 to 55] vs. 26 [23 to 40], P=0.003). ROC analysis revealed that 
a baseline PLD-Q score ≥32 points was the best cut-off point to differentiate between 
responders and patients that did not reach the MIC after six months follow up (Figure 3). 
In total, 15 out of 17 (89%) of the responders had a baseline PLD-Q score ≥32 points, 
compared to only 5 out of 15 (33%) patients with non-clinically relevant changes in 
health status. 
Figure 2. ROC analysis of changes in PLD-Q scores and change in health status. Patients were divided 
into two groups: improved (better and much better) and not improved (about the same, worse or much 
worse). A decrease ≥16 points in PLD-Q score had a sensitivity and specificity of respectively 65% and 
78% for improvement (AUC 0.807, P=0.008). 
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DISCUSSION
Our study showed that the PLD-Q and cyst volume were both highly responsive to 
change after aspiration sclerotherapy. Specifically, PLD-Q discriminates between patients 
that clinically benefit from this therapy or not, in contrast to cyst volume changes. We 
demonstrated that a decrease in PLD-Q score of ≥16 points can be used to identify 
good responders to this therapy. Good response was associated with more symptoms at 
baseline, defined by a PLD-Q score ≥32 points. Patients with a beneficial outcome were 
more often patients with solitary cysts compared to patients that did not reach the MIC.
The results of our study emphasize that there is no direct relationship between clinical 
and technical response after aspiration sclerotherapy. A proportion of patients clinically 
improved after aspiration-sclerotherapy with just a small reduction in cyst volume in our 
study, which is in line with previous literature. A previous study showed that one-third of 
patients with suboptimal technical response reached complete clinical response.16 Based 
on these findings, we hypothesize that a slight decrease in hepatic cyst wall pressure by 
fluid reduction can lead to symptom relief. 
Another possible explanation for the lack of relation between clinical and technical 
response is that a proportion of patients perceive symptoms independent of the treated 
cyst. In patients with PLD, it is more difficult to distinguish mass-related symptoms of 
Figure 3. ROC analysis of baseline PLD-Q scores and minimally important change (MIC) in PLD-Q score 
after six months follow up. Patients were divided into two groups: patients that reached the MIC 
(PLD-Q change -16 points) and patients that did not. A baseline PLD-Q score of ≥32 points in PLD-Q 
score had a sensitivity and specificity of respectively 88% and 67% for reaching the MIC at follow up 
(AUC 0.800, P=0.004).
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the total cystic liver from symptoms of a dominant hepatic cyst. This may be the reason 
that there were more responders in the group of solitary cysts compared to PLD in 
our study. 
Defining the MIC of an outcome measure facilitates interpretation of results beyond 
statistical significance. It can also be used to calculate sample sizes in trials with clinical 
outcomes as primary endpoint, although one should keep in mind that the MIC can vary 
in different populations and therapies.12 The MIC for more invasive therapies such as 
partial liver resection is probably higher, as these procedures should have larger efficacy 
on symptom relieve to justify the risks. 
The strength of this study is that we used data of a randomized controlled 
trial with protocolized measurement points. We used an extensively validated 
questionnaire for PLD patients and thoroughly assessed if we could extent the use 
to patients with solitary cysts. With this unique methodology, we were able to assess 
which outcome measure was most appropriate to evaluate treatment success in 
aspiration sclerotherapy. 
Limitation of this study is the small sample size. Some argue that a sample size of at 
least 50 patients is necessary to determine the MIC.11 However, a recent systematic review 
investigating the efficacy of aspiration sclerotherapy in symptomatic hepatic cysts showed 
a median of 21 treated patients per study, suggesting that large trials are not feasible in 
this condition.  
Second, responsiveness and the MIC are preferably assessed in a placebo or sham-
controlled study to minimize the subjective effect of the treatment itself. Although we 
used an uncontrolled design, we can compare our results with another randomized 
controlled trial that used the PLD-Q in polycystic liver disease patients.17 This trial showed 
no effect on liver volume, resulting in a non-significant mean change in PLD-Q scores 
of -7 points compared to baseline. This change is comparable to the change in our group 
that reported no change and can be considered as a placebo effect. Our MIC of -16 
points is larger and can therefore be considered as relevant change.
Finally, proportional change in cyst volume was measured by ultrasound, which 
measures cyst dimensions less accurate than CT or MRI. To optimize ultrasound accuracy, 
each measure was performed in triplicate and repeated by an independent investigator, 
resulting in low intra- and interobserver variability. The discrepancy between clinical and 
technical outcomes was also observed in CT-controlled study and therefore we believe 
that the use of ultrasound has not influenced our results.5 
Currently, there is a large paradigm shift in medicine from technical outcomes to 
patient-reported outcomes.18 Patient-reported outcomes gain acceptance as valid primary 
endpoint in studies of patients with symptomatic conditions. In the field of aspiration 
sclerotherapy, we are lagging behind in this shift. Many studies showed the technical 
effect of different sclerosing agents or treatment protocols.6,7,10,19,20 Our study implies that 
comparing clinical outcomes when using different agents or treatment protocols would 
be of more relevance. 
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To fuel the ongoing debate about the first-choice treatment of hepatic cysts, 
a randomized controlled trial of aspiration sclerotherapy and surgical fenestration with 
highly responsive outcome measures is required. Both PLD-Q and proportional cyst 
volume are sensitive to changes after aspiration sclerotherapy. Since technical outcomes 
did not reflect patient-reported treatment success in this population, the PLD-Q is a better 
outcome. The PLD-Q can be used to select patients with higher chances to achieve clinical 
benefit, as patients with high baseline PLD-Q scores (≥32 points) were more likely to 
respond to aspiration sclerotherapy. Another implication of this study is that the indication 
for aspiration sclerotherapy in PLD patients needs to be considered carefully, as these 
patients were less likely to reach a clinical relevant change in health status compared to 
patients with solitary cysts. 
In conclusion, we show that symptom relief measured with the PLD-Q is a better 
outcome measure for treatment success of aspiration sclerotherapy than technical 
outcomes in hepatic cysts. 
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ABSTRACT 
Background and aim 
Since current treatments of cirrhotic ascites are not associated with survival benefit, 
symptom relief is the major end-point. We developed an ascites questionnaire and 
assessed validity and responsiveness for symptom assessment in cirrhotic ascites.
Methods
We developed the Ascites-Questionnaire (Ascites-Q; a modified polycystic liver disease 
questionnaire), and compared it with FACIT-ascites index (FACIT-AI; developed for 
malignant ascites) and Japanese Ascites Symptom Inventory-7 (ASI-7) in cirrhotics 
undergoing large volume paracentesis. Convergent validity was defined as correlation 
of r>0.4 between ascites questionnaires and quality of life (QoL) visual analogue scale. 
Responsiveness was assessed by comparing scores at baseline and seven days post large-
volume paracentesis. To test discriminative ability, we compared scores of patients with 
cirrhotic controls without ascites (n=24) and diuretic-sensitive ascites (n=46).
Results
We included 90 refractory ascites patients (61% male, mean age 59 year, MELD-score 16, 
median paracentesis volume 4100 mL). All questionnaire scores correlated negatively with 
quality of life (Ascites-Q: r=0.479, P<0.001, FACIT-AI: r=0.313, P=0.007; ASI-7: r=0.340, 
P=0.004), but only Ascites-Q showed convergent validity (r>0.4). Scores decreased after 
paracentesis (Ascites-Q: 57 to 34, FACIT-AI: 53 to 42, and ASI-7: 57 to 25, all P<0.001). 
Ascites-Q and ASI-7 discriminated between controls without ascites, diuretic-sensitive, 
and refractory ascites (Ascites-Q: 16 vs. 35 vs. 56 points, ASI-7: 2 vs. 25 vs. 61 points, 
all P<0.05), whereas FACIT-AI (39 vs. 40 vs. 52 points) could not differentiate between 
controls without ascites and diuretic-sensitive ascites (P=0.314).
Conclusion
The newly developed Ascites-Q is the best ascites-specific outcome to evaluate symptom 
relief in cirrhotic ascites. The ASI-7 is adequate but the FACIT-AI should not be used to 
measure symptoms in patients with cirrhotic ascites.
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INTRODUCTION
Ascites is the most common complication of cirrhosis and develops in the majority of 
cirrhotics within ten years after diagnosis.1 The accumulation of fluid within the peritoneal 
cavity increases intra-abdominal pressure leading to pressure-related symptoms such as 
shortness of breath, abdominal distension and decreased quality of life (QoL).2-4 
When sodium-restricted diet and diuretic therapy fail to control ascites, current 
guidelines recommend repeated large volume paracentesis.5 Paracentesis leads to 
temporary symptomatic relief in most cases,6 but does not prevent reaccumulation 
of ascites. Transjugular intrahepatic shunts can control ascites in carefully selected 
patients, but are associated with an increased risk of hepatic encephalopathy without 
a survival benefit.7
Newer pharmacological therapies and devices that pump ascitic fluid from 
the peritoneal cavity into the bladder are being investigated currently.8-11 Survival and 
time to next paracentesis are frequently used objective measures to determine treatment 
efficacy of new therapies for ascites.9,12 However, survival has not been shown to be 
significantly increased with any treatment other than liver transplantation, and time to 
next paracentesis is weighed heavily against standard treatment which is dietary sodium 
restriction, diuretics and regular paracentesis. Therefore, symptom and QoL assessment 
become important outcomes when survival is unchanged.5
Some studies have used the SF-36 questionnaire to investigate general QoL, or 
the chronic liver disease questionnaire. Both instruments are lengthy and include a large 
number of items not related to ascites.13,14 A disease-specific questionnaire usually has 
better discriminative ability and is more sensitive to changes in symptoms in the disease 
of interest compared to generic tools.15 
To assess symptoms of ascites in patients with malignant ascites, the Functional 
Assessment of Chronic Illness Therapy-Ascites Index (FACIT-AI) is available.16 It is unclear 
whether this tool is useful in a population with ascites resulting from cirrhosis. Another 
ascites-specific questionnaire (ASI-7) for cirrhosis has been developed and validated in 
Japan.15 In view of important differences in score patterns between Asian and Western 
populations in several patient-reported outcomes,16,17 validating the ASI-7 in a Western 
population is paramount. Recently, a polycystic liver disease questionnaire was validated 
which included pressure-related symptoms similar to those experienced by patients with 
ascites.18 We tested the hypothesis that the polycystic liver disease questionnaire with 
modifications based on qualitative research may serve as the basis for an ascites-specific 
questionnaire (Ascites-Q). 
In this current study, we developed the Ascites-Q and compared validity and 
responsiveness with the FACIT-AI and ASI-7 to select the best outcome measure for 
evaluating patient related outcome measures in cirrhotic ascites. 
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METHODS
We conducted a prospective study at the Mayo Clinic, Rochester MN, US, from December 
2014 until December 2016. This study was approved by the Institutional Review Board 
(IRB 14-009366) and performed in accordance with the principles of the Declaration of 
Helsinki. Informed consent was obtained from all patients. 
Patients
Adult cirrhotic patients with refractory ascites scheduled for large-volume paracentesis 
and available for follow-up participated in the study. The diagnosis of cirrhosis was 
based on histological, clinical, and radiological criteria.19 Refractory ascites was defined 
as ascites that could not be managed by medical therapy alone either due to a lack 
of response to maximal diuretic treatment or because of intolerance to diuretics.20 
The decision to perform therapeutic paracentesis was made by the attending physician and 
the intervention was performed according to international guidelines.1,21,23 Clinical data 
on etiology and previous complications of liver disease were extracted from the medical 
charts. Severity of liver disease was assessed using the Model of End-Stage Liver Disease 
(MELD) score.21 Exclusion criteria included overt hepatic encephalopathy (grade two or 
higher following the West Haven Criteria22), hepatocellular carcinoma outside of Milan’s 
criteria23, insufficient knowledge of the English language, hospital admission at time of 
inclusion and paracentesis within seven days prior to inclusion.  
Study design
Patients completed a paper questionnaire set containing three ascites-specific 
questionnaires (Ascites-Q, FACIT-AI and ASI-7) and a QoL Visual Analog Scale (QoL VAS) 
prior to paracentesis.18,24-26 Weight and abdominal girth were measured prior to and 
directly after paracentesis. One week after paracentesis, a telephone follow up survey 
was conducted by a member of the Mayo Clinic Survey Center that was blinded for 
results of the first questionnaire set. In addition to baseline questionnaires, patients rated 
their global change in health on a five-point scale from ‘much worse’ to ‘much better’. 
Patients that received another paracentesis before follow up survey or that were admitted 
during the study were excluded from follow up.
Questionnaires
The Ascites-Q was developed by modifying the polycystic liver disease questionnaire that 
reflects pressure-related symptoms.18 To select ascites-specific items of this questionnaire, 
we performed literature review, semi-structured interviews with cirrhotic patients (n=9) 
and an email survey among clinicians (n=7). In total, 11 out of 16 original questions 
were selected, and one other ascites-specific symptom (insomnia) was added after 
the interviews. Supplementary Table 1 shows the symptom selection of the Ascites-Q. 
Selected symptoms were abdominal fullness, anorexia, early satiety, nausea, abdominal 
pain, back pain, dyspnea, reduced mobility, fatigue, insomnia, abdominal distension, and 
problems with sexual intimacy. 
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Each individual symptom was assessed with a frequency (six-point Likert scale 
‘never’ to ‘always’) and discomfort (five-point Likert scale ‘not at all’ to ‘a lot’) question. 
Severity scores of individual symptoms are the sum of the frequency and discomfort 
score (range 2-11). 
The FACIT-AI was previously developed for malignant ascites by selecting relevant 
questions from the FACIT library after interviewing 20 patients with ovarian cancer.16 
Symptoms include anorexia, insomnia, reduced mobility, dyspnea, nausea, vomiting, 
abdominal pain, abdominal distension, fatigue, early satiety, urinary frequency, 
constipation, and emotional distress. These thirteen symptoms are scored on a five-point 
Likert-scale from ‘not at all’ to ‘very much’ (range 0-4). The ASI-7 is an ascites-specific 
questionnaire developed with input of seven cirrhotic patients and clinicians and validated 
in an Asian population (n=175).15 Seven ascites-specific symptoms (heavy stomach, 
bloated stomach, reduced mobility due to bloated stomach, heavy stomach when lying 
down, exercise-induced dyspnea, cannot eat due to bloating, and dyspnea) are rated on 
a five-point Likert-scale from ‘not applicable’ to ‘very applicable’ (range 0-4). 
All questionnaire total scores were transformed to a score of 0-100, where a higher 
score indicates more symptoms. The Ascites-Q and FACIT-AI are related to symptoms 
experienced in the previous week, whereas the ASI-7 scores symptoms experienced the day 
the questionnaire is completed. The QoL VAS scale is part of the EQ-5D questionnaire and 
assesses health-related QoL state of the past week on a scale from 0-100, where 0 is 
‘worst imaginable health state’ and 100 the ‘best imaginable health state’.26  
Sample size 
For reliable testing of the ascites questionnaires, as a rule of thumb at least 50 patients are 
needed, with a minimum of five patients per question.27,28 The questionnaire containing 
the most questions (Ascites-Q, 12 questions) was used for the power calculation, leading 
to a minimum of 60 patients for reliable testing of several forms of validity. With an 
estimated drop-out rate of 33% for follow up, the total sample size required to adequately 
power the study was determined to be 90 patients with refractory ascites.   
Score distributions 
Comprehensibility and acceptance of the questionnaires was assessed by the percentage 
of missing values in each question. Total scores were considered missing when ≥2 
questions were not completed. A percentage of >10% of missing data was determined 
as problematic. Individual questions that lead to unacceptable amount of missing 
data (>10%), were deleted from the original questionnaire and excluded from further 
analysis.29 We investigated the proportion of patients obtaining the lowest and 
highest total score (floor and ceiling effects, respectively) to test if the questionnaires 
differentiated between patients on the extreme ends of the scale. A cut-off of >15% was 
set as a threshold for low discrimination. If >15% of patients obtained either the lowest 
or highest possible score, that question was considered to have more variance on 
the extreme ends of the scale than could be measured.28
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Convergent validity
Since QoL improvement is the main goal in ascites treatment, QoL should be reflected 
by symptoms included in the questionnaire (convergent validity). Sufficient correlation 
(Spearman r>0.4) of the questionnaire with QoL VAS indicates that included symptoms 
impact patients’ QoL significantly.30
Responsiveness 
Responsiveness is the ability of an instrument to detect change over time; there should 
be a significant difference in scores after large volume paracentesis. This was tested by 
comparing baseline and follow up scores with the Wilcoxon signed-rank test. Secondly, 
using the Kruskal-Wallis test, we determined whether median changes in ascites scores 
were significantly different across the patient-reported global ratings of changes. We 
expected larger decreases in symptom scores in patients that classified themselves as 
more improved according to the global ratings of change. Finally, we correlated changes 
in scores of the ascites questionnaires with the amount of drained fluid, changes in 
weight and abdominal girth with Spearman’s correlation coefficient.  
Discriminative ability
To identify whether the included symptoms were ascites-specific and not related to severity 
of liver disease, we compared baseline total scores of patients with refractory ascites with 
scores of cirrhotic controls without ascites and patients with diuretic-sensitive ascites. No 
ascites was defined as the absence of ascites on ultrasound. Diuretic-sensitive ascites was 
defined as presence of ascites on ultrasound but responsive to diuretic treatment and not 
requiring therapeutic paracentesis within six months prior to inclusion. Exclusion criteria 
for controls were the same as for patients. We expected higher scores with increasing 
severity of ascites. Differences in questionnaire scores between patients, controls without 
ascites and diuretic-sensitive ascites were compared with Mann-Whitney U test. To avoid 
multiple testing, we calculated whether scores were different within the three groups 
with the Kruskal-Wallis test for individual symptoms. 
Other statistics
Categorical data are presented as percentages and continuous data are presented as mean 
± standard deviation (SD) for normally distributed data and as median and interquartile 
range [IQR] for not normally distributed data. We used IBM SPSS statistical software 
package version 22.0 (SPSS Inc. Chicago, IL, US) for data analysis and significance was 
defined as P<0.05 in all statistics.
RESULTS
Patient characteristics
We approached 144 eligible patients for the study. In total, 90 (63%) patients with a mean 
age of 59 ± 9 years gave their consent (Figure 1). There were no significant differences 
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between age (P=0.187) and gender (P=0.198) of participants and patients that declined 
participating in the study. Table 1 shows baseline characteristics of the included patients. 
The most common origins of liver disease were alcohol-related cirrhosis (36%) and 
nonalcoholic steatohepatitis (NASH) (27%). Patients had advanced liver disease (median 
MELD score 16 ± 5 points).  
Score distributions 
Missing results were below the predefined cut-off of >10% for all total scores (Ascites-
Q 3%, FACIT-AI 8%, ASI-7 10%) and individual questions, except for sexual intimacy 
of the Ascites-Q (11%). This question was therefore excluded from further analysis. 
Supplementary File 1 shows the final Ascites-Q. None of the patients had a total score 
of 0 points (floor effect). Three patients (3%) scored the maximum score of 100 points 
(ceiling effect) on the ASI-7, which was below the predefined cut-off of >15%. Scores 
were distributed across the entire spectrum (Ascites-Q 13-88, FACIT-AI 12-81 and 
ASI-7 4-100 points). 
Convergent validity
Median VAS QoL score in refractory ascites patients was 49 [30 – 70] on a scale from 
0-100, reflecting severely impaired QoL. Higher scores on all ascites questionnaires were 
correlated with lower QoL VAS scores (Ascites-Q r=0.477, P<0.001, FACIT-AI r=0.317, 
P=0.007, ASI-7 r=0.340, P=0.004), but only the Ascites-Q showed convergent validity 
defined by r>0.4. Thus, correlation between baseline ascites questionnaires and overall 
quality of life was best determined by the Ascites-Q score.
Figure 1. Flowchart inclusion
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Responsiveness
Follow up data after paracentesis was collected in 61 patients (68%). Figure 1 shows 
reasons for missing follow up. Age (P=0.245), gender (P=0.554), volume of ascitic fluid 
removed (P=0.993) and baseline scores (Ascites-Q P=0.624, FACIT-AI P=0.494, and 
ASI-7 P=0.274) of patients without follow up data were similar to patients included in 
this analysis. Median volume of ascitic fluid removed from patients with follow up data 
was 4100 mL [2690 – 6250]. Directly after paracentesis, weight decreased by 3.8 kg 
[-2.0 to -6.1] and abdominal girth by 5 cm [-2.9 to -11.0]. Ascites-Q score decreased 
significantly after paracentesis (57 (44 to 69] to 34 points [21 to 57], P<0.001). All 
symptoms of the Ascites-Q decreased after therapy, except for fatigue (P=0.830). Change 
in FACIT-AI was also significant (44 [37 to 55] to 33 [22 to 45], P<0.001), but only 8 out 
of 13 symptoms decreased. The symptoms of anorexia (P=0.151), insomnia (P=0.151), 
vomiting (P=0.489), urinary frequency (P=0.528), and emotional distress (P=0.115) did 
not demonstrate any change. On the other hand, ASI-7 scores demonstrated large 
decreases (57 [43 to 75] to 25 [7 to 43], P<0.001) and all symptoms were responsive 
to paracentesis. Supplementary Figure 1 shows changes in individual symptoms of 
all questionnaires.
Table 1. Baseline characteristics
Refractory 
ascites group 
(n=90)
Controls 
diuretic-sensitive 
ascites (n=46)
Controls 
without ascites 
(n=24)
Age, years ± SD 59 ± 9 57 ± 10 56 ± 9
Gender, male (%)  61 67 79
Race (%) Caucasian 91 93 79
Black/African 
American
2 2 8
Other 7 5 13
Etiology of cirrhosis (%) Alcohol 36 28 8
NASH 27 17 17
Viral hepatitis (B,C) 14 33 37
Cholestatic (PBC, PSC) 14 13 17
Other 9 9 21
Previous complications of 
cirrhosis (%)
Esophageal varices 57 72 50
Gastrointestinal bleed 24 24 13
Spontaneous bacterial 
peritonitis 
17 7 4
Hepatic 
encephalopathy 
42 46 8
HCC (within Milan 
criteria)
7 24 29
MELD-score ± SD 16 ± 6 12 ± 4 11 ± 5
Data are mean ± SD or proportions (%). Abbreviations: NASH, nonalcoholic steatohepatitis; PBC, primary biliary 
cholangitis; PSC, primary sclerosing cholangitis. 
117
7
D
EV
ELO
PM
EN
T A
N
D
 VA
LID
A
TIO
N
 O
F A
N
 A
SC
ITES Q
U
ESTIO
N
N
A
IRE 
Table 2 shows median changes in scores of patients classified according to global 
ratings of change. The majority improved after paracentesis (better n=25, much better 
n=11), 15 patients remained the same, and a small number got worse (worse n=9, much 
worse n=1). The Ascites-Q (P=0.005) and ASI-7 (P=0.043) showed orderly improvements 
in score across the global ratings of change, while scores of the FACIT-AI were not 
significantly different across the health state groups (P=0.128).  
None of the ascites questionnaire score changes correlated with the volume of ascitic 
fluid removed, change in weight or abdominal girth (Supplementary Table 2). 
Table 2. Changes classified according to global ratings of change
Global rating of change Ascites-Q FACIT-AI ASI-7
Much worse (n= 1) -5 6 -4 
Worse (n=9) -1 [-13 to 11] 4 [-6 to 14] 12[-3 to 27]
Same (n= 15) 14 [5 to 23] 7 [0 to 15] 28 [16 to 41]
Better (n= 25) 21 [14 to 28] 14 [9 to 20] 32 [23 to 42]
Much better  (n= 11) 26 [15 to 37] 19 [11 to 28] 44 [30 to 58]
Data is presented as median [interquartile range]
Discriminative ability 
We approached 80 eligible controls, 10 of whom declined participation. Of the 70 
included controls, 24 controls had no ascites and 46 controls had diuretic-sensitive ascites. 
Characteristics of controls are described in Table 1. Figure 2 shows the ability of the ascites 
questionnaires to distinguish between controls without ascites, controls with diuretic-
sensitive ascites and patients with refractory ascites. The Ascites-Q (16 [5 to 35] vs. 35 
[25 to 47], P=0.003) and ASI-7 (2 [0 to 38] vs. 25 [10 to 43], P=0.021) were able to 
discriminate between controls without ascites and diuretic-sensitive ascites. They could 
also differentiate diuretic-sensitive ascites from refractory ascites (Ascites-Q 35 [25 to 47] 
vs. 56 [43 to 69], P<0.001 and ASI-7 25 [10 to 43] vs. 61 [43 to 75], P<0.001). The FACIT-AI 
could not differentiate between controls without ascites and diuretic-sensitive ascites (24 
[10 to 41] vs. 31 [19 to 46], P=0.147), but showed differences in scores between controls 
with diuretic-sensitive ascites and refractory ascites (31 [19 to 46] vs. 46 [37 to 58], 
P<0.001). Supplementary Figure 2 shows individual symptom scores of controls without 
ascites, controls with diuretic-sensitive ascites and refractory ascites patients. All symptoms 
of the Ascites-Q and ASI-7 increased with the amount of ascites, compared to only 10 
out of 13 symptoms of the FACIT-AI. The symptoms of vomiting (P=0.120), constipation 
(P=0.231) and emotional distress (P=0.337) of this questionnaire are unrelated to 
ascites severity. 
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DISCUSSION
This study supports the use of the Ascites-Q and the ASI-7 score in determining 
symptomatic improvement in patients with ascites. The FACIT-AI has unfavorable 
properties to reliably measure symptoms in cirrhotic ascites. 
The current study provided evidence of good score distributions, responsiveness 
and discriminative ability between patients with refractory ascites and controls only of 
the Ascites-Q and ASI-7. Scores ranged widely across the scale, indicating that these 
questionnaires provide relevant information for the full range of clinical symptoms in 
patients with cirrhotic ascites. Both Ascites-Q and ASI-7 showed large changes in scores 
after paracentesis, whereas only 8 out of 13 symptoms of the FACIT-AI were responsive 
to change resulting in smaller changes in total scores. The Ascites-Q has the additional 
advantage that it correlates best with QoL (convergent validity). 
Given that only one-third of patients survive one year after development of refractory 
ascites,31 we consider QoL key in the evaluation of therapeutic interventions in ascites. 
The Ascites-Q best captures QoL, possible because this questionnaire includes a broader 
range of ascites-specific symptoms than the FACIT-AI and ASI-7. In the FACIT-AI, almost 
a quarter of the symptoms are not disease-specific as they did not change with the degree 
of ascites. Although all symptoms included in the ASI-7 were ascites-specific, some 
symptoms are highly similar such as ‘heavy stomach’ and ‘heavy stomach when lying 
down’, or ‘bloated stomach’ and ‘cannot eat due to bloated stomach’. This can limit 
the correlation with QoL, as other important symptoms were not measured. Another 
factor that can possible contribute to lower correlation of the ASI-7 with QoL is the one 
day recall period of the ASI-7 compared to an one week recall period of the Ascites-
Q. The lower correlation may suggest that the ASI-7 could be less accurate to assess 
therapies that aim for long-term efficacy.
Figure 2. Ascites questionnaire scores of patients with refractory ascites, controls with ascites controlled 
on diuretics and controls without ascites. Boxplots indicate median and interquartile ranges, whiskers are 
the minimum and maxium scores.
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There was no correlation between the volume of fluid removed, changes in weight or 
abdominal girth and change in questionnaire scores. Since abdominal habitus is different 
between patients, the identical volume of ascitic fluid removed might provide varying 
levels of relief in the individual patient. For example in a patient with a small abdomen, 
five liter paracentesis might provide considerable relief of symptoms, but in a large patient 
provide only minor relief. The absent correlations between decrease in symptom scores 
with the volume of ascitic fluid removed, and decline in weight and abdominal girth is 
therefore not surprising. Original validation of the ASI-7 showed that changes in body 
weight correlated with changes in ASI-7 scores.25 However, body weight of Japanese 
patients was significantly lower than the average weight of the patients included in our 
study (63 vs. 87 kg), leading to a proportional larger difference after similar volumes of 
ascitic fluid removal. This proportionately larger volume removed may explain the larger 
impact on symptomatology in Japanese patients. Alternatively, symptom relief may be 
achieved when intra-abdominal pressure drops below a certain threshold, independent 
of total volume reduction.
It is important that ascites-specific questionnaires are able to distinguish symptoms 
directly related to ascites rather than symptoms related to cirrhosis. Differences in 
symptom scores between patients and controls were smaller in the FACIT-AI compared 
to Ascites-Q and ASI-7. The ASI-7 questionnaire was developed with input from patients 
with malignant ascites rather than a cirrhotic population, which limits content validity.32 
Malignant ascites is usually not responsive to sodium-restricted diet or diuretics33 and may 
be associated with a more rapid increase in ascites and a different symptom pattern. Both 
Ascites-Q and ASI-7 were developed with input from cirrhotic patients with ascites and 
have good discriminative ability for refractory ascites. 
The symptom sexual intimacy of the Ascites-Q was not suitable for inclusion in the final 
questionnaire due to the high percentage of missing data. As our data shows that half of 
the patients had at least moderate problems (item score≥6) with sexual intimacy, clinicians 
should be aware that this is a significant problem in cirrhotics. It remains to be elucidated 
to which extent sexual intimacy is affected by the amount of ascites. 
There are a number of strengths and weaknesses in this current study. A major strength 
of this study is the inclusion of patients with refractory ascites of varying etiologies of 
cirrhosis which increases the generalizability of our results. Several forms of validity of 
three different ascites-specific questionnaires were assessed using previous published 
quality criteria for patient-reported outcome development.28 This study also has certain 
limitations that should be acknowledged. First, patients that underwent paracentesis 
more often than once a week were excluded, as this could have interfered with the one 
week recall periods of the Ascites-Q and FACIT-AI. We hypothesized that a one week QoL 
assessment would be a better outcome for clinical trials in refractory ascites than a one 
day assessment since one strives for long-term QoL improvement. Therefore, we designed 
our study with a one week recall period.
Second, we could not assess reproducibility of the questionnaires. This involves 
the ability of the questionnaires to produce the same results in similar conditions.28 In 
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ascites, the amount removed with each paracentesis fluctuates considerably based on 
compliance with sodium restriction which creates dissimilar conditions at time of each 
paracentesis. Hence, differences in scores could be related to measurement error in 
the questionnaires, but also to a different volume of ascites accumulating. 
Finally, the mixed mail and telephone survey method may have induced response bias. 
Phone survey respondents usually shift towards more positive answers compared to mail 
surveys,34,35 which might overestimate symptom improvement. However, bias towards 
social desirable answers is higher in young adults, life-style or mental questions and 
when a non-experienced interviewer conducts these surveys.36,37 Our study population 
consisted particularly of older patients and we assessed physical symptoms by an 
extensively trained interviewer, reducing the risk of favorable answers. Apart from that, 
we compared changes in scores with a global rating of change, which should move in 
the similar direction as the symptom scores. 
Measurement of subjective patient-reported outcomes is a necessary addition 
to objective outcomes such as survival or time to next paracentesis in patients with 
refractory ascites to assess treatment efficacy from patient-perspective.9,12 To investigate 
which patients really benefit from ascites therapy, one should look at clinically important 
differences in questionnaire scores rather than merely statistically significant differences.38 
Patients that rated their health as ‘better’ according to the global rating of change had 
improvements of respectively 21 (Ascites-Q), 11 (FACIT-AI) and 32 (ASI-7) points. These 
values can be used as minimal clinical important difference to assess efficacy of new and 
existing treatments on symptom relief or as basis for sample size calculations in clinical 
trials with symptom assessment as primary endpoint.39
In conclusion, Ascites-Q is the best ascites-specific outcome to evaluate the effect of 
existing and experimental therapies on symptom relief in cirrhotic ascites. The ASI-7 is 
an adequate alternative, while the FACIT-AI should not be used in a cirrhotic population.
POTENTIAL USERS OF THE ASCITES-Q 
The authors reserve copyright for the Ascites-Q and encourage potential users to contact 
the authors. No charges or restrictions are placed on using the Ascites-Q for non-
commercial purposes. 
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2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Abdominal fullness 
(P<0.001)** 
Anorexia (P<0.001)** 
Early satiety (P<0.001)** 
Nausea (P<0.001)** 
Abdominal pain (P<0.001)** 
Back pain (P=0.016)* Dyspnea (P=0.001)** 
Reduced mobility (P=0.003)* 
Fatigue (P=0.830) 
Insomnia (P=0.006)* 
Adbominal distension 
(P<0.001)** 
0 
1 
2 
3 
4 
Anorexia (P=0.151) 
Insomnia (P=0.151) 
Reduced mobility (P<0.001)**
Dyspnea  (P=0.001)* 
Nausea  (P=0.001)* 
Vomiting  (P=0.489) 
Abdominal pain (P<0.001)**Adbominal distension  
(P<0.001)**
Fatigue (P=0.003)* 
Early satiety  (P<0.001)** 
Urinary frequency  
(P=0.528)
      (P=0.115) 
Constipation  (P=0.015)* 
Emotional distress
0 
1 
2 
3 
4 
Heavy stomach 
(P<0.001)** 
Bloated stomach 
(P<0.001)** 
Reduced mobility due to 
bloated stomach 
(P<0.001)** 
Heavy stomach when 
lying down (P<0.001)** 
Exercise-induced 
dyspnea (P<0.001)** 
Cannot eat due to 
bloated stomach 
(P<0.001)** 
Dyspnea (P<0.001)** 
Supplementary Table 2. Correlations between change in ascites questionnaires and change in ascitic fluid 
removed, weight and abdominal girth in patients with refractory ascites 
Ascitic fluid 
removed
Weight  
change
Abdominal girth 
change
r P-value r P-value r P-value
Change in Ascites-Q total score 0.132 0.317 0.011 0.945 -0.179 0.288
Change in FACIT-AI total score 0.047 0.730 -0.073 0.654 -0.130 0.443
Change in ASI-7 total score 0.114 0.393 -0.052 0.752 -0.093 0.585
Supplementary Figure 1. Median individual symptom scores at baseline and seven days post paracentesis 
of of the Ascites-Q (upper panel), FACIT-AI (middle panel) and ASI-7 (lower panel).  *P<0.05, ** P<0.001.
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0 
1 
2 
3 
4 
Anorexia (P=0.001)* 
Insomnia  (P=0.003)* 
Reduced mobility (P=0.001)*
Dyspnea (P<0.001)** 
Nausea  (P=0.003)* 
Vomiting  (P=0.120) 
Abdominal pain (P<0.001)Abdominal distension  
(P<0.001)**
Fatigue (P<0.001)** 
Early satiety  (P<0.001)** 
Urinary frequency  (P=0.039)*
Constipation  (P=0.231) 
Emotional distress (P=0.337)
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Abdominal fullness 
(P<0.001)** 
Anorexia (P<0.001)** 
Early satiety (P<0.001)** 
Nausea (P<0.001)** 
Abdominal pain 
(P<0.001)** 
Back pain (P=0.031)* Dyspnea (P<0.001)** 
Reduced mobility 
(P<0.001)** 
Fatigue (P<0.001)** 
Insomnia (P<0.001)** 
Abdominal distension 
(P<0.001)** 
 
0 
1 
2 
3 
4 
Heavy stomach 
(P<0.001)** 
Bloated stomach 
(P<0.001)** 
Reduced mobility due to 
bloated stomach 
(P<0.001)** 
Heavy stomach when 
lying down (P<0.001)** 
Exercise-induced 
dyspnea (P<0.001)** 
Cannot eat due to 
bloating (P<0.001)** 
Dyspnea (P<0.001)** 
Supplementary Figure 2. Discriminative ability of of the Ascites-Q (upper panel), FACIT-AI (middle panel) 
and ASI-7 (lower panel). *P<0.05, ** P<0.001. 
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SUPPLEMENTARY FILE 1. ASCITES-QUESTIONNAIRE
Instructions: this questionnaire consists of 11 questions. The following questions relate 
to how you felt the last 7 days. For each question mark one box, see the example below:
1a. How often did you experience fullness in your abdomen? 
1b. How much did this bother you? 
2a. How often did you experience a lack of appetite? 
2b. How much did this bother you? 
3a. How often have you felt full quickly after beginning to eat? 
3b. How much did this bother you? 
4a. How often did you experience nausea?  
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
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4b. How much did this bother you? 
5a. How often did you have abdominal pain?
5b. How much did this bother you? 
6a. How often did you have back pain? 
6b. How much did this bother you? 
7a. How often were you short of breath?
7b. How much did this bother you? 
8a. How often were you limited in your mobility? 
8b. How much did this bother you?  
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
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9a. How often were you tired? 
9b. How much did this bother you?
10a. How often did you have a problem with sleeping? 
10b. How much did this bother you?
11a. How often were you dissatisfied by the size of your abdomen?
11b. How much did this bother you? 
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Never Seldom Sometimes Regularly Often Always
     
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
Not at all A little Somewhat Quite a bit A lot
    
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CHAPTER 8
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ABSTRACT
Background and aim
Polycystic liver disease is associated with impaired quality of life (QoL). Somatostatin 
analogues reduce hepatomegaly in polycystic liver disease. We aimed to determine 
whether somatostatin analogues improve QoL and to identify factors associated with 
change in QoL in polycystic liver disease. 
Methods
We pooled data from two randomized, double-blind, placebo-controlled trials that 
evaluated QoL using the Short-Form 36 (SF-36) in 96 polycystic liver disease patients 
treated 6-12 months with somatostatin analogues or placebo. The SF-36 contains 
a summarizing physical and mental component score and was administered at baseline 
and at the end of treatment. We used random effect models to delineate the effect of 
somatostatin analogues on QoL. We determined the effect of demographics, height-
adjusted liver volume, change in liver volume, somatostatin analogue-associated side 
effects with change in QoL. In patients with autosomal dominant polycystic kidney 
disease, we estimated the effect of height-adjusted kidney volume and change in kidney 
volume in relation to QoL. 
Results
Physical component scores improved with somatostatin analogues, but remained 
unchanged with placebo (3.41 ± 1.29 vs. -0.71 ± 1.54, P=0.044). Treatment had no 
impact on the mental component score. Large liver volume was independently associated 
with larger QoL decline during follow up (-4.04 ± 2.02 points per logarithm liver volume, 
P=0.049). In autosomal dominant polycystic kidney disease, patients with large liver and 
kidney volumes had larger decline in QoL (5.36 ± 2.54 points per logarithm liver volume; 
P=0.040 and -4.00 ± 1.88 per logarithm kidney volume; P=0.039). 
Conclusion
Somatostatin analogues improve QoL in symptomatic polycystic liver disease. Halting 
the progressive nature of polycystic liver disease is necessary to prevent further decline of 
QoL in severe hepatomegaly.
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INTRODUCTION
Polycystic liver disease (PLD) occurs in two hereditary conditions: isolated in autosomal 
dominant polycystic liver disease (ADPLD) and as extra renal manifestation in autosomal 
dominant polycystic kidney disease (ADPKD).1 Quality of life (QoL) is negatively impacted 
in these patients, most likely due to mass-related symptoms such as abdominal distension, 
early satiety, and limited mobility as a result of severe hepatomegaly.2-4 Although the natural 
course of polycystic liver disease is benign, treatment is indicated in symptomatic patients 
and should focus on improving QoL.5
Current treatment options for polycystic liver disease include aspiration sclerotherapy, 
fenestration of large cysts, partial liver resection and ultimately liver transplantation.6 
Not all patients are eligible for these treatment options as efficacy depends on size 
and distribution of cysts, technical feasibility and presence of comorbidity.7 In addition, 
surgical treatment is associated with significant complication rates and open procedures 
may complicate future liver transplantation.6,8
Improved knowledge of the pathophysiology of cyst growth has led to the introduction 
of somatostatin analogues as promising non-invasive therapy for polycystic liver disease.9 
Treatment with somatostatin analogues (octreotide or lanreotide) for 6-12 months 
resulted in a mean decrease in liver volume of 5.3% compared to placebo and they seem 
to curtail the growth of kidney cysts in ADPKD patients.2,10-13
Although QoL is increasingly used as endpoint to investigate the benefit of treatment 
from patients’ perspective,14,15 the impact of somatostatin analogues on QoL is unclear. 
Different studies that investigated the efficacy of somatostatin analogues showed 
inconsistent results on QoL.2,12,16-18 As a consequence, it is still unknown whether 
somatostatin analogues improve QoL in polycystic liver disease, and how this effect is 
affected by demographic variables, liver volume and side-effects. 
A recent study demonstrated that in particular the physical domain of QoL is reduced 
in patients with polycystic liver disease, whereas the mental component is not affected.3 
In this study we investigated the impact of somatostatin analogues on QoL in patients 
with polycystic liver disease after 6-12 months of treatment by pooling data from two 
placebo-controlled randomized clinical trials that assessed QoL. We hypothesize that 
only the physical component score of the SF-36 responds to treatment. The impact of 
somatostatin analogues on QoL might be larger in ADPKD patients, as somatostatin 
analogues target both liver and kidney cysts. Our secondary objective was to identify 
factors associated with change in QoL in polycystic liver disease patients during follow up, 
in order to guide treatment decisions.
METHODS
Study selection
We included all randomized placebo-controlled trials that investigated the impact of 
somatostatin analogues in patients with polycystic liver disease on QoL as a primary or 
secondary outcome in our individual patient data pooled analysis. Two previously published 
8SO
M
A
TO
STA
TIN
 A
N
A
LO
G
U
ES IM
PRO
V
E H
EA
LTH
-RELA
TED
 Q
U
A
LITY
 O
F LIFE IN
 PO
LY
C
Y
STIC
 LIV
ER D
ISEA
SE
134
studies fitted our inclusion criteria.2,12 The authors M.N. and T.G. independently assessed 
the quality of the included trials using Cochrane Collaboration’s tool for assessing risk of 
bias in randomized trials.19 
Patients and design
In both studies, patients aged 18 years or older with polycystic liver disease within 
the context of ADPLD or ADPKD were eligible. The Dutch study included patients with 
>20 cysts revealed by CT. Patients were randomized to lanreotide 120 mg (Somatuline, 
Ipsen Pharma, Beaufour, France) subcutaneous injections or placebo treatment (1:1) and 
were followed for 6 months. The US study had a follow up time of 1 year and randomized 
patients with an liver volume of >4000 mL (unadjusted for height) or with symptomatic 
polycystic liver disease to long acting octreotide (Novartis Pharma, Basel, Switzerland) 40 
mg intramuscular or placebo (2:1). Exclusion criteria for both studies were exogenous 
estrogen therapy, pregnancy, breast-feeding, symptomatic gallstones, end-stage renal 
failure and severe comorbidity that could interfere with completion of the study. Details 
of the included studies have been published elsewhere.2,12 Additionally, for our analysis 
we excluded patients with incomplete QoL assessment and patients with a history of 
kidney transplantation, as kidney transplantation and post transplantation medication 
can affect QoL.20,21 
Health-related quality of life assessment 
Patients completed the SF-36 at baseline and at the end of study to assess change in 
QoL.22 The SF-36 is a validated generic questionnaire which incorporates two composite 
scales, the physical component scale (PCS) and mental component scale (MCS).23 
The scores of the MCS and PCS range from 8-73 and 10-74 respectively, whereas lower 
scores represent lower QoL. Scores of the SF-36 were calculated according to the user’s 
manual.24 The scores are standardized to a universal reference norm with a score of 50 
points and a standard deviation of 10 points.22 
Outcome measures
Our main outcome was change in PCS and MCS after 6-12 months of treatment 
with somatostatin analogues in patients with polycystic liver disease. Additionally, 
we investigated the impact of somatostatin analogues on change in PCS and MCS in 
a subgroup of ADPKD patients with polycystic liver disease. As a secondary analysis, 
we assessed the independent effect of six potential determinants of change in PCS 
and MCS. These determinants were based on possible confounders, reference values 
of the SF-36, literature of QoL in polycystic liver disease and the mechanism of action 
of somatostatin analogues.4,9,13,24 The determinants age, gender, diagnosis, liver volume 
at baseline, change in liver volume (%), the occurrence of somatostatin analogue-
associated side effects and, in the ADPKD subgroup, baseline kidney volume and change 
in kidney volume (%) were selected. In the original studies, liver and kidney volumes 
were measured blindly at baseline and at the end of treatment with CT or MRI. Kidney 
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volumes were only measured in ADPKD patients. Detailed information about liver and 
kidney volumetry is described elsewhere.25 We identified patients that reported at least 
once the occurrence of somatostatin analogue-associated side effects (granulomas, loose 
stools, steatorrhea and abdominal cramps) using the original case report forms in both 
treatment and placebo group. 
Statistical analysis
All statistical analyses were performed according to the intention-to-treat principle as 
described in the original studies.2,12 All liver and kidney volumes are height-adjusted. We 
checked the distribution of all our data and found that liver and kidney volumes were 
skewed. Therefore, liver and kidney volumes were transformed to logarithmic values. To 
calculate the difference among baseline characteristics between the original studies and 
treatment and placebo groups, we used the independent t-test or chi-square test. We used 
random effect models (mixed models) to investigate the effect of somatostatin analogues 
(independent variable) on the change in PCS and MCS (dependent variables). We included 
the variable ‘study center’ in the main model as a random effect to correct for possible 
heterogeneity. Results are presented as estimated change in mean score ± standard error. 
As secondary analysis we determined the associations of the possible determinants age, 
gender, diagnosis, liver volume, change liver volume, somatostatin analogue-associated 
side effects, kidney volume and change in kidney volume (independent variables) on 
change in PCS and MCS (dependent variables) by including these determinants into 
the main model. Determinants with a P-value <0.1 were retained in the main model 
using a backward elimination process.26 P-values were two-tailed and a P-value of <0.05 
was considered to indicate statistical significance. The analyses were performed with IBM 
SPSS Statistics version 20 (SPSS Inc., Chicago, IL).
RESULTS
Risk of bias assessment 
The two included trials show no high risk of bias on study or outcome level, see 
Supplementary Figure 1. 
Baseline characteristics
Of the 96 patients included in the original studies, 87 were eligible to be included in 
our pooled analysis. We have excluded 4 patients because of kidney transplantations 
and 5 patients based on incomplete (n=3) or missing (n=2) QoL assessment. Baseline 
characteristics of the included studies were similar between both studies, except that 
mean PCS score at baseline was lower in the Dutch study compared to the US study (41.3 
vs. 46.5 points, P=0.027) and the percentage of ADPKD patients was higher in the US 
study compared to the Dutch study (58.0% vs. 78.4%, P=0.041). In total 51 patients 
were allocated to somatostatin analogue treatment (24 to octreotide, 27 to lanreotide) 
and 36 to placebo. Baseline characteristics of the treatment and placebo group are 
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reported in Table 1 and showed no significant differences. Mean age of patients was 
49 years, the majority female (89%, n=77) and patients had a median height-adjusted 
liver volume of 2646 mL. Mean baseline scores of PCS and MCS were 43.51 ± 10.81 
and 50.02 ± 10.11 respectively. Two-third (67%, n=58) of patients had ADPKD, with an 
estimated glomerular filtration rate (eGFR) of 63 mL/min/1.73 m2 and median height-
adjusted kidney volume of 550 mL. Baseline PCS and MCS of ADPKD did not significantly 
differ from ADPLD patients (respectively 43.31 ± 10.69 vs. 43.92 ± 11.21, P=0.80 and 
49.26 ± 10.73 vs. 51.54 ± 8.71, P=0.29). One patient was excluded for the ADPKD 
subgroup analysis because kidney volume could not be measured because of a history 
of nephrectomy. 
Impact of somatostatin analogues on QoL
In the pooled analysis with correction for study center and baseline PCS, patients on 
somatostatin analogues had an improvement in PCS of 3.41 ± 1.29 points after 6-12 
months, while the placebo group did not improve (-0.71 ± 1.54 points; P=0.044; Figure 1, 
left panel). There was no significant difference in change in MCS between the treatment 
group and placebo group in the pooled analysis (-1.16 ± 1.40 vs. 1.10 ± 1.57, P=0.253). 
Determinants associated with change in QoL 
Age (P=0.505), gender (P=0.753), diagnosis (P=0.688) and change in liver volume 
(P=0.748) were not associated with change in PCS, see Table S1. Larger liver volume at 
baseline was associated with larger decline in PCS at follow-up (-4.04 ± 2.02 points per 
logarithm liver volume, P=0.049). Figure 1 (right panel) shows that the PCS of patients 
Table 1. Baseline characteristics of included patients with polycystic liver disease per treatment allocation. 
Treatment allocation
Somatostatin analogues 
(n=51) 
Placebo  
(n=36)
P-value
Age, years 49 ± 9 49 ± 7 0.691
Gender: male/female, % 6/45 (11.8% / 88.2%) 4/32 (11.1% / 88.9%) 0.926
Diagnosis: ADPKD/ADPLD, % 32/19 (62.7 / 37.3%) 26/10 (72.2% / 27.8%) 0.362
Total liver volume, mL 2613.9 ± 1400.6 2680.4 ± 1415.9 0.577
Total kidney volume, mLa 277.8 ± 461.4 306.6 ± 486.5 0.688
eGFR, ml/min 71.1 ± 22.9 70.6 ± 25.1 0.915
Physical component score  
SF- 36 baseline, points
43.0 ± 10.7 44.2 ± 11.1 0.598
Mental component score 
SF-36 baseline, points
51.1 ± 8.8 48.5 ± 11.7 0.281
Data are given as mean ± standard deviation, unless indicated otherwise. aLiver and kidney volume are height-
corrected and presented as mean ± standard deviation. Kidney volume was exclusively measured in ADPKD patients. 
eGFR: estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula.
8SO
M
A
TO
STA
TIN
 A
N
A
LO
G
U
ES IM
PRO
V
E H
EA
LTH
-RELA
TED
 Q
U
A
LITY
 O
F LIFE IN
 PO
LY
C
Y
STIC
 LIV
ER D
ISEA
SE
137
with somatostatin analogue-associated side effects decreased with 1.32 ± 1.56 points, 
while the PCS of the group without somatostatin analogue-associated side effects 
improved with 4.60 ± 1.80 points. This difference was statistically significant (P=0.021). 
In total, 84% of patients in the treatment group reported somatostatin analogue-
associated side effects compared to 19% in the placebo group (P<0.001), see Table 2 for 
more details. No variables were associated with change in MCS; age (P=0.529), gender 
(P=0.281), diagnosis (P=0.314), liver volume (P=0.491), change in liver volume (P=0.691), 
and somatostatin analogue-associated side effects (P=0.854). 
ADPKD subgroup
In ADPKD patients, treatment improved the PCS with 4.61 ± 1.74 points compared to 
a decline in PCS in the placebo group of 2.36 ± 1.96 points, P=0.010, see Figure 1, middle 
panel. There was no significant difference in change in MCS between the treatment 
Figure 1. Estimated changes (mean ± 95% CI) in physical component score of the SF-36 after 6-12 
months follow up calculated by random effect models. Left panel: individual estimated changes of patients 
treated with somatostatin analogues versus placebo. Middle panel: subgroup of autosomal dominant 
polycystic kidney disease patients (ADPKD) treated with somatostatin analogues versus placebo. Right 
panel: patients with somatostatin analogue-associated side effects versus patients with no side effects.  
Table 2. Prevalence of most common somatostatin analogue-associated side effects per treatment allocation. 
Total group  
(n=87)
Autosomal dominant polycystic 
kidney disease subgroup (n=58)
Somatostatin 
analogue group 
(n=51)
Placebo group 
(n=36)
Somatostatin 
analogue group 
(n=32)
Placebo group 
(n=26)
Granuloma 24% 19% 22% 23%
Flatulence 22% 11% 28% 15%
Loose stools 51% 33% 56% 38%
Abdominal cramps 31% 8% 31% 12%
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group and placebo group (-1.20 ± 1.42 vs. 1.16 ± 1.59, P=0.254). Large baseline liver 
volume and kidney volume were both associated with larger decline in PCS at follow-up 
(respectively -5.36 ± 2.54 points per logarithm liver volume; P=0.040 and -4.00 ± 1.88 
per logarithm kidney volume; P=0.039), see Supplementary Table 1. PCS in the group that 
experienced somatostatin analogue-associated side effects remained stable with -0.64 ± 
1.67 points, while patients without side effects improved with 4.80 ± 2.12 points, P=0.071. 
In the treatment group, 84% of patients reported somatostatin analogue-associated 
side effects compared to 27% in the placebo group, see Table 2. The determinants age 
(P=0.758), gender (P=0.987), change in liver volume (P=0.297) and change in kidney 
volume (P=0.267) had no significant impact on the PCS. Again, none of the determinants 
were associated with change in MCS; age (P=0.413), gender (P=0.318), liver volume 
(P=0.520), change in liver volume (P=0.712), somatostatin analogue-associated side 
effects (P=0.532); kidney volume (P=0.486) and change in kidney volume (P=0.511). 
DISCUSSION
This pooled analysis of data of two randomized controlled trials shows that 6-12 
months treatment with somatostatin analogues improves QoL in patients with polycystic 
liver disease in comparison to placebo. In line with our hypothesis, there was a larger 
improvement in QoL in ADPKD patients compared to the total group. Irrespective of 
treatment, patients with severe hepatomegaly showed a larger decline in QoL than 
patients with smaller liver volumes and somatostatin analogue-associated side effects 
were associated with a decrease in QoL. In the ADPKD subgroup, larger liver and kidney 
volume were both associated with larger decline in QoL.  
The original data of the included studies indicated a positive trend towards 
improvement of QoL after somatostatin analogue treatment, but lacked statistical power 
due to small sample sizes.2,12 Two other studies that evaluated the impact of somatostatin 
analogue treatment on QoL using the generic EQ-5D health state questionnaire showed 
no change in the five domains after treatment.18,27 However, the EQ-5D is less sensitive to 
change than the SF-36.28,29 We were able to show a significant improvement in QoL after 
somatostatin analogue treatment and we could investigate determinants associated with 
QoL in a relatively large sample of patients with polycystic liver disease. 
The impact of other treatment modalities for polycystic liver disease on QoL has 
not been studied extensively. A few studies on surgical options reported improved 
QoL after laparoscopic fenestration and liver transplantation.30-33 Two studies reported 
only postoperative QoL values while two other studies asked patients to assess their 
preoperative QoL retrospectively, a method that bears a high risk for bias.34 Postoperative 
physical component scores of the SF-36 after cyst fenestration 49 and hepatic resection 45 
are comparable with the physical component scores of patients treated with somatostatin 
analogues for 6-12 months,47 indicating that somatostatin analogues may be a suitable 
alternative for patients ineligible for surgery.32
Our results showed that QoL of patients with severe hepatomegaly decreased more 
than QoL of patients with smaller liver volumes during follow up, suggesting that curtailing 
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liver growth is necessary to prevent QoL decline. This is in line with the results of a recent 
cross-sectional study in a large population of early stage ADPKD patients (n=558) that 
showed lower QoL in patients with larger liver volumes.4 
Surprisingly, change in liver volume was not associated with change in QoL in this 
study. Possibly, the change in total liver volume was too small to measure an independent 
effect on QoL. Strategically located reductions in liver volume may have reduced pressure 
on adjacent organs or structures, thereby relieving symptoms without large reduction 
in liver volume. However, this did not translate in a tangible effect in gastrointestinal 
symptoms on the generic gastrointestinal questionnaire administrated in the Dutch 
study.12 Although we could not show an independent impact of change in liver volume in 
this study, the larger decline of QoL in severe hepatomegaly provides a strong rationale 
for volume reducing therapies. 
Somatostatin analogue-associated side effects were associated with a decrease in QoL 
and this may curtail the beneficial effect on QoL. Although a large proportion of patients 
reported at least once somatostatin analogue-associated side effects, we still observed an 
overall beneficial effect on QoL in the treatment group. Most side effects occur in the first 
months and disappear after prolonged use.7 Discontinuation of somatostatin analogue 
treatment should be considered in patients with persistent side effects, as these agents 
are expensive and selective use is important to limit the economic burden. 
ADPKD patients with large liver and kidneys showed a larger decline in QoL, indicating 
that treatments targeting both liver and kidney cysts should be considered in these 
patients. In addition to somatostatin analogues, vasopressin V2 receptor antagonists are 
investigated in ADPKD and showed delayed growth of kidney cysts.35 In our opinion 
somatostatin analogues are preferred in ADPKD patients with symptomatic polycystic 
liver disease to improve QoL as these agents target liver and kidney cysts, whereas the V2 
receptor is not expressed in liver tissue.36 Furthermore, vasopressin V2 receptor antagonists 
are associated with side effects including increased aquaresis that may compromise QoL.35
The main strength of this study is the use of individual patient data of two randomized 
controlled trials with highly comparable baseline characteristics. A recent pooled analysis 
showed equal reduction in liver volume of octreotide and lanreotide and therefore we 
expected a similar impact on patient’s QoL.13 
A limitation of this study is the difference between both studies regarding the duration 
of follow up and the country where the study originated that could have affected 
the impact on QoL. However, we have shown a similar impact of somatostatin analogues 
and placebo on QoL in both groups. Baseline physical component scores were slightly 
lower in the Dutch study, leading to a somewhat greater improvement in the physical 
domain after treatment (data not shown). Additionally, we reduced bias by inclusion of 
the random effect ‘study center’ in our statistical model. 
Secondly, we could only assess the impact of 6-12 months somatostatin analogue 
treatment on QoL. A prior study showed that discontinuation of somatostatin analogues 
immediately led to recurrent cyst growth, which indicates that continuous treatment is 
indicated.17 An ongoing observational study that follow polycystic liver disease patients 
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treated with octreotide during four years will show whether the beneficial effects of 
somatostatin analogues on QoL can be extended.   
Thirdly, it is unclear if the significant improvement in QoL after use of somatostatin 
analogues has led to a clinically relevant improvement in patients’ wellbeing. There is no 
literature on what constitutes a clinically relevant difference in SF-36 score in polycystic 
liver disease. However, a Cohen’s effect size of 0.5 often correlates with a clinical important 
difference.37 We found an effect size of 0.38 in physical component score change after 
somatostatin analogue treatment in the total group and an effect size of 0.65 in ADPKD 
patients, indicating that the change was clinically significant in the ADPKD subgroup.  
Our primary outcome was change in QoL measured by a generic QoL questionnaire, 
while disease specific questionnaires are in general more sensitive to change.38 Since 
a polycystic liver disease-specific questionnaire was lacking, only generic questionnaires 
have been used to assess the impact of somatostatin analogue treatment on QoL. 
Finally, we cannot rule out a placebo effect of somatostatin analogue treatment on 
QoL. Although it was a double blind randomized controlled trial, the high frequency 
of gastrointestinal side-effects (84.3%) in the treatment group may have compromised 
blinding. However, 19.4% of patients in the placebo group reported similar complaints 
and in the case of a placebo effect of somatostatin analogues one might also expect 
improvement in the mental component in this group. 
In conclusion, somatostatin analogue treatment can be used to improve QoL in patients 
with symptomatic polycystic liver disease. Halting the progressive nature of polycystic liver 
disease is necessary to prevent further decline of QoL in severe hepatomegaly.
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Supplementary Figure 1. Risk of bias summary of the included trials judged by the authors. 
Definition of symbols: − low risk of bias; ? unclear risk of bias; + high risk of bias.   
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
The main aim of this thesis was to define patient-reported health in patients with 
polycystic liver disease (PLD). This main aim is divided in three objectives: 
I. To assess the impact of polycystic liver disease on quality of life
II. To develop and validate a patient-reported polycystic liver disease questionnaire
III. To investigate which therapies improve patient-reported health in polycystic 
liver disease
I. QUALITY OF LIFE OF POLYCYSTIC LIVER DISEASE PATIENTS
This thesis has contributed to the paradigm shift from objectively measurable liver 
volumes towards subjectively patient-reported outcomes in PLD. We showed that 
the physical dimension of quality of life (QoL) was significantly impaired in severe PLD 
patients compared to the general population, while the mental dimension was not 
affected (Chapter 2). 
In a meta-analysis of QoL in ADPKD, we demonstrated that heterogeneity in QoL 
can be partially explained by differences in liver volume (Chapter 3). Larger liver volume 
was associated with lower QoL, while renal function and kidney volume were not. These 
findings emphasize the importance of patient-reported health as outcome measure to 
determine treatment efficacy in PLD.    
II. DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED 
POLYCYSTIC LIVER DISEASE QUESTIONNAIRE
To measure patient-reported health accurately, we developed and validated a PLD-specific 
questionnaire (PLD-Q) that reflects symptom burden and its impact on patients’ well-
being (Chapter 4). Evidence was provided for content validity, reliability, good score 
distributions, convergent validity, reproducibility and discriminative validity in a Dutch 
and US cohort. The PLD-Q correlated with QoL and was able to distinguish between 
symptoms of polycystic livers and kidneys. 
Using the PLD-Q, we demonstrated that PLD patients with larger liver volumes 
experienced more symptoms and QoL impairment (Chapter 5), providing a strong 
rationale for liver reducing therapies. All symptoms included in the PLD-Q were related 
to liver volume, except for abdominal pain. Treatment indications can be tailored 
towards these volume-related symptoms. A height-corrected liver volume ≥1600 mL was 
associated with substantial symptom burden measured and QoL impairment. This cut-off 
volume can be used as evidence-based inclusion criteria for symptomatic disease in future 
studies.
Subsequently, we showed that the PLD-Q is a better outcome than cyst volume 
reduction to measure treatment efficacy from patients’ perspective in aspiration 
sclerotherapy (Chapter 6). Both PLD-Q and cyst volume reduction were responsive to 
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therapy. In contrast to cyst volume changes, the PLD-Q also discriminated between 
patients that clinically benefit from the intervention or not. 
Finally, we used the qualitative framework of the PLD-Q as template for the Ascites-Q, 
a modified PLD-Q for symptoms in cirrhotic ascites. Both multiple cysts in PLD and ascites 
lead to fluid-related mass effects. We showed that the Ascites-Q correlated with QoL, was 
responsive to changes in symptoms after paracentesis, and had good discriminative ability 
between patients with no, mild, and severe ascites (Chapter 7).
III. THERAPIES THAT IMPROVE PATIENT-REPORTED HEALTH IN 
POLYCYSTIC LIVER DISEASE
Using the PLD-Q and a general measure for QoL assessment, we investigated the efficacy 
of aspiration-sclerotherapy and somastatin analogues on patient-reported health 
in a standardized manner. In patients with symptomatic dominant cysts, aspiration 
sclerotherapy ameliorates all PLD-related symptoms, except for fear or anxiety for the future 
(Chapter 6). In patients with diffuse cystic disease, somatostatin analogue treatment may 
improve physical QoL (Chapter 8). Larger liver volume at baseline was associated with 
larger decline in physical QoL at follow-up. Therefore, halting the progressive nature of 
PLD is necessary to prevent further decline of QoL. 
REFLECTION
Strength of this thesis is that all patient-reported outcomes were collected prospectively, 
as retrospective assessment is highly subjected to recall bias. Furthermore, we pooled 
individual patient data of prospective studies in Chapter 2, 5 and 8, which usually lead to 
more reliable results than meta-analysis on study level.1 Finally, the collaboration between 
two world wide expert centers for PLD (Radboud University Nijmegen Medical Center, 
the Netherlands, and Mayo Clinic, US) has resulted in a solid qualitative framework and 
extensive validation process for the PLD-Q. Using this qualitative foundation, we could 
develop an ascites-specific questionnaire as a spin-off project. The high quality of our 
work was acknowledged by the Food and Drug Administration (FDA), which has accepted 
the PLD-Q in their qualification program for patient-reported outcomes that can support 
drug-labeling claims. 
This thesis also has certain limitations that should be recognized. First, we mainly 
assessed symptoms and QoL of patients included in clinical studies. It is known that these 
patients do often not reflect the real life population.2,3 In addition, a Hawthorne effect 
may occur.4 This indicates the beneficial effect on health perception simply related to study 
participation, regardless of the intervention they may receive. Recently, an international 
registry has started to collect data of all PLD patients that visit the outpatient departments 
in at least ten different international hospitals. This registry will provide an overview of 
patient-reported health of PLD patients in daily clinical practice and will reveal whether 
their health is different from patients in clinical  studies.
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Second, cultural differences may influence symptom presentation and their impact on 
QoL.5 Although symptom presentation of PLD was fairly similar in Dutch and US patients, 
this cannot be accepted without formal replication and adaptation for non-Western 
cultures. Apart from differences in clinical presentation, items of the PLD-Q may be 
interpreted differently and assessment of some PLD-related symptoms such as problems 
with intercourse may be culturally not accepted. For example, Japanese translations of 
the SF-36 showed that there was no Japanese equivalent for lifting or carrying groceries, 
which is an ordinary activity in the Dutch culture.6 Therefore, we advise to perform decent 
translations and cultural adaptations of the PLD-Q prior to use in other countries.   
Finally, the effect of coping, the strategy to deal with disease-related problems 
and stress, on patient-reported health was not assessed in our studies. Patients with 
adequate coping strategies may have less symptoms and better QoL than patients that 
do not cope with their disease.7 Previous studies showed that cognitive behavior therapy 
to develop adequate coping strategies improved symptoms and QoL in other chronic 
diseases including diabetes and irritable bowel disease.8-11 It would be of interest to assess 
whether coping strategies of PLD patients are adequate and whether improvement can 
reduce disease burden.  
IMPLICATIONS AND FUTURE PERSPECTIVES
From liver volume to patient-reported health
We have shown that subjective wellbeing is the primary interest from patients’ perspective 
in this benign disease. Patient-reported outcomes such as the PLD-Q can support drug-
labeling claims in chronic conditions for which the intention is not necessarily to cure, but 
to ameliorate symptoms or improve QoL.12 Disease specific outcomes such as the PLD-Q 
are preferable for that purpose, as they are usually more sensitive to smaller differences 
in health compared to general QoL tools.13  
In drug-labeling, the cost effectiveness of a drug is also taken into account. The costs 
of a drug that diminishes liver volume without improvement of patients’ subjective health 
cannot be justified in PLD. However, there is no indication for liver volume reducing 
therapy in asymptomatic patients with large liver volumes. Similarly, we do not think that 
volume reducing therapy will be effective in highly symptomatic patients with a normal 
sized liver. Therefore, liver volume remains the targeted pathway to improve patient-
reported health in PLD. Until a more accurate biomarker is discovered, liver volume cannot 
be omitted as secondary outcome. 
PLD-Q in clinical practice
Previous studies have shown that routine measurement of patient-reported outcomes 
can improve health outcomes.14 Two randomized controlled trials in the field of oncology 
showed that it facilitates communication about symptoms, resulting in better QoL.15,16 
Defining a minimally important change in PLD-Q score that requires change in clinical 
management may lead to less unnecessary routinely follow up visits and radiological 
imaging in PLD. 
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Ideally, the PLD-Q can differentiate between liver- and kidney related problems in 
ADPKD patients with both large liver and kidneys. Although PLD patients scored 
higher than ADPKD patients without PLD on all PLD-Q symptoms except for back pain 
(Chapter 4), there are no cut-off scores known that direct towards liver or kidney specific 
treatment. As there is no golden standard to differentiate between liver or kidney origin of 
symptoms, such cut-off scores can only be investigated in patients that undergo (partial) 
liver resection or nephrectomy. 
Dynamic liver volume
We provided evidence for a cross-sectional relation between liver volume and patient-
reported health, but were unable to investigate the role of dynamic changes in liver 
volume. Young women have larger natural growth rates compared to older women and 
men.17,18 We do not know yet whether patients with fast cyst growth rates are also 
more prone to symptomatic disease. The DIPAK observational study, a large study in 
ADPKD patients with annual symptom assessment and triennial volume measurements 
will elucidate this question in the near future.        
Patient-reported health in current therapies
In this thesis, we assessed the effect of somatostatin analogues and aspiration sclerotherapy 
on patient-reported health. To optimize PLD treatment, a number of remaining questions 
must be solved. In case of a large dominant hepatic cyst, available treatment options are 
aspiration-sclerotherapy or laparoscopic fenestration. Although aspiration sclerotherapy 
improved patient-reported health, remaining question for patients with a large dominant 
cyst is whether this therapy achieves comparable improvements of symptoms and QoL 
as laparoscopic fenestration. The latter is a more invasive treatment with higher risk of 
complications,19 but is considered as more effective by some doctors. A formal comparison 
of both therapies that elucidates this question is lacking. 
For patients with severe PLD, treatment options are limited to partial liver resection, liver 
transplantation and somatostatin analogues. A recent study showed sustained long-term 
liver volume reductions after partial liver resection.20 However, its effect on symptoms 
and QoL was not investigated. With the scarcity of donors for liver transplantation, it 
would be of interest to assess whether similar long-term improvements in wellbeing are 
achieved after partial liver resection compared to liver transplantations. 
In non-surgical candidates, somatostatin analogues can improve QoL. We showed 
improvements after 6-12 months of therapy, while a more recent study showed that 
QoL improvements can be extended up to four years.21 Due to high cost and limited 
experience in long-term use, these agents should be restricted to patients with very 
progressive disease awaiting a liver transplantation.    
Future therapies
With the current treatment strategies for PLD, we are not able to improve symptoms and 
QoL of all PLD patients. Not all patients are candidates for aspiration sclerotherapy or 
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surgery due to comorbidity or liver phenotype. Liver volume reductions of somatostatin 
analogues are modest and treatment does not restore QoL completely. Together, this 
justifies the need for new treatment options. 
A new candidate drug for PLD is the more potent somatostatin analogue Pasireotide 
long-acting release (Novartis Pharma, Basel, Switzerland). This drug led to larger liver 
volume reductions in rodents and a clinical study is currently in progress to assess 
the effect on liver volume and QoL (NCT01670110). Another potential target is matrix 
metalloproteinase, as polycystic human and rat cholangiocytes expressed increased 
activity of these enzymes.22 Treatment with a metalloproteinase inhibitor lead to decreased 
cystogenesis in vitro and in an animal model, but no clinical data is available yet. Other 
possible targets for therapy are components of cyst growth pathways such as intracellular 
calcium, receptor tyrosine kinase and histone deacetylase.23 More pre-clinical studies are 
needed to explore their potential. 
CONCLUSION
This thesis revealed that severe hepatomegaly lead to significant symptom burden 
and impaired QoL in PLD. We provided the PLD-Q as valid patient-reported outcome 
measure that can be used to evaluate effectiveness of current and new therapies for PLD. 
Aspiration sclerotherapy and somatostatin analogues can be used to improve wellbeing 
of these patients. 
RESEARCH AGENDA
 y Investigate the effect of liver volume growth rate on symptoms and QoL
 y Explore the effect of routine measurement of symptoms and QoL in PLD
 y Assess the impact of surgical therapies on symptoms and QoL
 y Develop more effective drug therapies to improve symptom burden and QoL
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ENGLISH SUMMARY
Polycystic liver disease (PLD) is a genetic disorder characterized by progressive growth 
of multiple liver cysts. It is part of the phenotype of two inherited disorders: autosomal 
dominant polycystic liver disease (ADPLD) and as an extrarenal manifestation of autosomal 
dominant polycystic kidney disease (ADPKD). Clinical presentation varies from a few liver 
cysts up to liver volumes of more than ten liter. 
Although liver volume is an objective measure that can reflect disease severity, this does 
not necessarily reflect patient well-being. From patient perspective, liver volume is only 
a surrogate outcome that mediates treatment success. As the natural course of PLD is 
usually benign, therapies for PLD should focus on improving symptoms and QoL instead 
of mere liver volume. This thesis focuses on patient-reported health in PLD. 
In Chapter 2, we have assessed the impact of PLD on quality of life (QoL). The physical 
dimension of QoL was significantly impaired in severe PLD patients compared to 
the general population, while the mental dimension was not affected. In this study we 
found no relation between liver volume and QoL, possibly because we did not investigate 
the total spectrum of liver volumes but included only patients with severe hepatomegaly.
Chapter 3 describes a meta-analytic summary of available evidence on QoL in ADPKD. We 
showed that the physical component of QoL was impaired in ADPKD patients compared 
to the general population. The large differences in QoL between studies could partly 
be explained by differences in liver volumes, as larger liver volume was associated with 
lower QoL. 
In Chapter 4, we have developed and validated a PLD-specific questionnaire (PLD-Q) that 
reflects symptom burden and its impact on patients’ well-being. Evidence was provided 
for content validity, reliability, good score distributions, convergent validity, reproducibility 
and discriminative validity in a Dutch and US cohort. The PLD-Q correlated with QoL and 
was able to distinguish between symptoms of polycystic livers and kidneys. 
The developed PLD-Q was used in Chapter 5 to measure PLD-related symptoms. We 
demonstrated that larger liver volumes are associated with more symptoms and QoL 
impairment. All symptoms included in the PLD-Q were liver volume related, except for 
abdominal pain. Particularly, polycystic livers above twice the normal size were associated 
with symptomatic disease and QoL below levels seen in the general population. 
Chapter 6 describes that aspiration sclerotherapy significantly improved all PLD-related 
symptoms in patients with large symptomatic hepatic cysts, except for fear or anxiety for 
the future. We showed that the PLD-Q is a better outcome from patients’ perspective 
to measure efficacy of aspiration sclerotherapy than cyst volume reduction. Both PLD-Q 
and cyst volume reduction were responsive to change after therapy. The PLD-Q also 
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discriminated between patients that clinically benefit from the intervention or not, in 
contrast to cyst volume changes. 
In Chapter 7, we developed the Ascites-Q, a modified PLD-Q for cirrhotic ascites, and 
assessed validity and responsiveness of this and two other patient-reported outcomes 
(FACIT-AI and ASI-7) for symptom assessment in cirrhotic ascites. The Ascites-Q was 
the best ascites-specific outcome to evaluate the effect of existing and experimental 
therapies on symptom relief in cirrhotic ascites. The ASI-7 is an adequate alternative, 
while the FACIT-AI should not be used in a cirrhotic population.
Chapter 8 shows that somatostatin analogue treatment can be used to improve physical 
QoL in patients with symptomatic PLD. Treatment had no impact on mental QoL. More 
severe hepatomegaly at baseline was associated with larger decline in physical QoL 
at follow-up. 
This thesis revealed that severe hepatomegaly lead to significant symptom burden and 
impaired QoL in PLD. Therefore, halting the progressive nature of PLD is necessary to 
prevent further decline of QoL. We provided the PLD-Q as valid patient-reported outcome 
measure that can be used to evaluate effectiveness of current and new therapies for PLD. 
Aspiration sclerotherapy and somatostatin analogues can be used to improve wellbeing 
of these patients. 
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Polycysteuze leverziekte (PLD) is een erfelijke aandoening waarbij meerdere cysten 
aanwezig zijn in de lever. Polycysteuze leverziekte komt voor in twee ziektebeelden: 
autosomaal dominante polycysteuze leverziekte (ADPLD) en autosomaal dominante 
polycysteuze nierziekte (ADPKD). Als gevolg van de levercysten kan de lever tot wel 
tien keer vergroot zijn. Ondanks dat levervolume objectief gemeten kan worden, geeft 
levervolume niet altijd een goede afspiegeling van het welzijn van de patiënt. Vanuit 
patiëntenperspectief moet behandeling gericht zijn op het verbeteren van symptomen 
en kwaliteit van leven (KvL) (ook wel patiëntgerapporteerde gezondheid genoemd), in 
plaats van op het verminderen van levervolume alleen. Dit proefschrift focust zich op 
patiëntgerapporteerde gezondheid in PLD.
In Hoofdstuk 2 is de invloed van PLD op KvL onderzocht. De fysieke component van 
KvL van ernstige PLD patiënten was significant lager vergeleken met de algemene 
populatie, terwijl de mentale component niet was aangedaan. In deze studie werd 
geen relatie gevonden tussen levervolume en KvL. Mogelijk komt dit omdat niet het 
gehele spectrum van levervolumina onderzocht werd, maar er alleen naar ernstige PLD 
gekeken is. 
Hoofdstuk 3 beschrijft de resultaten van een systematisch literatuuronderzoek en meta-
analyse van KvL bij patiënten met ADPKD. De fysieke component van KvL was lager 
bij ADPKD patiënten vergeleken met de algemene populatie. De grote verschillen in 
KvL tussen de verschillende studies konden deels verklaard worden door verschillen in 
levervolume. Grotere levervolumes waren geassocieerd met lagere KvL. 
In Hoofdstuk 4 wordt de ontwikkeling en validatie van een PLD-specifieke vragenlijst 
(PLD-Q) beschreven. Deze vragenlijst meet ziektespecifieke symptomen en een hogere 
score wijst op meer symptomen. Resultaten van deze studie laten zien dat de PLD-Q 
goede inhoudsvaliditeit, betrouwbaarheid, spreiding in scores en reproduceerbaarheid 
heeft in een Nederlandse en Amerikaanse patiëntenpopulatie. Patiënten met hogere 
PLD-Q scores hadden lagere KvL (convergente validiteit). De vragenlijst kon onderscheid 
maken tussen symptomen van polycysteuze lever en nieren (discriminante validiteit). 
De ontwikkelde PLD-Q werd gebruikt in Hoofdstuk 5 om ziektespecifieke symptomen 
te meten in patiënten met milde, matig-ernstige en ernstige PLD. Alle symptomen 
van de PLD-Q namen toe in ernst in patiënten met grotere levervolumina, met 
uitzondering van buikpijn. Voornamelijk patiënten met polycysteuze levers meer dan 
tweemaal de normale grootte (groter of gelijk aan matig-ernstige PLD) hadden last 
van PLD-gerelateerde symptomen. Bij deze patiënten zakt de KvL onder het niveau van 
de algemene populatie. 
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Hoofdstuk 6 toont dat aspiratie sclerotherapie bij patiënten met grote symptomatische 
levercysten resulteert in verbetering van alle PLD-gerelateerde symptomen, behalve 
het symptoom angst voor de toekomst. Voor het meten van behandelsucces vanuit 
patiëntenperspectief blijkt de PLD-Q een betere uitkomstmaat dan cystevolume. 
Zowel de PLD-Q als cystevolume kon verandering registreren na behandeling. 
De PLD-Q kon daarnaast ook patiënten onderscheiden waarbij er patiëntgerapporteerde 
gezondheidverbetering optrad, terwijl verandering in cystevolume niet gerelateerd was 
aan patiëntgerapporteerde gezondheidverbetering. 
In Hoofdstuk 7 werd een ascites-specifieke vragenlijst (Ascites-Q) ontwikkeld, door 
de PLD-Q aan te passen voor patiënten met ascites op basis van levercirrose. De validiteit 
en responsiviteit van de Ascites-Q en twee andere patiëntgerapporteerde vragenlijsten 
voor ascites (FACIT-AI and ASI-7) werden vergeleken. De Ascites-Q was de meest geschikte 
ziektespecifieke vragenlijst om het effect van behandeling voor ascites bij levercirrose te 
meten. De ASI-7 is een goed alternatief, terwijl de FACIT-AI niet gebruikt dient te worden 
bij patiënten met levercirrose.
Hoofdstuk 8 laat zien dat somatostatine analogen gebruikt kunnen worden om de 
fysieke component van KvL te verbeteren bij patiënten met symptomatische PLD. 
Behandeling had geen effect op de mentale KvL. Ernstige leververgroting bij start 
van de studie was voorspellend voor snellere achteruitgang in fysieke KvL na zes tot 
twaalf maanden. 
Concluderend laat dit proefschrift zien dat ernstige leververgroting als gevolg van 
polycysteuze leverziekte leidt tot een duidelijke ziektelast en verminderde kwaliteit van 
leven. Remmen van het progressieve beloop van polycysteuze leverziekte is noodzakelijk 
om verdere achteruitgang van kwaliteit van leven te voorkomen. De ontwikkelde PLD-Q 
en Ascites-Q kunnen gebruikt worden als valide patiëntgerapporteerde uitkomstmaat 
om het behandeleffect op symptomen van bestaande en nieuwe therapieën te meten. 
Aspiratie sclerotherapie en somatostatine analogen kunnen worden toegepast om het 
welzijn van polycysteuze leverziekte patiënten te verbeteren. 
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DANKWOORD
Met dit laatste hoofdstuk komt er een einde aan een fantastische periode als arts-
onderzoeker. Ik heb dit proefschrift met veel plezier geschreven, maar had dit nooit 
kunnen doen zonder hulp van velen. Graag wil ik allen bedanken die mij hebben geholpen 
bij de totstandkoming van dit werk. 
Allereerst, heel veel dank aan alle patiënten die mee hebben geholpen aan mijn onderzoek. 
Jullie kwamen van heinde en verre om vragenlijsten in te vullen, bloed af te laten nemen 
en scans te ondergaan. Ik hoop dat we samen een steentje bij hebben kunnen dragen 
aan een betere behandeling voor polycysteuze leverziekte. 
Prof. dr. J.P.H. Drenth, beste Joost, jij zei tijdens mijn sollicitatie dat je altijd voor het 
hoogst haalbare gaat, en niets is minder waar. Ik heb grote bewondering voor jouw 
gedrevenheid. Door jouw netwerk kreeg ik de mogelijkheid een deel van mijn promotie 
door te brengen in de Mayo Clinic, Rochester (MN). Deze unieke kans heb ik met 
beide handen aangegrepen. Dat dit midden in de winter was, heb ik maar voor lief 
genomen. Naast wetenschap, bood je mij de ruimte voor persoonlijke ontwikkeling 
in de vorm van medisch leiderschap, timemanagement en presentatievaardigheden. 
Vooral van dat laatste kan ik nog veel van je leren. Zelfs voor de rol van presentator van 
het UEG summer school songfestival draai jij je hand niet om! Vele malen dank voor 
de prettige samenwerking. 
Dr. T.J.G. Gevers en Dr. W. Kievit, beste Wietske en Tom, wat heb ik mij gelukkig 
geprezen met twee fantastische copromotoren. Jullie enthousiasme voor onderzoek is 
aanstekelijk en heeft mij veel motivatie gegeven. Met een scherpe methodologische blik 
hebben jullie mij veel geleerd over het doen van onderzoek. Waar ik jullie in het begin 
regelmatig kwijt was wanneer jullie over ingewikkelde statistische methodes spraken, 
kom ik tegenwoordig aardig mee. Wietske, ik vind het knap hoe jij jouw drukke baan 
combineert met je gezin en daarbij nog tijd hebt voor leuke dingen. Ik ben erg blij dat ik 
een aantal timemanagement tips van jou heb gekregen! Tom, jij was al mijn copromotor 
voordat je überhaupt zelf gepromoveerd was. Ik denk dat dit genoeg zegt over jouw 
grote talent voor wetenschap. Ik ben trots op het resultaat wat we samen neer hebben 
weten te zetten. Heel erg veel dank daarvoor! 
Leden van de manuscriptcommissie, Prof. dr. G.P. Westert, Prof. dr. J.F.M. Wetzels 
en Prof. dr. R. T. Gansevoort, hartelijk dank voor de tijd en energie die jullie gestoken 
hebben in het doorlezen van mijn proefschrift. 
Dr. M.C. Hogan, dear Marie, thank you for your supervision during my time in 
Rochester. Besides a great supervisor, you were an excellent tour guide during our trips in 
the Minnesota countryside. Dr. P.S. Kamath, you inspired me by showing how to be an 
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excellent physician and great researcher at the same time. Thank you for your confidence 
in me! Prof. dr. J. A. Sloan, dear Jeff, thank you for your unceasing enthusiasm. Hopefully 
we can cash in on our successful collaboration with FDA-approval of the PLD-Q. 
Marie (E.), you were of great help with measuring liver volumes, but most of all, thank 
you for being a great friend during my time in Rochester. Karuna and Erik, I have 
never met such welcoming people as you are! Karuna, it was a great pleasure to be 
your roommate. Erik, happy to have you as a colleague in the future! Tuesday Newts 
group, thanks for the burger and beer breaks during my research fellowship. Fouad, 
Maria and Alfonso, I really enjoyed our international food parties. Good luck with your 
scientific careers. 
Alle leden van het DIPAK-consortium, dank voor alle leerzame en gezellige 
bijeenkomsten. Heel veel succes met het voortzetten van deze samenwerking. Speciale 
dank aan Lianne voor alle hulp bij de DIPAK observationele studie en aan Marieke voor 
de helpende hand bij de dataverzameling in de Mayo Clinic. 
AIOS en MDL-artsen van het Radboudumc, naast dat ik veel van jullie geleerd heb 
tijdens de overdracht en het onderwijs, wil ik jullie ook bedanken voor de fijne werksfeer 
en de gezelligheid op de piste, congressen en borrels.
Beste studenten Ralf en Stef, jullie waren fantastische hulp bij mijn onderzoek. Ik ben blij 
dat dit heeft geleid tot twee mooie publicaties. Succes in jullie verdere carrière! 
Jody, Daisy, Hennie en René, heel erg bedankt voor alle hulp en de gezellige praatjes 
tijdens het werk op het lab. Dames van het secretariaat, dank voor alle ondersteuning 
bij de polipatiënten en het klinische onderzoek. Karin, met jou is het altijd gezellig op 
de dagbehandeling! 
Lieve Floor, Lauranne, Angelique, Dorian, Edgar, Govert, Hedwig, Isabelle, Jos, 
Karina, Mark L, Mark B, Marten, René, Simon, Titus, Wybrich, Xavier, Yasmijn 
en Yannick, jullie waren de leukste collega’s die ik mij kon wensen! Naast de vele 
leerzame momenten op het werk, was er ook veel gezelligheid daarbuiten. Stappen 
tijdens congressen in Barcelona, Wenen en San Francisco, biertjes op de NVGE, 120 
km op de racefiets, skiën in Oostenrijk, borrelen in de Aesculaaf en zo kan ik nog wel 
even doorgaan! 
Nieuwe collega’s van het Rijnstate, dank voor het warme welkom en alle hulp in 
mijn eerste maanden als arts-assistent. Ik hoop dat we er een paar mooie jaren van 
gaan maken! 
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Lieve Cogroepgenoten, dank voor alle kopjes koffie tijdens het onderzoek en biertjes in 
de Aesculaaf of elders. Wanneer gaan we weer naar de Schnabbelhoeve? 
Oud NSSR-bestuursgenoten Marit, Joris, Alieke en Mike, ik denk met heel veel plezier 
terug aan onze bestuurstijd en heb veel geleerd van deze periode. Ik hoop jullie snel weer 
te zien.
Lieve Margriet, Sarah en Anouk, jullie oprechte interesse en luisterend oor zijn 
ontzettend fijn. Ik ben blij met zulke lieve vriendinnen als jullie! Teun, Wies, Mirte, 
Denise en homie Manon, jullie zijn mijn ‘oudste’ vriend(inn)en en ik hoop dat onze 
vriendschap nog heel lang voort duurt! 
Lieve ‘Lekkere Mokkels’, ‘Paarse Leeuwtjes’, Sue, David, Dennis, Jaap-Jan en Petra, 
het is heerlijk om af en toe afleiding te hebben in het (beach)volleybalveld, met een 
spelletje Pictionary, champagne in de jacuzzi en noem maar op. Zoals Wien zou zeggen: 
‘’Alleen maar liefde!’’. 
Lieve Papa en Mama, dank voor de onvoorwaardelijke steun en liefde die jullie mij 
altijd hebben gegeven. Pap, ik vrees dat ik jouw nieuwsgierigheid en reislust geërfd heb. 
Mama, jouw zorgzaamheid is goud waard! Lieve Stijn en Thomas, samen met jullie is er 
altijd iets te beleven. Ik ben trots dat ik jullie als paranimfen naast mij heb staan vandaag. 
Lieve Imke, tweepoot, bedankt voor je vriendschap, inlevingsvermogen en luisterend oor. 
Lieve Ruud, Elmar, David en Marga, ook jullie zijn elk op eigen wijze heel belangrijk 
voor mij. Het is fijn om een familie te hebben die er altijd voor mij is. 
Lieve Gijs, het leven is fijn samen met jou! Jij geeft mij de ruimte om mijn grenzen 
(letterlijk) te verleggen en laat mij zien dat ik meer kan dan ik soms denk. Ik geniet van de 
zomers op het strand, onze reizen rond de wereld, maar ook van de simpele momenten 
thuis. Ik zie uit naar alle nieuwe avonturen die we samen tegemoet gaan. Ninakupenda! 
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Myrte Karlijn Neijenhuis werd geboren op 1 september 1988 
te Nijmegen. In 2006 behaalde zij haar VWO diploma aan het 
Montessori College om aansluitend Geneeskunde te gaan studeren 
aan de Radboud Universiteit Nijmegen. Na het behalen van haar 
bachelor was zij een jaar actief als fulltime penningmeester en 
vice-voorzitter van de Nijmeegse Studenten Sport Raad (NSSR). In 
2010 startte Myrte met haar coschappen, welke werden afgesloten 
met een tropencoschap in het Designed District Hospital te 
Sumve, Tanzania. In de laatste jaren van haar studie groeide haar interesse in de Maag-, 
Darm- en Leverziekten en deed ze haar wetenschappelijke stage naar symptomen bij 
polycysteuze leverziekte. Na haar afstuderen in 2013, kreeg dit onderzoek vervolg in 
een promotieonderzoek getiteld ‘Patient-Reported Health in Polycystic Liver Disease’ 
onder supervisie van Dr. T.J.G. Gevers, Dr. W. Kievit en Prof. Dr. J.P.H. Drenth. Tijdens dit 
promotietraject heeft zij zes maanden onderzoek gedaan in de Mayo Clinic, Rochester 
(MN), Verenigde Staten onder supervisie van Dr. M.C. Hogan en Dr. P.S. Kamath. In het 
laatste jaar van haar promotie ontving Myrte het Christine Mohrmann Stipendium, een 
prijs voor veelbelovende vrouwelijke promovendi van de Radboud Universiteit, en werd 
zij genomineerd voor de Young Hepatologist Award van de Nederlandse Vereniging voor 
Hepatologie. Myrte is per 1 februari 2017 gestart met haar opleiding tot Maag-, Darm- en 
Leverarts in het Rijnstate te Arnhem onder leiding van Dr. L.J.M. Reichert (vooropleiding 
Interne Geneeskunde) en Dr. P.J. Wahab (Maag-, Darm- en Leverziekten).
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